2018 DIRECTORY OF KOREAN PHARMACEUTICAL INDUSTRY

2018 Table of Contents

Greetings ...... 004

Overview of the Korean Pharmaceutical Industry ...... 005

Information of Pharmaceutical Companies ...... 009 - Regular Members - Associated Members

KPBMA Member Company List ...... 233

No Company Page No Company Page No Company Page No Company Page

Elyson Pharmaceutical Co. Ltd. 068 Korea Otsuka Pharmaceutical Co.,Ltd. 131 Seoul Pharma Co.,Ltd. 188 Regular Members 28 56 84 29 GC Pharma 070 57 KOREA PHARMA CO., LTD. 133 85 SHIN POONG PHARM. CO., LTD. 190 A~G 30 Green Cross Cell Corporation 074 58 Korea Prime Pharm. Co., Ltd. 135 86 SINSIN Pharmaceutical Cp., Ltd. 192 1 Ahngook Pharmaceuticals Co., Ltd. 010 31 GUJU PHARM. CO. LTD. 077 59 KOREA UNITED PHARM.INC. 137 87 SK Chemicals Co., Ltd. 194 2 AJU PHARM CO., LTD. 012 60 Korea Vaccine 139 88 SS Pharm.Co.,Ltd. 196 3 Astellas Pharma Korea 014 H~K 61 KOREAN DRUG CO., LTD. 141 89 Suheung Capsule. Co., Ltd. 198 4 BC World Pharm. Co., LTD. 016 32 Hana Pharm Co., Ltd 079 62 KUKBO SCIENCE 143 90 Taejoon Pharmaceutical 200 5 Binex Co., Ltd. 018 33 HanAll Bio Pharma 081 63 Kukje Pharma Co., Ltd. 145 91 Taiguk Pharm. co., Ltd. 203 6 Boryung Pharmaceutical Co., Ltd. 020 34 HANDOK Inc. 083 64 Kwang Dong Pharmaceutical Co.,Ltd. 147 92 THERAGEN ETEX CO., LTD. 205 7 CHO-A PHARM.CO.,LTD. 022 35 Hankooksinyak Pharm. Co., Ltd. 086 65 Kyongbo Pharmaceutical Co., Ltd. 149 93 Union Korea Pharma Co., Ltd. 207 8 Chong Kun Dang Pharmaceutical Co. 024 36 HANLIM PHARM. CO., LTD. 088 66 Kyowa Hakko Kirin Korea Co., Ltd. 151 94 WHITE LIFE SCIENCE 209 9 CJHealthCare Corp. 027 37 Hanmi Pharm. Co., Ltd 090 67 Kyung Dong Pharm. Co., Ltd. 154 95 WhanIn Pharm Co., Ltd. 211 10 CMG Pharmaceutical Co., Ltd. 030 38 Han Wha Pharma Co., Ltd. 092 68 Kyung Nam Pharm. Co, Ltd 156 96 Won Kwang Pharm. Co., Ltd 213 11 CORESTEM Inc. 032 39 Hawon Pharmaceutical Corporation 094 97 WOORIDUL PHARMACEUTICAL LTD. 215 12 CTCBIO, Inc 034 40 Humedix Co., Ltd 096 M~Y 98 YOOYOUNG PHARMACEUTICAL 217 13 Daewoo Pharmaceutical Co., LTD 036 41 HUONS CO., LTD. 098 69 Medica Korea Co., Ltd. 158 99 Yuhan Corporation 219 14 Daebong LS Co., Ltd 038 42 Hyundai Pharm 100 70 MG Co., Ltd. 160 100 Yuyu Pharma., Inc. 221 15 DAE HWA PHARMACEUTICAL CO., LTD. 040 43 ICURE Pharmaceutical Inc 102 71 MOTHER'S PHARMACEUTICAL CO., LTD. 162 16 DAEWON Pharm. Co., Ltd 042 IKSU PHARMACEUTICAL CO., LTD. 104 Myung In Pharm. Co., Ltd. 164 44 72 Associated Members 17 Daewoong Pharmaceutical Co., Ltd. 044 45 ILDONG Pharmaceutical 107 73 Myung Moon Pharm. Co., Ltd. 166 18 DAI HAN PHARM. CO., LTD. 046 46 Ilsung Pharmaceuticals 109 74 Pharmbio Korea Co., Ltd 168 101 C&R Research Inc. 223 19 Daiichi Sankyo Korea 048 47 IL-YANG PHARM. CO., LTD. 111 75 PMG Pharm 170 102 CrystalGenomics, Inc. 225 20 Dalim BioTech Co., Ltd. 050 48 ISU Abxis Co., Ltd. 115 76 Richwood Pharmaceutical Co., Ltd. 172 103 GL PharmTech 227 21 DHP KOREA CO.,LTD. 052 49 JEIL Pharmaceutical Co., Ltd. 117 77 RP Bio 174 104 Medi Help line 230 22 DongKoo Bio&Pharma Co., Ltd. 055 50 JINYANG PHARM. Co., Ltd. 119 78 SamChunDang Pharm. Co., Ltd. 176 105 Pharmicell Co., Ltd. 231 23 Dongkook Pharmaceutical Co., Ltd. 057 51 JW Pharmaceutical Corporation 121 79 SAMA PHARM CO.,LTD. 178 24 Dongkwang Pharm. Co., Ltd. 059 52 KMS Pharm Co., Ltd. 123 80 Samik Pharm. Co., Ltd. 180 25 DONGWHA PHARM 061 53 Kolmar Korea Co.,Ltd. 125 81 Samil Pharm. Co., Ltd. 182 26 Dong-A ST(Science & Technology) 063 54 Kolon Pharma 127 82 Samjin Pharmaceutical Co., Ltd. 184 27 Dongsung Bio Pharm 066 55 Korea Arlico Pharm Co.,Ltd. 129 83 Samyang Biopharmaceuticals Corporation 186

2 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 3 Greetings Overview of Korea’s Pharmaceutical Industry The market size of Korea’s pharmaceutical industry was USD 18.7 billion (as of 2016), making up 1.8% of approximately USD 1.1 trillion of the global pharmaceutical market, 1.2% of domestic GDP, and 4.3% of domestic manufacturing GDP. During the same period, domestic pharmaceutical production was USD 16.2 billion with export and import volumes accounting for USD 3.1 billion and USD 5.6 billion respectively, while domestic biopharmaceutical production was USD 1.73 billion, composing 9.2% of the domestic pharmaceutical market. As of 2016, there were 737 pharmaceutical companies who manufactured drug products. Of these, 367 manufactured Greetings from Korea Pharmaceutical and Bio-Pharma Manufacturers Association(KPBMA). This is Jung-Hee finished drug products, 204 manufactured drug substance, and 379 manufactured quasi drugs. Average revenue Lee, Chairman of the Directors Board. for publicly-traded pharmaceutical companies was USD 143 million, while 45 drug manufacturers generated USD 100 million or more in revenue and two manufacturers (Yuhan Corporation and Green Cross) recorded USD 1 Representing about 200 KPBMA member companies, I would like to express my sincere gratitude to all the billion or more (as of 2016). relevant readers who have interest in Korean pharmaceutical industry.

Korean pharmaceutical companies are manufacturing quality medicines in compliance with ICH guidelines as Market Size (Unit: USD million, %) well as Pharmaceutical Affairs Act in Korea, in order to provide consumers with safe medicines. 2012 2013 2014 2015 2016 Market size (yearly growth rate) 17,060 (0.32) 17,648 (0.51) 18,395 (0.24) 16,992 (-0.69) 18,729 (12.94) As a result, the Ministry of Food and Drug Safety in Korea was able to join PIC/S in 2014, and became the Production 13,943 14,955 15,593 15,004 16,212 regular member of ICH in 2016. Export 2,077 2,128 2,416 2,946 3,121 Even with short history of 120 years, the Korean pharma industry was able to develop 29 new drugs(NCEs) Import 5,194 4,821 5,219 4,948 5,638 and as of the end of 2016, 82 incrementally modified drugs was developed by Korean pharma companies. As for Trade balance -3,117 -2,693 -2,803 -2,002 -2,517 clinical trials, Seoul is the best city of all city level in terms of the number of clinical trials. Biopharmaceuticals are other area that Korea is making real result. Following the recent trend, efforts to combine the advanced IT technology with new drug development is being made to usher in the 4th industrial revolution. Pharmaceutical Production and Quality The purpose of KPBMA Directory is to provide all related people from government, international organization and companies oversea with precise information regarding Korean pharma companies, thus to facilitate co- Management Capacities operation. Following the 2016 version, the KPBMA spared no efforts to list precise and recent information of each Equipped with advanced production and quality management capacities, Korean pharmaceutical manufacturers Korean company to highlight the strength of KPBMA member companies. are producing high quality pharmaceutical products. Additionally, efforts by domestic drug manufacturers to I hope that this directory can be helpful to promote the cooperation between Korean companies and readers. As improve Good Manufacturing Practice since the mid-2000’s, have allowed them to build cGMP facilities compliant for the KPBMA, we will make a promise to continue to update the information of the directory. with what are required by major countries such as the U.S. Thank you. As regulatory and quality management systems for drugs have improved with the sincere efforts of regulatory and private agencies, Korean drugs are now receiving great confidence as quality drugs not only from countries in Southeast Asia, Central and South America, but also from those in Europe and the U.S.. Furthermore, recent Jung-Hee Lee, Chairman of the Directors Board, KPBMA efforts by the Ministry of Food and Drug Safety (MFDS) to introduce Quality by Design (QbD) are leading Korea’s pharmaceutical industry to establish a production infrastructure that will meet the requirements that are expected of advanced countries. Korea also boasts world-class drug regulatory systems. The MFDS having joined the Pharmaceutical Inspection Cooperation Scheme (PIC/s) in May, 2014, is an international testament to the quality and management

4 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 5 capabilities of Korean drug manufacturers, and has improved export conditions, including inspection exemptions product that obtained a marketing authorization from the US FDA in 2016. And it only took the world’s first of local drug manufacturing plants located in the PIC/s member nations. In addition, gaining Membership to the antibody biosimilar Remsima by Celltrion four years to exceed the USD 1 billion mark in aggregate export International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for revenues since its launch in 2013. Human Use (ICH) in November, 2016, has proved that the level of drug regulatory systems in Korea is on par with that of advanced countries, including the U.S., Japan and the EU, and has earned Korea elevated standing as one of the countries that is leading drug regulatory policies. This is expected to be a great stepping stone for Korea to Vigorous Global Market Entry advance in the global market as it will create favorable circumstances conducive to signing mutual agreements Korean drug manufacturers equipped with a global competitive edge in new drug development and drug with other national regulatory authorities and discussing exemptions required for gaining marketing approvals. formulation technologies, production management facilities and quality control practices are successfully entering markets around the world. Investments in R&D In 2016, Korean-manufactured drug products reached markets in 188 countries, and total export volume was USD 3.121 billion which was an 8.6% increase from the year before. Thus, the Korean pharmaceutical industry Domestic drug manufactures are well aware that the pharmaceutical industry is technology-intense, thus they had embarked on a high growth trajectory with an annual average growth rate of 13.6% between 2011 and 2016. have been making greater investments to develop new drugs. Furthermore, 27 drug manufacturers opened 69 local offices, and 18 pharmaceutical companies conducted 64 The average spending on R&D in 2016 by drug manufacturers was 6.0% of sales revenues, and that figure clinical trials overseas (as of 2014). reached 8.9% in publicly-traded drug manufacturers. In particular, Innovative Pharmaceutical Companies (selected by the Ministry of Health and Welfare) spent 11.7% of revenue, far exceeding the 3.7%-mark recorded in the In 2015 and 2016, when technology exports occurred in earnest, Korean drug manufacturers signed 25 manufacturing sector. The R&D budget of drug manufacturers in 2016 hit USD 1.156 billion with an annual technology export contracts with multinational pharmaceutical companies, and in 2017 alone, eight technology average increase of 6.7% over the previous five years. export contracts were concluded with their total volume reaching close to USD 1.23 billion.

Drug Export Volume by Export Destination (Unit: USD 1,000, %) 2016 Ranking Export destination Change Development of New Drugs Finished drug product Source material Sum 1 Japan 158,180 304,626 462,806 -6.6 Since the development of Korea’s first drug product “Sunpla Injection (cancer treatment)” in 1999, 29 new drugs 2 Croatia 397,830 28 397,858 356.1 have been developed in Korea as of March, 2018. With an average annual roll-out of 1.7 new drugs from 1999 to 3 Ireland 2,771 228,835 231,606 75.1 2017, Korea is gradually becoming a global pharmaceutical powerhouse. Furthermore, there are close to 20 drug 4 China 112,084 95,938 208,022 23.8 products that have established a foothold in major global pharmaceutical markets including the U.S. and Europe. 5 Vietnam 158,980 23,472 182,452 31.6 And starting with Amosartan (hypertension treatment) in 2009, 83 Incrementally Modified Drugs (IMD) had been Total 1,711,325 1,409,072 3,120,397 5.9 developed as of the end of 2016.

Government’s Policies to Promote and Support Biopharmaceuticals the Pharmaceutical Industry Four out of the seven globally commercialized stem cell therapy products were developed in Korea and they In December 2017, the government announced the Second Comprehensive Plans to Promote and Support the include the world’s first stem cell therapy, Hearticellgram-AMI (Pharmicell). Additionally, a hemophilia treatment Pharmaceutical Industry (Second Comprehensive Plans) to help make the pharmaceutical and healthcare sectors NBP601 (AFSTYLA) developed by SK Chemical, became the first new domestically-developed biopharmaceutical as a whole, leading industries that will drive innovative growth.

6 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 7 When the new administration took office in May 2017, it identified pharmaceuticals as a future-oriented new industry in its National Initiatives that can create high added value, and presented the Second Comprehensive Plans in which a blue print detailed how to further grow the pharmaceutical industry in the future. The Second Comprehensive Plans, with their vision of “Catapulting into a Pharmaceutical Powerhouse that Offers Health and Jobs to the Public,” are composed of four specific areas, namely, R&D, employment opportunities, export support measures and streamlining of rules and regulations. 1. Ways to strengthen R&D efforts to improve new drug development capacities - Foster promising areas for the next generation that will lead the Fourth Industrial Revolution, and Information of sophisticate support mechanisms that will improve new drug development success rates while increasing pharmaceutical R&D investments that are designed to benefit the public Pharmaceutical 2. Ways to foster professional talent and help start businesses aimed at securing future growth engines in the pharmaceutical industry - Build a pool of pharmaceutical talent in different disciplines, create quality jobs, and lay the foundation for Companies new businesses that will help increase the number of pharmaceutical and biopharmaceutical growth drivers.

3. Seek ways to reinforce export support systems based on field demands 2018 DIRECTORY OF KOREAN PHARMACEUTICAL INDUSTRY - Lay the foundation to help domestically-manufactured drug products enter global markets, help domestic pharmaceutical companies strengthen export capacities, and support domestic drug manufacturers in order to overcome entry barriers to respective markets. 4. Find ways to lay the foundation for the domestic pharmaceutical industry to help Korea become a leading pharmaceutical country. - Help boost private investments by offering policy loans, tax cuts, and strengthening institutional foundations to help develop more new drugs, while simultaneously implementing rules and regulations that can improve the pharmaceutical ecosystem.

8 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY Main Products

Product (Ingredient) Use Exporting Countries Remarks Ahngook Pharmaceuticals Co., Ltd. 1. Synatura Syrup (Ivy leaf 30% Ethanol Ext. 2.625mg/ Antitussive and Iran, South Africa, Mexico, New herbal medicine mL + Coptis Rhizoma Butanol Ext. 0.875mg/mL) Expectorant Colombia, Vietnam, Kuwait with new composition 10mg&20mg: Treatment of New formulation 2. Valkyrie OD!FS (Tadalafil 5mg, 10mg, 20mg) erectile dysfunction - Orally Dissolving in a 5mg: Treatment of ED, BHP Few Seconds 1st chirally pure 3. Letopra Tab.(S-Pantoprazole 10/20mg) Treatment of GERD, PPI Kuwait, Vietnam S-pantoprazole Company Profile New and non-opioid 4. Anycough Cap.(Theobromine 300mg) Relief of cough symptom Kuwait antitussive Ahngook is a fully integrated pharmaceutical company dedicating to 1st chirally pure development, manufacture, marketing, and sales of good medicines 5. Levotension Tab.(S-amlodipine 2.5/5mg) Hypertension Philippines, Vietnam S-amlodipine in Korea since 1959. And currently Ahngook has a strong presence Functional dyspepsia. in Respiratory, Gastroenterology, and Cardiovascular. For the future 6. Anytin SR tab. (Trimebutine maleate 300mg) - - Irritable Bowel Syndrome growth Ahngook is concentrating its R&D efforts on Bio products as Primary Hyperlipidemia well as various chemical products. 7. Sustar Tab.(Rosuvastatin 5/10/20mg) Guatemala - and mixed dyslipidemia Ahngook is dreaming to be a global company. It has its own entity in Benign Prostatic Philippines, Vietnam, 8. Xaltrin XL Tab.(Alfuzosine HCL 10mg) - Representative China and is trying to expand its presence outside Korea. Ahngook Hyperplasia Guatemala, Peru has entered several out-license agreements and a number of 9. Curost Granules Prevention and continuos JIN AUH(President & CEO) Philippines, Vietnam - export agreements with many overseas partners. Ahngook has (Montelukast Sodium 4.16mg) therapy of asthma Headquarter Address many differentiated products and it is flexible for collaboration and 613 Siheung-daero, Yeongdeungpo-gu, business models to ensure for mutual benefits with its partners. R&D Pipeline Seoul 07445, Korea Ingredient Code Use Stage of Development Foundation Date Sep. 03. 1959 AG-1301 Naturalsubstance new drug Respiratory Therapeutics Non-clinical Research Focus AK903 Natural substance new drug Periodontal disease treatment Phase 2 Clinical Study IMDs, NCEs and Bio drugs AG-1502 IMD Circulatory system treatment Research Total Staff AGB-P1 IMD Musculoskeletal Therapeutics Research 510 persons UAI-101 Compound drug Metabolic disease treatment Non-clinical Representative Phone AG-B1511 Bio better (long acting) Neutropenia Non-clinical 82-2-3289-4200 AG-B1512 Bio better (long acting) Human Growth Hormone Deficiency Non-clinical completed Web www.ahn-gook.com AG-B1622 Bio Drug Immune anticancer agent Research Contact Person Jay Kim New Active Substances Contact Phone Product (Ingredient) Use Approval Date/Country 82-2-3289-4359 Anycough cap. (Theobromine 300mg) Antitussive Jun. 2008, Korea Synatura Syrup (Ivy leaf 30% Ethanol Ext. 2.625mg/mL+ Mar. 2011, Korea, Iran, Contact E-mail Antitussive & Expectorant [email protected] Financial Figures Coptis Rhizoma Butanol Ext. 0.875mg/mL) Kuwait, South Africa Apr. 2017, Korea Rupafin Tab. (Rupatadine 10mg) Antihistamine Summary (1 Million Won) (In-licensed product) Fiscal Year 2015 2016 2017 Sales 180,435 100,529 175,000 Others R&D Expenditure 15,875 15,467 13,282 We welcome inquiries about our products export or R&D collaboration. Also we are specialized in the development of NCE and Capital 175,667 144,554 176,178 IMD drugs for domestic development. If you are interested in Korean market, please feel free to contact us.

10 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 11 Main Products AJU PHARM CO., LTD. Product (Ingredient) Use Exporting Countries Remarks 1. Ceftriaxone Sod 0.25, 0.5, 1.0g Injection Antibiotics Georgia etc. - 2. Cefotaxime Sod 0.25, 0.5, 1.0g Injection Antibiotics Mongolia etc. - 3. Ezetimibe+Rosuvastatin Cardiovascular Peru etc. - 10/5, 10/10, 10/20mg Tablet 4. Eperison HCl 75mg SR Tablet Neuro-Muscular Azerbaijan etc. - 5. Omeperazole+NaHCO3 Company Profile Gastro-Intestinal - - 20/1100, 40/1100mg Tablet Founded in 1953, Aju Pharm has been well know as a quality-oriented 6. Candesartan 8, 16mg Tablet Circulatory Philippines etc. - pharmaceutical company. 120+ pharmaceutical products comprised of in-licensed products, our own value-added products, generics. 7. Pregabalin 75mg, 150mg Capsule CNS Peru etc. - medical devices, and consumer health products. 8. Bisoprolol fumarate+Hydrochlorothiazide Circulatory Philippines etc. - Exporting products to more than 15 countries, always developing new 10/6,25, 5/6.25, 2.5/6.25mg Tablet opportunities around the world. 9. Thiotic acid 25mg Injection Antioxidant Vietnam etc. - 10. Olive leaf extract Spray Daily throat care Saudi Arabia etc. Food Item Representative Joong-Kil KIM Headquarter Address #600 Gyeongin ro, Guro-gu, Seoul, Korea R&D Pipeline Foundation Date 1953. Ingredient Use Stage of Development Research Focus Esomeprazole+ NaHCO3 Tablet Gastro-Intestinal Under clinical trial Antibiotics, Cardiovascular Total Staff About 400 Representative Phone 82-2-2630-0700 Others

Representative Fax Olea, our consumer health brand, aspires to help people live healthier lives by offering dietary supplements and other consumer 82-2-849-4123 health products made with the highest quality olive leaf extract. Web Medical device(Soft tissue repairs and reconstruction). www.ajupharm.co.kr Biocomposite and bioabsorbable suture anchors for rotator cuff repair(First biocomposite suture anchor developed in Korea) and Disposable cannula with dual silicone seal system Contact Person Jeeyoun Sung Contact Phone 82-2-2630-0729 Contact E-mail Financial Figures

[email protected] Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 85,504 104,029 118,700 R&D Expenditure 2,401 2,226 - Capital 4,200 4,200 4,200

12 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 13 Main Products Astellas Pharma Korea Product (Ingredient) Use Exporting Countries 1. Harnal D(Tamsulosin HCI) benign prostatic hyperplasia Japan 2. Vesicare(Solifenacin Succinate) Overactive Bladder Netherland 3. Oldeca(Barnidipine HCl) Hypertension Japan 4. Berasil(Beraprost sodium) Peripheral Arterial Disease Japan 5. Protopic(Tacrolimus) Atopic Dermatitis Japan Company Profile 6. Nasea(Ramosetron HCI) Nausea and Vomiting Japan Astellas Pharma Korea., Inc. is alocal subsidiary of Japanese 7. Prograf(Tacrolimus) Post-transplant rejection Ireland pharmaceutical corporate with superior R&D and worldwide sales network. It was founded in April 1st 2005 by merging of Fujisawa 8. Irribow(Ramosetron HCI) Irritable Bowel Syndrome Japan pharma Korea.,Co.and Yamanouchi pharma Korea.,Co,with 100% 9. Rapamune(Sirolimus) Post-transplant rejection - Japanese ownership. 10. Perdipine(Nicardipine HCI) Hypertension -

Representative Jeong Hai Do Headquarter Address 6F, Kumha Bldg.41-2, Chungdam-Dong, Kangnam-Ku, Seoul, Korea Foundation Date 2005.04.01. Total Staff 246 persons Representative Phone 82-2-3448-0504 Representative Fax 82-2-3448-0510 Web www.astellas.com/kr

Financial Figures

Summary (1 Million Won) Fiscal Year 2008 2009 2010 Sales 105,800 132,300 150,400 R&D Expenditure - - - Capital 11,500 11,500 11,500

14 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 15 Main Products BC World Pharm. Co., LTD. Product (Ingredient) Use Exporting Countries Vietnam, 1.Meropenem 500mg, 1g, 2g / Injection Antibiotics Philippines and etc. Vietnam, Philippines, 2. Imipenem 500mg+Cilastatin Sodium Antibiotics Nigeria, 500mg / Injection Mongolia and etc. Azerbaijan, 3.Citicoline sodium 500mg/2ml / Injection Central nervous system Dominica and etc. Company Profile 4. Nicardipine HCl Circulatory system Taiwan and etc. We are a pharmaceutical company that discovers, develops, produces 10mg/10ml, 2mg/2ml / Injection and markets formulations. We are actively engaged in R&D, including 5. Vancomycin HCl 1g / Injection Antibiotics Yemen and etc. depot injectables, liposomes, and fast dissolving tablets. 6. Methylprednisolon Sodium Succinate Adrenal gland hormone Vietnam and etc. We are certified as Korea Innovative Pharmacetical Company (KIPC) 40mg/ Injection by Korea Ministiry of Health & welfare and designated as Advanced 7. Piroxicam 20mg/1ml / Injection Anti-inflammatory Vietnam and etc. Technology Center (ATC) by Korea Ministry of Knowledge Economy. 8. Acetaminophen 325mg+Tramadol HCl Anti-inflammatory Myanmar and etc. 37.5mg / Tablet Our newly facility constructed will be approved according to EU GMP Headquarter Address standards by 2018. The manufacturing site construction dedicated for 9. Glibenclamide 5mg+Metformin HCl 500mg, Glibenclamide 2.5mg +Metformin HCl 500mg/ Anti-Diabetes Bolivia and etc. Gyung Building, 78, Gaepo-ro, 22-gil, Carbapenem injection started in this year. Gangnam-gu, Seoul, 139-961, Korea Tablet Foundation Date 10. Acetazolamide 500mg/ Injection Circulatory system Iran and etc. 1980.03.19. Research Focus DDS (Drug delivery system) R&D Pipeline Total Staff Classification Code Use Stage of Development 272 persons BCWP-D001 Anti-cancer Formulation Representative Phone BCWP-D004 Anti-cancer Formulation 82-2-2182-0400 BCWP-D006 Anti-cancer Non-Clinical Web www.bcwp.co.kr Long-acting Microsphere Injection BCWP-D007 Parkinson's disease Formulation BCWP-D008 Alzheimer's disease Formulation Contact Person David Kim BCWP-D009 Anti-schizophrenia IND Contact Phone BCWP-D010 Anti-schizophrenia Formulation 82-2-2182-0452 BCWP-Y001 Anti-cancer Tech transfer Contact E-mail Liposomal Injection BCWP-Y002 Anti-fungal Pre-Clinical [email protected] BCWP-Y004 Analgesia Formulation BCWP-A001 Antibiotics Pre-Clinical Financial Figures Gastroretentive BCWP-C003 Hyperlipidemia/DM Clinical Summary (1 Million Won) Fiscal Year 2015 2016 2017 BCWP-E001 Anti-emetic Launching Sales 41,414 45,657 50,207 Fast-dissolving Tab. BCWP-E003 ADHD Formulation R&D Expenditure 5,794 6,556 6,649 BCWP-E004 Antiulcerant PIII Capital 1,335 1,335 1,461

16 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 17 Main Products Binex Co., Ltd. Product (Ingredient) Use Exporting Countries 1. Contract Development and Manufacturing Service - Binex manufactures client's products both in API and finished form based - - on clients' need. Products are manufactured at GMP quality with proficiency at reduced time and cost. Company Profile 2. Human Growth Hormone Growth Hormone Deficiency - Binex is currently comprised of three main business sectors: biologics, 3. Small molecule products digestion, ophthalmic solution, etc. - chemicals, and cell therapy. As the only biologics CDMO in Korea, Binex plays the key role in solving the manufacturing bottleneck of biopharmaceutical industry with accumulated experience and US and EU-GMP facility. R&D Pipeline

Ingredient Use Stage of Development

Representative Infliximab Rheumatoid Arthritis and other Phase 1 in Korea and Japan for Myoung-Ho Jeong (Remicade biosimilar) inflammatory conditions Rheumatoid Arthritis Headquarter Address #368-3 Dadae-ro, Saha-gu, Busan, 604- 846, Republic of Korea Foundation Date 1985.03.21. Research Focus biosimilar Total Staff 300 persons Representative Phone 82-32-850-3235 Representative Fax 82-32-850-3299 Web http://www.bi-nex.com

Financial Figures

Summary (1 Million Won) Fiscal Year 2009 2010 2011 Sales 32,252 47,243 53,458 R&D Expenditure 4,349 706 4,663 Capital 7,800 8,357 9,379

18 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 19 Main Products Boryung Pharmaceutical Co., Ltd. Product (Ingredient) Use Exporting Countries Remarks Mexico, Brazil, 1. Kanarb Tab. (Fimasartan) Anti hypertension NCE(New chemical entity) Russia, China, 2. Cilnidipine Tab. Anti hypertension - 4th generation CCB 3. Lafutidine Tab. Gastric Ulcer, Gastritis - new generation H2RA 4. Gelfos Susp. (ALPO4) Antacid China, Taiwan Top Antacid in East Asaia. Company Profile 5. Pitavastatin Hyperlipimedia Japan API Boryung Pharmaceutical Co., Ltd has put a strong presence as 6. Oncology Injectable Anticancer Chemotherapy ASEAN, MENA - TOP leading company in Korean pharmaceutical market since its 7. Cephalosporin Injectable Antibiotics Japan PMDA approved foundation in 1963. Boryung has made its continuous efforts and investment on R&D to produce high-quality products in its specialty areas such as cardiovascular, gastrointestinal, antineoplastic, antibiotics drugs and API. Boryung has devoted itself to achieve the aspiration of company, “Dedicating to the health of mankind.” R&D Pipeline Representative In particular, Kanarb (Fimasartan, 8th ARB NCE for anti- hypertension) has been already licensed out to 14 Latin countries including Mexico Tae-Hong, Choi Compound Name Code Use Stage of Development & Brazil, Russia and China (16 countries in total). Following the launch Headquarter Address of Kanarb in Mexico in Sept. 2014, further global market development Kanarb + CCB combo BKC002 Hypertension P3 #136, Changgyeonggung-ro, Jongno-gu, has been accelerated. In 2015, Kanarb is going to be licensed to Hypertension Kanarb + Statin combo BKC003 P3 Seoul, Korea APAC & MENA regions and be launched in Russia, Brazil, and China Hyperlipimedia in a few years. Also, the projects heading to the reference countries Foundation Date Hypertension such as EU & Japan have been carried out. Kanarb + CCB + Statin combo BKC004 P1 1963.10.01. Hyperlipimedia Following the remarkable success in Kanarb, Boryung is confident to Research Focus Incrementally modified drugs BNT002 Dementia P1 Cardiovascular, Oncology make another success story with its next key pipeline, Lafutidine(new generation H2RA), Cilnidipine (4th generation CCB), and Gelfos (Top Hypertension New Chemical Entity BNT001 Discovery Total Staff antacid in East Asia), with its best clinical values in class. Diabetes mellitus 1,100 persons Focus Area : Cardiovascular, Gastro-ntestinal, Antibiotics, Oncology, Gene therapy BCB002 Liver cancer P1 Representative Phone API synthesis 82-2-708-8000 Vaccine BVN002 Vaccine P3 Vaccine BVN003 Vaccine PC Representative Fax 82-2-744-0682 Web www.boryung.co.kr Contact Person Micheal park Jay Kim Contact Phone Financial Figures New Active Substances 82-2-708-8032 Product (Ingredient) Use Approval Date/Country 82-2-708-8051 Summary (1 Million Won) Fiscal Year 2012 2013 2014 Fimasartan Anti-hypertension Korea / 2011 Contact E-mail [email protected] Sales 312,075 327,279 359,491 - - Mexico / 2014 [email protected] R&D Expenditure 9% 7.4% 7.2% - - Ecuador / 2014 Capital 17,440 18,283 19.170

20 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 21 Main Products CHO-A PHARM.CO.,LTD. Product (Ingredient) Use Exporting Countries 1. Uratonyl (L-Ornithine-L-Aspartate) Acute,Chronic Vietnam 2. Hemopoly Iron deficiencya anemia Vietnam (Ferric hydroxide polymaltose complex) 3. Calcitonic (Calcium Lactate) Calcium deficiency Vietnam 4. Elemmen (Adenosine, Thymidine) Acute, chronic, hepatitis anemia Vietnam 5. New Hem (Ferrous gluconate hydrate, Company Profile Iron deficiencya anemia Yemen Manganese gluconate, Copper gluconate) CHO-A PHARM.CO.,LTD. has put all efforts to develop and supply 6. Lyvitol (L-Lysine HCl, Inositol, Nutrition disorder Vietnam excellent medicine under a corporate slogan, "Keep People Healthy Cyanocobalamin) and Happy Away from Diseases" since establishment in 1988. With 7. Ronalamin (Calcium Lactate) Calcium deficiency Vietnam fast growth over the last 20 years, CHO-A PHARM, is one of the leading pharmaceutical company in Korea producing about 300kinds 8. Manpos (L-Arginine-L-Aspartate) Physical mental asthemia Guatemala of drugs especially OTC products and health foods. CHO-A PHARM. 9. Babycolcol Reduction of symptoms resulting from the cold Mongolia began producing drinkable double-neck ampoule under technical cooperation with Laphal of France in 1994 and currently has 30kinds 10. Ginseng Korea (Korean Ginseng Ex.) Reduces fatigue, improve mental conditions. Vietnam Representative of proudcts and exports them to Vietnam, Yemen and Guatemala. Mr. Sung-Hwan Cho(CEO) After establishing a manufacturing factory in 1994, CHO-A has Headquarter Address invested to improve quantity and maximize production capacity by 1F Ace-Techno Tower, 55-7 obtaining an approval of KGMP in 1995 as well as ISO 9001 for the Mullea-dong 3ga, Youngduengpo-gu, first time in the pharmaceutical industry in 1996. Through the CHO-A Seoul, Korea Bio technical R&D center, CHO-A succeeded producing a somatic- Foundation Date cell cloned pig for the first time in Korea and cloned a pig with EPO 1988. gene character coverted in 2005. Thereby CHO-A is expected to be a prominent biotech company of the next generation. Total Staff 270 persons Representative Phone 82-2-2166-4000 Representative Fax 82-2-2166-4111 Web www.choa.co.kr

Financial Figures

Summary (1 Million Won) Fiscal Year 2008 2009 2010 Sales 24,709 29,567 34,943 R&D Expenditure 1,623 1,502 1,296 Capital 39,514 39,875 42,237

22 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 23 Main Products Chong Kun Dang Pharmaceutical Co. Product (Ingredient) Use Exporting Countries 1. Lipilou (atorvastatin calcium anhydrous) Hyperlipidemia Asia 2. Dilatrend (carvedilol) Hypertension - 3. Cipol-N (cyclosporine) Immunosuppressant Asia, S. America 4. Tacrobell (tacrolimus) Immunosuppressant Japan, Asia 5. Candemore plus (candesartan + HCTZ) Hypertension Asia Company Profile 6. Sarlotan (losartan potassium) Hypertension - Chong Kun Dang Pharmaceutical Corporaiton (CKD) was spin-off from 7. Imotun (avocado-soya) Arthritis - CKD Holdings on November 2, 2013. CKD is a new organization to manufacture, sales and market the pharmaceutical products, and has 8. Pregrel (clopidogrel resinate) Myocardial infarction - the excellent capabilities to develop new chemical entities (NCEs), 9. Avelox (moxifloxacin hydrochloride) Antibiotics - incrementally modified drugs and generics. CKD has invested over 12.3% of annual revenues for R&D (2016), and succeded to develop 10. Telminuvo (telmisartan, S-amlodipine) Hypertension - NCEs such as CAMTOBELL®, anti-cancer drug and DUVIE®, anti- diabetic drug. Representative Young-Joo Kim Camtobell® was launched in 2004, as the first CKD new drug developed by its own technology. Based upon this successful Headquarter Address experience, Duvie® (Lobeglitazone) which is a thiazolidinedione (TZD) R&D Pipeline #8, Chungjeong-ro, Seodaemun-gu Seoul derivative for type 2 diabetes has been launched on February 2014. 120-756, Korea Ingredient Use Stage of Development CKD has the capacity to research and develop drugs in broad areas: Foundation Date New Chemical Entity (NCE), Incrementally Modified Drug (IMD), and CKD-351 Glaucoma Phase II 1941. Biologics with a focus on antineoplastic, metabolic, immune and CKD-337 Dyslipidemia Phase I/III cardiovascular diseases. Research Focus CKD-333 Hypertension & Hyperlipidemia Pre-Clinical Oncology, Immunology, Metabolism, Cardiovascular CKD-391 Dyslipidemia Phase III Total Staff CKD-11101 Anemia Phase III 1,864 persons CKD-396 Type 2 Diabetes Phase I Representative Phone CKD-393 Type 2 Diabetes Pre-Clinical 82-2-2194-0300 CKD-516 Colorectal cancer Phase I/II Web CKD-381 Peptic ulcer Phase I http://www.ckdpharm.com CKD-394 Anti-coagulant Phase I Contact Person Ki-Su Lee CKD-519 Dyslipidemia Phase II (Head of Global Business Division) CKD-581 Multiple myeloma Phase I/II Contact Phone CKD-841 Cancer Phase I 82-2-3149-7849 Financial Figures CKD-495 Gastritis Phase II Contact E-mail [email protected] Summary (1 Million Won) CKD-506 Autoimmune disease Phase I Fiscal Year 2014 2015 2016 CKD-504 Huntington’s disease Phase I Sales 544,130 544,130 831,986 CKD-12101 Neutropenia Pre-Clinical R&D Expenditure 74,727 91,359 102,178 Capital 23,523 23,523 23,523 CKD-508 Dyslipidemia Pre-Clinical

24 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 25 R&D Pipeline Ingredient Use Stage of Development CJHealthCare Corp. CKD-509 Oncology Pre-Clinical CKD-701 AMD Pre-Clinical CKD-702 NSCLC Pre-Clinical

Company Profile CJ HealthCare, which launched as a professional pharmaceutical subsidiary of CJ Group on April 1, 2014, is preparing for the future through its active investment in R&D and Open Innovation. New Active Substances CJ Healthcare has concentrated on developing innovative new drugs, Product (Ingredient) Use Approval Date biopharmaceuticals, and Incrementally Modified Drug in a variety of therapeutic groups. Camtobell (belotecan) Ovarian cancer, SCLC October 22, 2003 / South Korea The new drug for gastroesophageal reflux disease (CJ-12420/ Duvie(lobeglitazone sulfate) Type II diabetes July 4, 2013 / South Korea Representative ingredient name: Tegoprazan), which is currently being developed, Seok Hee KANG is now attracting attention as a drug that can shake the market for Headquarter Address digestive system drugs in the near future. CJ CheilJedang Center, 330, Dongho-ro, Tegoprazan has been recognized for its competitiveness both Jung-gu, Seoul 04560, Republic of Korea domestically and internationally, and has achieved technology export Foundation Date of 100 billion won to China < Shandong Luoxin Pharmaceutical Group 1.April 2014. Stock Co., Ltd.> in 2015. Research Focus digestive disorders, anti-cancer, and immune diseases Total Staff 1,200 persons Representative Phone 82-2-6740-2119 Web www.cjp.co.kr Contact Person Headquaters Contact Phone 82-2-6740-2169 Contact E-mail Financial Figures [email protected] (Global Business) Summary (1 Million Won) [email protected] Fiscal Year 2015 2016 2017 (R&D Business Development) Sales 463,100 520,800 - R&D Expenditure - - - Capital - - -

26 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 27 Main Products R&D Pipeline

Product (Ingredient) Use Exporting Countries Compound Name Code Use Stage of Development Southeast Asia, Africa, Tegoprazan CJ-12420 Gastric Acid-Related Disorders NDA Treatment of anemia of hemodialysis The Middle East, North 1. Epokine Inj. (rh-EPO) patients with end-stage renal disease Africa and CIS, Latin UNDISCLOSED CJ-14199 NASH PC America JAK-1 inhibitor CJ-15314 Rheumatoid Arthritis PC Southeast Asia, Africa, Chemotherapy in advanced cancer patients The Middle East, North Atorvastatin, Metformin CJ-30056 Type 2 Diabetes / Hyperlipidemia NDA 2. Leukokine Inj. (rh- G-CSF) and Neutropenia caused by acute Leukemia Africa and CIS, Latin Valsartan, Amlodipine, Rosuvastatin CJ-30060 Hypertension / Hyperlipidemia P3 America Valsartan, Amlodipine, Atorvastatin CJ-30061 Hypertension / Hyperlipidemia P3 Treatment of serious, life-threatening 3. Vancorin Inj.(Vancomycin) China infections by gram-positive bacteria Gastric Acid-Related Disorders / Tegoprazan, Clopidogrel CJ-30064 DC Antithrombotics Treatment of serious infections Southeast Asia, 4. Tapocin Inj.(Teicoplanin) by gram-positive bacteria Latin America Tegoprazan CJ-30065 Gastric Acid-Related Disorders DC Treatment of acute bacterial sinusitis, acute - CJ-30066 Type 2 diabetes DC 5. Moveloxin I.V. solution bag (Moxifloxacin) bacterial exacerbation of chronic bronchitis, Southeast Asia community acquired pneumonia and so on - CJ-30067 Type 2 diabetes DC Treatment of Vancomycin-resistant Darbepoetin alfa biosimilar CJ-40001 Renal Anemia P3 6. Cinezolid I.V. solution bag (Linezolid) Southeast Asia Enterococcus faecium infections - CJ-40010 Hand, Foot & Mouth Disease PC 7. Calmtop Inj.(Irinotecan) Treatment of colorectal cancer Southeast Asia Ranibizumab biosimilar CJ-40012 Macular edema PC Treatment of pleural mesothelioma 8. Pemta RTU Inj.(Pemetrexed) Southeast Asia and non-small cell lung cancer 9. OmapOne Lipid Inj. Lipid emulsion for intravenous nutrition Southeast Asia (Soybean oil, MCT, olive oil and fish oil)

10. OmapOne Peripheral Inj. Emulsion for infusion Southeast Asia (Lipid, Amino acids and Glucose)

11. Machkhan Tab. (Candesartan, Amlodipine) Treatment of hypertension -

12. Vogmet (Voglibose, Metformin) Treatment of diabetes -

13. CONDITION CONDITION LADY Anti-hangover drink China, Japan, Vietnam (Hyaluronic acid) 14. HONGSAMJIN (4 years old red ginseng extract) Red Ginseng drink Vietnam HONGSAMJIN GOLD (6 years old red ginseng extract)

15. HUTGAESOO Natural oriental raisin tea with zero calories - (Oriental raisin tree fruit extract concentrate) and caffein

28 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 29 Main Products CMG Pharmaceutical Co., Ltd. Product (Ingredient) Use Exporting Countries Remarks 1. Kanarb Tab. (Fimasartan) Erectile dysfunction Taiwan, Hongkong 20, 10, 5mg 2. Amlodipine/Valsartan Tab. Hypertension - 5/80, 5/160, 10/160mg 3. Mosapride Tab. Acid reflux, IBS - 5mg 4. Rebamipide Tab. Gastric ulcer - 100mg 5. Loxoprofen Tab. Anti-inflammation - 60mg Company Profile 6. Rosuvastatin Tab. Hyperlipidemia - 5, 10, 20mg CMG Pharmaceutical is a fast growing mid-cap company listed Fatigue recovery, 7. Multi-Vitamin Tab. - Vit B1, B2, B6, C, E in KOSDAQ stock market in Korea. R&D focus area includes inflammation development of targeted cancer therapeutics (NCE), IMDs including Oral Soluble Film and fixed-dose combinations of established drugs 8. Hyaluronic acid micro needle Cosmetic Mexico, Ukraine - with therapeutic areas in cancer, CNS and cardiovascular disease. 9. Hyaluronic acid injectable Skin filler - - CMG is seeking Open Innovation partnership in various areas 10. Vitamin C solution Hair loss, scalp care - - including licensing, marketing/sales, R&D collaboration and Joint Representative Venture investment in healthcare industry. Joohyung Lee Headquarter Address CHA Bio Complex, Pangyo-ro 335, R&D Pipeline Bundang-gu, Seongnam, Gyeonggi-do 13488, Republic of Korea Compound Name Code Use Stage of Development Foundation Date Aripiprazole ODF - Schizophrenia, Bipolar I disease US Pre-NDA, 505(b)(2) August 1, 2001. NCE CHC-2014 Solid cancer Phase 1 Study Candidate Research Focus NCE CCN-002 Lung/stomach cancer Pre-clinical NCE, IMD, Oral Soluble Film NCE CCN-006 Prostate/bladder cancer Pre-clinical Total Staff 212 persons NCE CNN-006 Alzheimer's disease Pre-clinical Representative Phone NCE CCN-007 Solid cancer Hit selection 82-31-881-7600 Orlistat - Obesity Reformulation Web http://cmgpharma.com/ Contact Person Haekwan Eo Contact Phone Others 82-31-881-7679 CMG, part of CHA Hospital Group, is open to discuss business collaborations including open innovation, M&A, JV, R&D, and Contact E-mail Financial Figures investment with foreign companies and investors. [email protected] Summary (1 Million Won) Fiscal Year 2015 2016 2017(E) Sales 27,042 32,970 41,535 R&D Expenditure 6,009 2,404 2,799 Capital 44,149 54,354 54,431

30 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 31 Main Products CORESTEM Inc. Product (Ingredient) Use Exporting Countries Remark 1. NEURONATA-R Amyotrophic Lateral Sclerosis (ALS) All MFDA approval in 2015

Company Profile R&D Pipeline

CORESTEM is a bio-pharmaceutical company specializing in research Compound Name Code Use Stage of Development and development of personalized stem cell therapies for incurable disease. Allogenic Stem Cell CS20AT04 Systemic Lupus Erythematosus Phase I We developed the world’s first stem cell therapeutic product for ALS Autologous Stem Cell CS10BR05 Multiple System Atrophy Phase I (Amyotrophic Lateral Sclerosis) name of NEURONATA-R, received the Allogenic Stem Cell HYNR-CS-Allo Amyotrophic Lateral Sclerosis IIT permission of medicines by Korea’s Ministry of Food and Drug Safety Autologous Stem Cell NEURONATA-R Anoxic Brain Injury IIT in July 2014 and began commercialized medication to patients in Representative February 2015. Cartilage-derived Precursors CS30MS02 Osteoarthritis Preclinical Kyung Suk Kim CORESTEM, a global stem cell biotechnology company, leads the Headquarter Address market in meeting patient expectations beyond national, ethical 24, Pangyo-ro 255beon-gil, Bundang-gu, and economic limitations through ongoing research into incurable Seongnam-si, Gyeonggi-do, Korea diseases. Foundation Date 2003. Research Focus Personalized stem cell therapy for incurable diseases Total Staff 52 persons Representative Phone 82-2-497-3711 Web http://corestem.com/en/ Contact Person Yon Hui Sarah Kim Contact Phone 82-70-4707-3544 Contact E-mail Financial Figures [email protected] Summary (1 Million Won) Fiscal Year 2015 2016 2017 (~Sep.) Sales 18,571 17,953 50,037 R&D Expenditure 740 2,003 1,530 Capital 67,092 77,761 83,096

32 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 33 Main Products CTCBIO, Inc Product (Ingredient) Use Exporting Countries Lebanon, Iraque, 1. Sildenafil treatment of erectile dysfunction Taiwan, Japan etc.

Company Profile R&D Pipeline

CTCBIO is a Korean pharmaceutical company which holds top 50 Compound Name Code Use Stage of Development domestic pharmaceutical companies as solid clients and is involved in co-operative partnership with international pharmaceutical Donepezil free base CDFF0212 Treatment of Alzheimer's disease NDA applied companies. Its pharmaceutical business covers development and bioequivalence test / Treatment of primary enuresis, nocturnal production of super-generics with drug formulation and delivery Desmopressin CDFF0612 review of specification and enuresis technology. We are specialized in micro-encapsulation using fluid bed test method completed and OSF formulation. CTCBIO is capable of manufacturing various Entecavir CDFF0511 Treatment of chronic hepatitis B virus NDA applied types of oral dosage forms and has business capabilities starting from Representative 20mg: approved formulation development and all the way to commercial production. Tadalafil CDFF0213 Treatment of erectile dysfunction Ho Yeon Cho 5mg, 10mg : NDA applied Headquarter Address Clomipramine/sildenafil CDFR0812 Treatment of premature ejaculation IND (phase II) applied 13, 40-gil, Jungdae-ro, Songpa-gu, Seoul, Treatment of duodenal and gastric ulcer, Rep. of Korea omeprazole/sodium hydrogen caronate CDFR0209 GERD and symptoms of gastroesophageal NDA applied Foundation Date reflux disease June. 1993. eathartic for colonology and preoperatic sodium picosulfate etc. CDFR0613 Phase I Research Focus treatment Finished Formulations Total Staff 258 persons Representative Phone 82-1661-8800 Representative Fax 82-2-449-3886 Web www.ctcbio.com Contact Person Chae Young Ban Contact Phone 82-70-4033-0233 Financial Figures Contact E-mail Summary (1 Million Won) [email protected] Fiscal Year 2012 2013 2014 Sales 129,800 123,400 - R&D Expenditure 2,730 1,690 - Capital 125,400 150,500 -

34 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 35 Main Products Daewoo Pharmaceutical Co., LTD Product (Ingredient) Use Exporting Countries Remarks 1. Original Relief Eye Drops OTC Relieves red, Irritated eyes USA (Tetrahydrozoline HCl 0.5mg/Ophthalmic Eye Drops) (USA OEM) 2. Advanced Relief Eye Drops Relieves red, Irritated eyes, OTC (Tetrahydrozoline HCl 0.5mg + Dextran 70 1mg + Polyethylene USA Hydrating moisturizer (USA OEM) glycol 400 10mg + Povidone 10 mg/Ophthalmic Eye Drops) 3. Hyalsan Eye Drops 1) Single-use disposable type 0.8 mL Keratoconjunctival epithelial (Sodium hyaluronate 0.8mg/Ophthalmic Eye Drops) Vietnam - Company Profile disorder 2) Multi-use type Since its founding in 1976, Daewoo Pharmaceutical has endeavored (Sodium hyaluronate 1mg/Ophthalmic Eye Drops) to promote the public health with 3 business principles-sincerity, 4. Tobeson Eye Drops Eye steroids, Antiallergics Vietnam - correctness, research. (Tobramycin 3mg, Dexamethason 1mg/Ophthalmic Eye Drops) 5. Taspen-ER Tablet Other Analgesics, We have focused on the business of ethical drugs in the past 30 - - years in Korea. With the business experience, Daewoo has effort on (Acetaminophen 650mg/Tablet, Extended Release) Antipyretics continuous research, development and investment about facilities 6. Eperisone Tablet (Eperisone HCl 50mg/Tablet) Skeletal muscle relaxants Vietnam, Thailand - and human resources. 7. Simvasterol Tablet (Simvastatin 20mg/Tablet) Antilipidemic agents - - Representative Now, Deawoo is preparing to become a global pharmaceutical 8. Pantezol Tablet Dr. Yong-Hoon Ji MD company with new-drugs pipline, particularly anti-angiogenesis and (Pantoprazole sodium sesquihydrate 45.1mg, as Pantoprazole H+ Pump inhibitors - - 40mg/Tablet) Headquarter Address anticancer drug for the next 10 years. We are investing for world 9. Pseudoephedrine Tablet 153 Dadae-ro, Saha-gu class product facilities to increase oversea business and accomplish Decongestants, Nasal prep - - (Pseudoephedrine HCl 30mg/Tablet) Busan, Republic of Korea R&D projects in Daewoo R&D institute. Daewoo has committed Contract Manufacturing Organization(CMO) business with sufficient 10. Romicin Tablet (Roxithromycin 150mg/Tablet) Macrolide antibiotics Vietnam - Foundation Date technical and marketing resources. April. 1976. Even in challenging internal and external enviroment, Daewoo will be Research Focus a competent global pharmaceutical company with recognized ability. R&D Pipeline Ophthalmic product formula modification Focus Area : Opthalmic Products / Cancer Drugs / Generic Drugs & customization, Development of Compound Name Code Use Stage of Development targeted cancer drugs with inhibition of Int. CL. angiogenesis : A61K 31/335 :A61K 35/74 Total Staff Rivaroxaban : C12P 7/62 :A61P 29/00 Anti-inflammatory Non-clinical 280 persons Application number : 10-2010-0029016 Representative Phone Int. CL. 82-51-204-3831 : A61K 31/335 :A61K 31/335 Macrolactin A and its : A61P 19/02 :A61P 19/00 Anti-angiogenesis Non-clinical Representative Fax derivatives 82-51-202-3397 Application number : 10-2011-0012707 Web Int. CL. http://www.daewoopharm.co.kr The prevention : A61K 31/335 :A61K 31/365 or treatment of Macrolactin Compounds : A61P 1/00 :A61P 29/00 Non-clinical Contact Person inflammatory Financial Figures Application number Ji-Hoon Suh bowel disease : 10-2012-0011924 Contact Phone Summary (1 Million Won) Int. CL. 82-2-3477-1731 Fiscal Year 2012 2013 2014 : A61K 31/335 :A61K 31/365 Contact E-mail Sales 36,025 41,479 46,448 Macrolactin Compounds : A61P 35/00 Anticancer Drug Non-clinical [email protected] R&D Expenditure 1,414 1,547 1,180 Application number Capital 24,141 27,205 24,246 : 10-2013-0089955

36 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 37 Main Products Daebong LS Co., Ltd Product (Ingredient) Use Exporting Countries Remarks 1. Erdosteine Expoctorant - API 2. Olmesatan medoxomil Hypotensive Agent - API 3. Valsatan Hypotensive Agent - API

Mexico,Latin America 4. Amlodipine besylate Hypotensive Agent API and the Caribbean Company Profile Daebong LS specializes in pharmaceutical raw materials and cosmetics and is committed to our mission to be “a company that providesthe best solutions to enable people to live healthier and R&D Pipeline more beautiful lives” Through our “Total Solutions for Human Better- Compound Name CAS No Use Stage of Development Being”, we work to improve the Quality of Life (QoL) for all human beings. Rivaroxaban 366789-02-8 Pilot scale process development Anticoglurant We develop the API of major anti-aging, respiratory, hypertension and Apixaban 503612-47-3 Lab scale process development

Representative digestive-system treatments and medicines and supply excipients Sitagliptin phosphate · H2O 654771-77-9 Pilot scale process development to domestic companies as an agent for global companies. We are Jin Oh Park Vildagliptin 274901-16-5 Antidiabetics Pilot scale process development also able to meet the demands of our customers as we provide a Headquarter Address Total Service by supplying the pharmaceutical technologies we have Linagliptin 668270-12-0 Lab scale process development 123, Neungheodae-ro 649 beon-gil developed through our collaboration with top Formulation ventures to Sarpogrelate HCl 135159-51-2 Lab scale process development Namdong-gu, Incheon, Korea our client companies. Antithrombotic Cilostazol 73963-72-1 antiplatelet Lab scale process development Foundation Date Focus Area : Erdosteine, Olmesatan medoxomil, Valsatan, Amlodipine 1986. besylate Acetyl L-carnitine HCl 5080-50-2 Amino Lab scale process development Research Focus L-carnitine 541-15-1 Acids Derivatives Lab scale process development API Rosuvastatine Ca 147098-20-2 Antiarteriosclerotic Lab scale process development Total Staff Etoricoxib 202409-33-4 NSAIDs Lab scale process development 120 persons Tobramycin sulfate 49842-07-1 Antibiotics Lab scale process development Representative Phone 82-32-712-8800 Choline fenofibrate 856676-23-8 Dyslipidemia Plant scale process development Linoleamide Seriol - Pseudo Ceramide Lab scale process development Representative Fax 82-32-817-8808 Linoleneamide Serinol - Pseudo Ceramide Lab scale process development Web Cetyl ethylhexanoate 59130-69-7 Emollient Lab scale process development www.daebongls.co.kr Pentaerythritol 7299-99-2 Emollient Lab scale process development Contact Person tetra(2-ethylhexanoate) Hyun Cheol Kim Hydrogenated Natural Oil - Skin Conditioning Lab scale process development Contact Phone 82-32-712-8884 Financial Figures Contact E-mail Summary (1 Million Won) [email protected] New Active Substances Fiscal Year 2014 2015 2016 Sales 47,696 53,414 63,362 Product (Ingredient) Use Approval Date R&D Expenditure 1,524 1,856 2,422 Launched in 4Q Pro Multi White Cysteine Whitening/Antiinflammatory Agents Capital 5,543 5,543 5,543 2015(Korea)

38 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 39 Main Products DAE HWA PHARMACEUTICAL CO., LTD. Product (Ingredient) Use Exporting Countries Remarks New 1. Liporaxel solution (paclitaxel 10mg/mL) Gastric cancer - formulation as oral solution Relieve of 2. PROTASE Tab. Myanmar, Vietnam, inflammatory - (Bromelain 40mg, Crystallized Trypsin 1mg) Cambodia symptoms 3. Top-Roll Soft capsules Tonic, nutritive Myanmar, Cambodia, - Company Profile (Korea Ginseng 100mg with multivitamins) supplement Bolivia, Ghana and others 4. ALMETAMIN Tab. Acute rash, allergic DAEHWA Pharmaceutical Co., Ltd., was established in the spirit of “contribute Ethiopia, Cambodia - to society by providing a more human-centered pharmaceutical business.” Its (Betamethasone 0.25mg, Dexchlorpheniramine maleate 2mg) rhinitis Vietnam, Bolivia, main goal is to improve National health and people’s life. 5. DEMACOT Cream (Batamethasone dipropionate 0.64mg, Allergic dermatitis Cambodia, Ghana, - Clotrimazole 10mg, Gentamicin sulfate 1.0mg) Since its foundation in 1984, DAEHWA continuously seeks new paths for its Mongolia business development with a consistent progress-oriented core-target. Relief of symptoms of Bolivia, Cambodia, 6. KEBANON Plaster (Ketoprofen 30mg) - With its own platform technologies, DAEHWA produces APIs and finished muscular pain Hongkong, Vietnam products. Some of them are: Cephametyl, which is ranked third in the oral Relief of symptoms of 7. LOXONA Plaster (Loxoprofen 56.7mg) Cambodia, Hongkong - Representative cephalosporin antibiotic market; Flospan, ranked first in the antispasmodic muscular pain Eun-Seok, Kim market; and Liporaxel Solution, which is the result of DAEHWA’s 17 year- Respiratory distress study and which achieved astonishing results proving its efficacy, safety caused by airway 8. RESNALIN Patch (Tulobuterol 0.5/1/2mg) Myanmar, China - Headquarter Address and convenience. DAEHWA’s DH-LASED technology created this first oral obstruction of 495, Hanu-ro, Hoengseong-eup, Paclitaxel anticancer drug in the world. bronchial asthma Hoengseong-gun, Gangwon-do, Republic DAEHWA also developed DH-HERBAL Technology specialized for elderly Treatment of chronic of Korea people, and represents the biggest unique CMO Company for transdermal 9. BARATIS ODF (Entecavir 0.5/1mg) hepatitis B virus - - infection Foundation Date drug delivery system (TDDS) product in Korea. Wrinkle Made in 1984.01.19 10. Amalian Filler (Hyaluronic acid) Worldwide DAEHWA invests more than 10% of its sales into R&D and focuses most improvement Germany Research Focus of its company resources into the development of QoL products. DAEHWA API, TDDS, Finished product, etc. currently exports more than 60 products to 20 countries in the world. DAEHWA runs a representative office in Vietnam, and took over Redoxbio Total Staff Inc. as well as a German cosmetics & medical device manufacturing and R&D Pipeline 350 persons distribution company. Consequently, DAEHWA has grown from a middle- Representative Phone sized Korean company into a global company specialized in pharmaceutical Compound Name Code Use Stage of Development 82-2-6716-1071 products. Breast cancer, Gastric cancer, Paclitaxel DHP107 Non-small cell lung cancer, Clinical Study Phase II & III Web Ovarian cancer www.dhpharm.co.kr Jujube extract DHP1401 Dementia Clinical Study Phase II Contact Person Han-Woong, Seo Ramosetron DHP26002 Antiemetics New formulation Contact Phone DHP23007 DHP23007 Antiviral agent New formulation 82-2-6716-1071 DHP32002 DHP32002 Rare disease Pre-Clinical Study Contact E-mail Financial Figures [email protected] Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 72,191 81,960 86,204 R&D Expenditure 3,710 5,074 5,470 Capital 30,960 30,960 30,960

40 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 41 Main Products DAEWON Pharm. Co., Ltd Product (Ingredient) Use Exporting Countries Remarks Anti-inflammatory, *12th Korean 1. Pelubi/Pelubi CR Tab. (Pelubiprofen 30/45 mg) analgesic(RA, OA, BP, Mongolia, Georgia New Drug Fever) Supplementation of Philippines, Nigeria, Export Over 2. Oramin Soft Capsule (Ginseng, Multi Vitamin) vitamins and minerals Myanmar, Iran, etc 30 Countries 3. Trigel Susp. Vietnam, Cambodia, Export Over High-potency antacid (Aluminum hydroxide gel, Magnesium, Oxethazaine) Taiwan, Peru, etc 10 Countries Company Profile Guatemala, Iran, Export Over 4. Megex-I Susp.(Megestrol acetate) Anorexia and cachexia Since the establishment in 1958 with a founding idea of “Realization of Colombia, Taiwan 10 Countries 5. Codaewon Tab. /Syrup (Dihydrocodeine, Guaifenesin, Potent Antitussives, Hongkong,Mongolia human health”, Daewon Pharm has produced reliable and safe medicines by - securing world-class manufacturing facilities and superior R&D capabilities. Methylephedrine, etc) Expectorants Cambodia We, Daewon Pharm is a capable company that has developed new drugs 6. Renamezin Cap.(Oral adsorptive charcoal) Renal failure Taiwan - using excellent technological basis and manufacturing facility. We are 7. Freefol MCT Inj. (Propofol Inj.) Anesthesia, sedation Ukraine, Syria, Georgia - devoting ourselves to develop numerous new products to improve the quality Taiwan, Guatemala, of life, and trying our best to become the representative pharmaceutical 8. Wontran ER Tab.(Acetaminophen, Tramadol) Pure analgesic *IND Drug company of the Republic of Korea. Hongkong Representative We, Daewon Pharm has developed Pelubi, Pelubi CR Tab. (pelubiprofen Seung Ho Baek, Seung Ryel Baek 30mg, 45mg), the first NSID-class antiphlogistic/analgesic drug in Korea. Hyangnam factory is a new GMP standard applied high-tech facility equipped Headquarter Address with excellent infrastructures, and manufactures internal solid dosage forms, Cheonhodaero 386, Sungdong-gu, Seoul, injections, sex hormone drugs, and other various products. Korea. R&D Pipeline Starting from sales expansion to Vietnam in 1994, we are currently exporting Foundation Date our products to China and 40 other countries in Asia, South America, Compound Name Code Use Stage of Development January 7, 1958. Middle-East, Africa, and further. By licensing-out new drugs, incrementally NCE DW-325 Hyperlipidemia - modified drugs, and high-value original drugs such as Pelubi Tab, Megex-I Research Focus Suspension(anti-cancer supplement), and Privituss Suspension(antitussive) to NCE BAL-110 Prostate, Cervical Cancer - DDS Research, New Drug Chronic large pharmaceutical markets like China, Daewon Pharm is preparing another diseases, Improving dosage forms rapid growth. We are also moving forward to export medical devices such as NCE DW-4301 Hyperlipidemia - hearing aids. Total Staff BIO (TERROSA™) Osteoporosis - Delight, a subsidiary company specialized in hearing aid business, produces 870 persons IMD DW-1404 RHINITIS - hearing aids using 3D scanner and patented technology called 'standarized Representative Phone hearing aid.' We provide worldwide customers high performance hearing IMD DW-1501 Hypertension/Hyperlipidemia - 82-2-2204-7000 aids with reasonable price, delivering joy and happiness of hearing. IMD DW-1502 Neuropathic Pain - Representative Fax Focus Area : Ethical Drug, Over-the-Counter Drug, Contract Manufacturing, Medical Instrument IMD DW-1601 Acute Bronchitis - 82-2-499-9110 IMD DW-1606 Osteoporosis - Web www.daewonpharm.com Contact Person Junggun Park Contact Phone Financial Figures 82-2-2204-7086 Summary (1 Million Won) Contact E-mail New Active Substances Fiscal Year 2015 2016 2017(E) [email protected] Sales 216,187 240,722 270,000 Product (Ingredient) Use Approval Date R&D Expenditure 16,713 18,978 20,000 Anti-inflammatory, analgesic Pelubi/Pelubi CR Tab. (Pelubiprofen 30/45 mg) - Capital 194,749 214,682 230,426 (RA, OA, BP, Fever)

42 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 43 Main Products Daewoong Pharmaceutical Co., Ltd. Product (Ingredient) Use Exporting Countries Australia, Canada, CIS 12 countries, EU 28 countries, Hong Kong, Macao, Glabellar lines, Post stroke, 1. Nabota (Botulinum toxin type A / Injectable) LATAM 15countries, Macao, Middle East Upper limb spasticity 10 countries, Philippines, South Africa, Taiwan, Thailand, Turkey, USA, Vietnam Chile, Columbia, Hong Kong, Dental sinus lifting, 2. Novosis (rhBMP-2 / Lyophilized Powder) Indonesia, Malaysia, Peru, Company Profile Spinal fusion Philippines, Thailand, Vietnam Daewoong Pharmaceutical was established in 1945 and has Diabetic foot ulcer, Algeria, Armenia, Azerbaijan, Egypt, become one of the leading pharmaceutical companies in Korea with 3. Easyef (rhEGF / Topical Solution, Ointment) Oral mucositis, Georgia, Iraq, Jordan, Russia, Syria, approximately 800 million USD in annual revenues. Acute wound healing Turkey, Uruguay As it is our vision to become a global healthcare group, Daewoong Belarus, Ecuador, Georgia, Hong Kong, 4. Caretropin (Somatropin /Injectable) Growth hormone deficiency Pharmaceutical has established 3 manufacturing sites in Indonesia Iran, Kazakhstan, Peru, Ukraine, Uruguay and China and 8 branch offices in China, Japan, Indonesia, Thailand, Algeria, Azerbaijan, Georgia, Indonesia, Anemia in end stage renal Vietnam, Philippines, India and USA. Thus, we are actively striving to 5. Eposis (rhEPO / Injectable) Iraq, Kazakhstan, Mongolia, Sri Lanka, diseases Representative export our high value added portfolio to the world. Syria, Thailand, Turkey, Vietnam Jongwook Lee As it is our mission to provide the most beneficial total solutions in Concomitant hypertension 6. Olostar (Olmesartan, Rosuvastatin / Tablet) Australia, Canada, Japan, Taiwan, USA Headquarter Address pharmaceuticals and services that contribute to improving the quality and dyslipidemia of life of valued consumers, we have been reinforcing R&D capacities 12, Bongeunsa-ro 114-gil, Gangnam-gu, Azerbaijan, China, Georgia, Iraq, Jordan, through the establishment of R&D centers globally in Korea, China, Liver & bile disease including Seoul, Republic of Korea 7. Ursa (Ursodeoxycholic acid / Tablet, Capsule) Kazakhstan, Malaysia, Mongolia, cholestasis, Gallstone, etc. India and Indonesia and focusing on developing new chemical Philippines, Ukraine, Uruguay, Vietnam Foundation Date entities, biologics, incrementally modified drugs and high-value 1945. Gastric & duodenal ulcer, added APIs. Our most recent R&D achievements include the initiation 8. Albis (Ranitidine, Bismuth, Sucralfate / Tablet) Azerbaijan, Ecuador, Georgia, Vietnam Gastritis Research Focus of Phase II trials for our reversible acid pump antagonist, DWP14012, an NCE expected to become the best in its class based on its potent Prostate cancer, GI, CV, Neuroscience & Pain, Fibrotic 9. Luphere depot acid suppressive effect. Furthermore, we foresee great potential for Endometriosis, Japan, Malaysia, Myanmar, Russia Disease, Immuno-Oncology, Autoimmune (Leuprorelin Acetate / Injectable) Disease DWP17011, a PRS inhibiting anti-fibrosis NCE that has demonstrated Precocious puberty both anti-fibrotic and anti-inflammatory effects with a novel MOA, Complicated skin and skin Total Staff which have been demonstrated in the pre-clinical studies that have structure infections, 1,600 persons been conducted. 10. Meropenem (Meropenem / Injectable) Complicated intra-abdominal USA Representative Phone infections, 82-2-550-8800 Bacterial meningitis Web www.daewoong.com R&D Pipeline Contact Person Doyoung (Brian) Kim Compound Name Code Use Stage of Development APA (Reversible) DWP14012 Gastrointestinal Disease Phase II Contact Phone 82-2-550-8112 SGLT-2 inhibitor DWP16001 Diabetes Phase I Financial Figures Contact E-mail PRS Inhibitor DWP17011 Fibrotic disease Pre-clinical [email protected] Summary (1 Million Won) Ion channel blocker DWJ208 Neuropathic pain, cancer pain Pre-clinical Fiscal Year 2015 2016 2017 Dual Target Inhibitor DWJ212, 213 Autoimmune disease (RA) Research Sales 800,517 797,010 861,500 R&D Expenditure 99,924 107,993 92,000 Long acting insulin DWP457 Diabetes Research Capital 492,694 517,660 563,642 Undisclosed Protein DWJ815 Osteoarthritis Research

44 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 45 Main Products DAI HAN PHARM. CO., LTD. Product (Ingredient) Use Exporting Countries Myelography, angiography, urography, Computerized- Vietnam, Costa Rica, 1. Iohexol Inj. 300 (Iohexol 300mg/50mL) tomography(CT)-contrast enhancement Philippines Myelography, angiography, urography, Computerized- 2. Iohexol Inj. 350 (Iohexol 350mg/50mL) Vietnam tomography(CT)-contrast enhancement 3. Luminal 10% Inj. Sedation (if urgently required), epilepsy and status Vietnam (Phenobarbital sodium 100mg/ml) epilepticus pneumonia, acute pyelonephritis, multiple urinary tract Company Profile 4. Lefquin Infusion (Levofloxacin 500mg) infection, acute sinusitis, infection of skin and tissue, Philippines, Vietnam DAI HAN PHARM. Co., Ltd. makes Good Pharmaceutical Products in etc. the GMP plant, We make Infusions (Bag, Glass bottles), Injections 1. Anesthesia: epidural anesthesia, nerve block, Hong Kong, Philippines, (PE, PP Ampoules), Solutions for external use and Contrast Media 5. Lidocaine HCL 2% (Lidocaine HCL 2%) infiltration anesthesia and surface anesthesia. Myanmar, Mongolia, products. We have exported the product since 2005. 2. Internal medical use: ventricular arrhythmia. Costa Rica Supply of vitamins and prophylaxis of deficiency of Cambodia, Vietnam, 6. Pan-B-Comp Inj. (Vitamin B complex) Focus Area : Infusion, Injection, Contrast Media, and Solutions for vitamin B series Philippines external uses. 1.Prophylaxia and treatment of hemorrhage disease for Iran, Vietnam, 7. Vitamin K1 Inj. (Phytonadione 10mg/ml) a newborn Philippines, Myanmar Representative 2.Hypoprothrombinemia 8. Orni Inj. Vietnam, Azerbaijan, Yoonwoo Lee Hepatic coma, Treatment of precoma (L-Ornithin L-Aspartate 500mg/1ml) Uzbekistan, Mongolia Headquarter Address 9. Heparogen Inj. Detoxication of liver disease(hepatitis and sequela, Vietnam, Azerbaijan, 3 Seonyu-ro 45-Gil Yeongdeungpo-gu (L-Ornithin L-Aspartate 100mg/1ml) tissue damage, hepatic cirrhosis) Mongolia Seoul Hemorrhage(by leukimia, aplastic anemia, purpura, 10. Tranexamin Inj. 500mg Vietnam, Philippines, cancer, pulmonary hemorrhage, renal hemorrhage, Foundation Date (Tranexamic acid 500mg/5ml) Myanmar Oct. 14, 1945. genital bleeding, etc.) Treatment and prophylaxis of vitamin B6 deficiency 11. Bidoxin inj. (Pyridoxine HCl 100mg/ml) Costa Rica, Mongolia Research Focus symptom Injections and Infusions 12. Ketorolac Inj. Severe pain Philippines, Panama Total Staff (Ketorolac tromethamine 30mg/mL) 13. Sod. Bicarbonate Inj. Iraq, Philippines, 621 persons Acidosis, Acute pruritus (Sod. Bicarbonate 8.4%) Costa Rica Representative Phone Rheumatic arthritis, osteoarthritis, 14. Piroxicam Inj. (Piroxicam 20mg/ml) Vietnam 82-2-2678-8445 ankylosing spondylitis etc. Disturbance of consciousness by head trauma and Representative Fax 15. Statirin Inj. (Citicoline 500mg/2ml) Vietnam, Myanmar 82-2-2671-9636 surgery of brain etc. Respiratory tract, ENT infections, renal or urinary tract 16. Ciprofloxacin Inj. Web infections, genital infection including gonorrhoea, GI Philippines (Ciprofloxacin 2mg/mL) www.daihan.com infections, bone or joint infections, etc. Contact Person Supply of amino acids in following cases George Kim 17. Aminohex Inj. (Aminoacid Infusion) (Hypoproteinemia, hypoalimentation, and before/after Vietnam, Mongolia surgery) Contact Phone Supply of amino acids in following cases 82-2-2620-8952 Financial Figures 18. Amicomplex Inj. (Aminoacid Infusion) (Hypoproteinemia, hypoalimentation, and before/after Mongolia surgery) Contact E-mail Summary (1 Million Won) [email protected] Improvement of encephalopathy due to acute/chronic Fiscal Year 2015 2016 2017 19. Hepavia Inj. (Aminoacid Infusion) hepatic impairment, supply of amino acids to a patient Vietnam, Mongolia Sales 124,276 139,437 150,000 with hepatic impairment Relief of bronchial asthmatic paroxysm, symptoms by Costa Rica, Philippines, R&D Expenditure - - - 20. Epinephrine Inj. (Epinephrine 1mg/ml) serum disease, hives and angioneurotic edema. Mongolia Capital - - -

46 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 47 Main Products Daiichi Sankyo Korea Product (Ingredient) Use Exporting Countries 1. Olmetec (Olmesartan) Anti Hypertension Imported

2. Olmetec plus (Omesartan + Hydrothiazide) Anti Hypertension Imported

3. Mevalotin (Pravastatin) Anti dislipidemia Imported

4. Sevikar (Olmesartan+amlodipine) Anti Hypertension Imported

Company Profile 5. Cravit (Levofloxacin) Antibiotics Imported

Daiichi Sankyo Korea.,Ltd. is the Korean subsidiary of Daiichi Sankyo 6. Sunrythm (Pilsicainide HCI) Antiarrhythmic agent Imported Japan, a global Pharmaceutical enterprise. Consolidation of the Daiichi Pharmaceuticals Co.,Ltd. and Sankyo Co. Ltd., gave birth to 7. Effient (Prasugrel) Antiplatelet agent Imported Daiichi Sankyo Korea Co.,Ltd. in April 2007, which since its launch has expanded its domain of expertise from anti-inflammatory area to cardiovascular area. Daiichi Sankyo Korea offers a fluoroquinolone antibacterial agent named Cravit, an anti-hypertension agent Olmetec and sevikar as well as an anti-dyslipidemia agent Mevalotin. The Representative company will continue to make strides forward to secure a leading Mr. Dae Jung Kim / CEO status in the pharmaceutical industry by leveraging and further Headquarter Address diversifying its product offerings. Posco Center west wing 3rd floor, Daiichi Sankyo Daechi4-dong 892, Kangnam gu. Seoul The Daiichi Sankyo Group is dedicated to the creation and supply of Foundation Date innovative pharmaceutical products to address the diversified, unmet July 16, 1990. medical needs of patients in both mature and emerging market. Total Staff While maintaining its portfolio of marketed pharmaceuticals for 122 persons hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders Representative Phone and focused on the discovery of novel oncology and cardiovascular- 82-2-3453-3300 metabloic therapies. Furthermore, the Daiichi Sankyo Group has Representative Fax created a "Hybrid Business Model" which will respond to market and 82-2-3452-9756 customer diversity and growth opportunities across the value chain. For more information, please www.daiichisankyo.com Web www.daiichisankyo.co.kr

Financial Figures

Summary (1 Million Won) Fiscal Year 2008 2009 2010 Sales 36,300 50,200 56,700 R&D Expenditure - - - Capital - - -

48 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 49 Main Products Dalim BioTech Co., Ltd. Product (Ingredient) Use Exporting Countries Remark 1. Metformin hydrochloride 500mg Azerbaijan, World 1st combination of Oral hypo-glycemics + Gliclazide 80mg Tab Uzbekistan Metformin HCl + Gliclazide

2. Repaglinide 0.5mg/1mg/2mg Tab Oral hypo-glycemics - World 1st generics

3. Repaglinide 1mg/2mg Oral hypo-glycemics - World 1st generics Company Profile + Metformin HCl 500mg Tab 4. Norepinephrine bitartrate 2mg/1ml Amp Acute hypotension, Dalim Biotech is a family company of Dalim Corporation Co., Ltd, Thailand - started to produce the medicines at first hand that were released (Norepinephrine 4mg/10mg/20mg) Shock by importation or production partnership after it was established in 5. Conjugated equine estrogens Postmenopausal - World 1st generics 2001, and concentrated on the area of endocrinology led by diabetes 0.3/0.625mg Tab syndrome to affirm its position as the best company specializing in the area of diabetes despite a short time. Moreover, it came to produce and Postmenopausal 6. Tibolone 2.5mg Tab - apply hormone preparations at first hand which have depended syndrome on importation only by completing the construction of building to Produced by Dalim BioTech’s 7. Desogestrel 0.15mg Representative exclusively produce sex hormone site in 2006. Contraceptive - facility (Dedicated sex + Ethinyl Estradiol 0.02mg Tab Jong sup Chung hormonal premiss) Headquarter Address Emergency 8. Levonorgestrel 1.5mg Tab - 107, Jeyakgongdan 3-gil, Hyangnam-eup, contraceptive Hwasung-si, Gyeonggi-do, Korea, Solely produced by Dalim 9.Carbimazole 5/10mg Tab Hyperthyroidism - Foundation Date BioTech in Korea 2001. 10.Cholecalciferol concentrate powder 10mg Research Focus Tab.(Cholecalciferol 1,000IU) Highest strength of Vitamin D Endocrinology(Diabetes, Thyroid, Sex Cholecalciferol concentrate powder 70mg Vitamin D deficiency - (Cholecalciferol 30,000IU) in Tab (Cholecalciferol 7,000IU) hormone), Vitamin D Korea (Finished Pharmaceutical Products) Cholecalciferol concentrate powder 300mg Tab (Cholecalciferol 30,000IU) Total Staff 200 persons Diabetic neuropathy, 11. Evening primrose oil 450mg Soft cap. Atopic eczema, - Developed 1st in the world ( -linolenic acid 40mg) Representative Phone Breast pain 82-2-3140-3787 Web www.dalimpharm.co.kr Contact Person Mr. Mark Choi Contact Phone 82-2-3140-3787 Financial Figures Contact E-mail [email protected] Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 29,345,548 31,469,565 35,00,000 R&D Expenditure 1,746,84 1,416,375 2,000,000 Capital 500,000 500,000 500,000

50 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 51 Main Products DHP KOREA CO.,LTD. Product (Ingredient) Use Remarks · Preservative-free, 30 Single Dose 1. Tearinfree EYE DROPS Keratoconjuntival epithelial disorder with Units per Box (Sodium Hyaluronate 0.1%) symptoms following : · 6 mL Multi Dose Bottle 1. Endogenous disease: Sjogren syndrome, 2. TearinS EYE DROPS Dry eye syndrome. · Preservative-free, 30 Single Dose (Sodium Hyaluronate 0.18%) 2. Enthetic disease: Drug-induced trauma Units per Box after operation, Enthetic disease due to Company Profile 3. TearinF EYE DROPS wearing contact lenses. · Preservative-free, 30 Single Dose (Sodium Hyaluronate 0.3%) Units per Box DHP KOREA was created for the purpose of being an special company in the field of ophthalmic drugs. As the leading ophthalmic · For the temporary relief of burning, irritation, and discomfort due to dryness of drugs company in Korea, DHP KOREA seeks to be a world-class that 4. Dr.Fresh EYE DROPS · Preservative-free, 30 Single Dose the eye or exposure to wind or sun. continuously tries to meet customer’s need by offering safe and (Sodium Carboxymethylcellulose 0.5%) Units per Box stable drugs. Also, we make constantly effort to comfort demand · May be used as a protectant against further irritation. of various customers, through ceaseless produce and offer more developed products. · For the increase tear production in patients whose tear production is presumed to be · Preservative-free, 30 Single Dose Focus Area : Ophthalmic Drugs 5. DryFree EYE DROPS (Cyclosporine 200ug) Representative suppressed due to ocular inflammation Units per Box Yoeu Daehoon associated with keratoconjunctivitis sicca. Headquarter Address · Open angle glaucoma 1106 starvalley, 99, Digital-ro 9-gil, . For the reduction of elevated intraocular 6. Tearsopt Free EYE DROPS (Dorzolamide · Preservative-free, 10 Single Dose Geumcheon-gu, Seoul, Korea pressure in patients with open-angle HCl 22.26mg Timolol Maleate 6.83mg) Units per Box Foundation Date glaucoma or ocular hypertension who are August. 30, 2005. insufficiently responsive to beta-blocker. · Preservative-free, 10 Single Dose Research Focus 7. Floson EYE DROPS (Fluorometholone 1mg) . To treat eye inflammation Ophthalmic Drugs (Dry eye, Anti- Units per Box glaucoma, Anti-allergy/inflammatory/ . For the allergic, noninfectious conjunctivitis infective, etc) & keratitis, severe swelling & hyperaemia, Total Staff noninfectious inflammation of the anterior 110 persons 8. Flotera EYE DROPS (Fluorometholone segment of the eye (including anterior · Preservative-free, 10 Single Dose 1mg, Tetrahydrozoline HCl 250ug) uveitis, episcleritis & scleritis) and post- Units per Box Representative Phone operative conditions. 82-2-2027-0078 . Inflammation after operation (glaucoma, cataract) Representative Fax 82-2-2027-0079 . To treat by helping to kill the bacteria which 9. LevoFresh EYE DROPS (Levofloxacin 0.5%) · 6 mL Multi Dose Bottle are causing the infection. Web http://www.dhpkorea.co.kr · Tired Eyes · Preservative-free, 30 Single Dose 10. SmileO EYE DROPS (Sodium Chloride · Dryness Contact Person 2Tears Units per Box 5.5mg, Potassium Chloride 1.5mg) · Contact Lens Discomfort Ko Jin-Sook · 15 mL Multi Dose Bottle Financial Figures · Dimed Eyes Contact Phone Summary (1 Million Won) · Preservative-free, 10 Single Dose 82-43-230-0304 11. Allervid EYE DROPS · To treat itching associated with allergic Units per Box Fiscal Year 2012 2013 2014 (Olopatadine HCl 1.11mg) conjunctivitis. Contact E-mail · 6 mL Multi Dose Bottle [email protected] Sales 21,870 26,850 32,566 R&D Expenditure 181 245 342 12. KetofinFree EYE DROPS · To treat itching associated with allergic · Preservative-free, 30 Single Dose Capital 7,490 44,914 56,716 (Ketotifen Fumarate 552ug) conjunctivitis. Units per Box

52 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 53 Product (Ingredient) Use Remarks · Dryness 13. FINECLE EYE DROPS (Chondroitin · Redness DongKoo Bio&Pharma Co., Ltd. Sodium Sulfate 2mg, Cyanocobalamin · Gritty Feeling/Foreign Body Sensations 100ug , Dipotassium Glycyrrhizinate · Preservative-free, 30 Single Dose · Photophobia (sensitivity to light) 1.5mg, Naphazoline HCl 20ug, Units per Box · Itching Panthenol(pantothenol) 500ug, · Blear Eyes/Dimed Eye Pyridoxine HCl 500ug) · Hard Contact Lens Discomfort

14. one&day FRESH EYE DROPS · Tired Eyes (Chondroitin Sodium Sulfate 5mg, Hydr Company Profile · Dryness · Preservative-free, 30 Single Dose oxypropylmethylcellulose(hypromellose) · Hard Contact Lens Discomfort Units per Box Since 1970, DongKoo Bio&Pharma Co., Ltd. has been evolving into a 2910 3mg, Potassium Chloride 800ug, · Dimed Eyes Sodium Chloride 4.4mg) global healthcare leader. DongKoo Bio&Pharma, consolidated with world-class research centers and PIC/s fulfilled GMP facilities, is in 15. Eyemarine EYE DROPS vigor expanding its commercial territories to global markets in the (Aminocaproic acid 10mg, · Epidemic[contagious] Conjunctivitis a stye field of generic drugs and contract manufacturing. The company is · Preservative-free, 10 Single Dose Dipotassium Glycyrrhizinate 2mg, · Itching Units per Box also growing its influence in stem cell technology, developing world Sulfamethoxazole Sodium 40mg, · Blear Eyes/Dimed Eye 1st SVF extraction kit (SmartX) and stem cell conditioned media Taurine(aminoethylsulfonic acid) 2mg) cosmeceutical (CELL BLOOM). With synergy between bio technology Representative and pharmaceutical, DongKoo Bio&Pharma pursues a total healthcare 16. Predia EYE DROPS (Phenylephrine HCl · Mydriasis required treatment or · Preservative-free, 30 Single Dose Yong Joon, CHO 5mg, Tropicamide 5mg) Accommodative Units per Box solution that contributes in improving people’s quality of life. Headquarter Address B-14F, Mstate, 114, Beobwon-ro, Songpa- gu, Seoul, South Korea Foundation Date May 1st, 1970. R&D Pipeline Total Staff 217 persons Code Use Stage of Development Representative Phone DHPNP01 Dry Eye Plant scale process development 82-2-2684-5421

DHPNP02 Dry Eye Plant scale process development Web www.dongkoo.co.kr DHPNP03 Glaucoma Lab-scale process development Contact Person DHPNP04 Glaucoma Formulation development Ji-Yong, Park Contact Phone DHPNP05 Allergic conjunctivitis Formulation development 82-2-2684-5421 (Ext:387) DHPNP06 Cataract Formulation development Contact E-mail [email protected]

Financial Figures

Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 80,369 87,363 102,500 R&D Expenditure 3,929 4,116 6,125 Capital 2,409 3,414 3,811

54 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 55 Main Products Product (Ingredient) Use Exporting Countries Dongkook Pharmaceutical Co., Ltd. 1. Dermotasone MLE Cream Inflammation reacting to corticoide ASEAN (Mometasone Furoate1mg/g) 2. Uropa SR Tablet 0.2 mg| BPH ASEAN (Tamsulosin HCl 0.2mg) 3. Heparos Soft Capsule Hepatic function supplement ASEAN (L-cystine 250mg, Choline Bitartrate 250mg) Company Profile 4. Cernilton Tablet BPH, CP/CPPS ASEAN (Cernitin T60 60mg, Cernitin GBX 3mg) Dongkook Pharmaceutical was founded in 1968 and from the early stage since its foundation, Dongkook has concentrated on R&D and 5. A-Clo Cream Herpes Labialis ASEAN technology innovation. (Acyclovir 50mg, Hydrocortisone 10mg) We, Dongkook Pharmaceutical is well known for its OTC products 6. A.C. Cure MLE Gel Acne ASEAN (Benzoyl Peroxide 33.3mg/g, Adapalene 1mg/g) boasting of high brand values in Korea. Besides OTC products, Dongkook has developed and produced outstanding therapeutic 7. Amepox Soft Capsule (L-Cystine 500mg) Acne ASEAN products through various clinical trials, e.g. Pofol Injection, 8. Betatriol Ointment Representative intravenous anesthetic agent, and Lorelin Depot, an anti-cancer (Betamethasone Dipropionate 0.643mg/g, Psoriasis ASEAN Hung Joo, Oh agent, earning raves in both domestic and overseas markets. Calcipotriol 50ug/g) Headquarter Address Dongkook completed its registration in PMDA of Japan regarding GMP approval and product registration for the finished product such 9. Priga Capsule (Pregabalin) Central, peripheral neuropathic pain ASEAN 7, Teheran-ro 108-gil, Gangnam-gu, Seoul, Korea as Antibiotic agent, and anesthetic agent. Teicoplanin acquired COS(Certificate of Suitability) in 2009 from EDQM, and also Lactation prevention and inhibition, 10. Caverlactin Tablet (Cabergoline 0.5mg) ASEAN Foundation Date completed the GMP approval in TGA of Australia in 2010. hyperprolactinemia Oct, 1968. Currently, Dongkook Pharmaceutical exports finished pharmaceutical Research Focus products and API to over 50 countries around the world. It seeks to Nano-emulsions, Long-acting release, grow into a global leading pharmaceutical company that is trusted Liposomal drug, HA dermal filler, and loved by all domestic and overseas customers backed by the Antibiotics, etc. R&D Pipeline greatest global competitiveness. Total Staff Focus Area : Nano-emulsions, Long-acting release, Liposomal drug, Compound Name Code Use Stage of Development 718 persons HA dermal filler, Antibiotics, etc. - DKB15001 BPH Completed non-clinical study Representative Phone 82-2-2191-9800 Omega3+ Atorvastatin DKB15003 Hyperlipidemia DDI Representative Fax 82-2-2191-9869 Web www.dkpharm.co.kr/english Contact Person Ms. Eugene Jang Financial Figures Contact Phone 82-2-2191-9800 Summary (1 Million Won) Fiscal Year 2016 2017 2018 Contact E-mail [email protected] Sales 304,408 323,496 356,829 R&D Expenditure 10,414 12,271 17,049 Capital 22,230 22,230 22,230

56 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 57 Main Products Product (Ingredient/Formulation)) Use Exporting Countries Dongkwang Pharm. Co., Ltd. Japan, Brazil, Uruguay, Russia, 1. Profofol Injection General Anaesthesia Georgia, Iran, UAE, Iraq, Philippines, Thailand, etc. Mexico, Peru, Uruguay, India, 2. Leuprolide Acetate Injection Prostatic Cancer Endometriosis Iran, Pakistan, Kazakhstan, etc. 3. Octreotide LAR lnjection Acromegaly Carcinoid Tumors Chile, Peru, etc. Injectable implant for filling wrinkles Peru, Mexico, Georgia, 4. Cross-linked Hyaluronic Acid Injection Company Profile and folds in skin Indonesia, Philippines, Syria, etc. Dongkwang has been contributing to advancement of pharmaceutical 5. Sodium Hyaluronate Injection Osteoarthiritis Under registration industry by developing pharmaceutical products for over the past 60 years Austrailia, Japan, Spain, France, since its establishment in 1952. We are always striving for 'Fulfillment of 6. Teicoplanin(API) Antibiotics UK, Begium, Brazil, Greece, Human Health and Human Happiness' with 3 ideas of its philosophy. Turkey, Tunisia, Ukraine, etc. One of the 3 ideas is, leading the pharmaceutical industry with a clear sense 7. Liposomal Amphotericin B Injection Antibiotics Ready to launch of duty. Dongkwang is committed to be the leading company based on the values of sincerity, passion and creativity. The second is, making efforts to realize a welfare society for the public. We 8. Daptomycin(API) Antibiotics Ready to launch Representative are constantly manufacturing high-quality medicines to make human life ByungGil Yoo healthy and happy with a sense of duty. Foundation Date Lastly, enabling the growth of individuals and the company with outstanding Sep. 1952 creativity. It means all members of the company maximize their abilities to contribute to not only growth of the company, but also national development. R&D Pipeline Research Focus Injectable production line With this philosophy, we have been investing in the production facilities and Compound Name Code Use Stage of Development focusing on the R&D to supply excellent pharmaceutical products for people. Total Staff And Dongkwang has various product line-ups, in total approximately 170 Daptomycin Injection DKF3152 Antibiotics Process validation 365 persons kinds of products. Moreover, we are exporting good-quality medicines to over 10 countries and fulfilling the values of Dongkwang around the world. Liposomal doxorubicin DKF3151 Ovarian cancer treatment Formulation Representative Phone 82-2-776-7641 Based on all these mentioned above, we will accomplish the vision of 'first or Donepezil Depot Injection DKF310 Alzheimer treatment Formulation best' and pioneer the future. Representative Fax Aripiprazole Depot Injection DKF002F Major tranquilizer Formulation 82-2-776-1204 Focus Area : Injectables production line * Equipped with prefilled syringe system Web Dutasteride + Tadalafil Combo DKF331 Protestitis treatment Formulation * Equipped with freeze-drying line www.dkpco.co.kr Nonsteroidal anti-inflammatory Risedronate + Vit D3 solution DKF335 Formulation Contact Person Ulcer treatment drug Junku Shim Long acting cross-linked Injectable implant for filling DKF352 Formulation Contact Phone hyaluronic acid injection wrinkles and folds in skin 82-2-776-7641 (ext.153) Contact E-mail [email protected] Financial Figures

Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 83,458 93,194 - R&D Expenditure 2,277 2,438 - Capital 15,000 15,000 -

58 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 59 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks DONGWHA PHARM 1. Aragan Injection (sodium hyaluronate 25mg/2.5mL) Pre-filled Osteoarthritis 6 countries syringe 2.Aragan Plus Injection (sodium hyaluronate 20mg/2mL)

Corticoid reactive skin 3. Silkron Cream disease where infection is (Betametasone dipropionate 0.64mg, 2 countries Ointment Company Profile concerned, bacterial or fungal Clotrimazole 10mg, Gentamycin sulfate 1mg) infection DONGWHA PHARM, as Korea’s first and oldest pharmaceutical company, is pursuing the ultimate goal of pharmaceutical industry, which is the development of new drugs. Whal Myung Su, Korea’s first western-style medicine, by integrating the advantages of Western medicine into the royal court’s secret recipe in 1897, the first year of The Great Korean Empire. Furthermore, many pharmaceutical products such as Fucidin ointment Foundation Date and Pancold A etc., have been developed after DONGWHA PHARM. 1897.09.25 Research Institute was founded in 1973. Since present state-of-the- art laboratory building was built in 2010, it is now set to become a Research Focus global hub for new drug development. The DONGWHA Chungju Plant Antibiotic, Cancer, New Herbal Drug (established in 2009) is equipped with equipment and facilities that Total Staff satisfy Current Good Manufacturing Practice (cGMP) Regulations of 687 US F. D. A. In addition, the plant has been evaluated as a world- class pharmaceutical company by the installment of high-tech plant Representative Phone automation system. Utilizing multi-component resources, DONGWHA 82-2-2021-9300 strategizes to develop numerous superior medicines, the most Web advanced drugs and new pharmaceutical products. http://www.dong-wha.co.kr Contact Person Yoon Kyung Kim, Director, Global Business Team Contact Phone 82-2-2021-9341 Contact E-mail [email protected]

Financial Figures

Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 223,201 237,470 257,200 R&D Expenditure 13,329 13,717 14,000 Capital 27,931 27,931 27,931

60 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 61 Main Products Product (Ingredient/Formulation) Use Exporting Countries Dong-A ST(Science & Technology) Japan, Indonesia, Mexico, 1. Ambroxol Hydrochloride API Philippines 2. Pantoprazol Sodium Sesquihydrate API Portugal, Indonesia 3. Levosulpiride API Spain 4. Whal Myung Su Alimentary System USA, Mongolia 5. M-Cobal 500 90C (mecobalamin/Capsule) peripheral neuropathy Vietnam Company Profile The relief of common cold Dong-A ST focuses on drugs, such as domestically developed new 6. Pan Cold-S(Oral Solution) Mongolia, Cambodia symptoms drugs like Stillen, Zydena, and Motilitone, medical devices, diagnosis, and overseas businesses. 7. Silmazin1%Cream (silver sulfadiazine) burn, bedsore, skin ulcers Mongolia With its optimized research infrastructures such as its world-class, sophisticated research center completed in 2011, as well as its excellent researchers, Dong-A ST is furthering its efforts to develop global new drugs. Also, with the backing of these infrastructures, R&D Pipeline Representative Dong-A ST vows to positively explore overseas markets, to expand its overseas exports, and to establish itself as a global pharmaceutical Ingredient Code Use Stage of Development Chan-il Park 0company, operating beyond the domestic market. Zabofloxacin Acute Exacerbations of Chronic Launched in Korea. Headquarter Address DW224 (Quinolones Antibiotics) Obstructive Pulmonary Disease Signed Agreement in MENA and China. 64, Cheonho-daero, Dongdaemun-gu, Focus Area : Manufacture of ETC drug, overseas business, medical Seoul, Korea equipments and diagnostics Zabofloxacin - Community acquired pneumonia Clinical preparation (Quinolones Antibiotics) Foundation Date DW1018 DW1018 breast cancer Phase I March. 2013 DW1017 DW1017 AML Candidate Research Focus New drugs DW2005 DW2005 Overactive bladder Preclinical completed Total Staff DW2007 DW2007 ulcerative colitis Phase II 1,582 persons (R&D Personnel : 212) DW2008 DW2008 asthma Preclinical completed Representative Phone DW6008 DW6008 pain Phase I 82-2-920-8114 DW6009 DW6009 antiplatelet Phase I Representative Fax 82-2-926-9400 DW6010 DW6010 dementia Phase I Web DW2009 DW2009 Mild cognitive impairment Clinical study http://en.donga-st.com DW2010 DW2009 Anti-Obesity Clinical study Contact Person Geunsung Kim Contact Phone 82-2-920-8366 Financial Figures Contact E-mail Summary ((1 Billion Won) New Active Substances [email protected] Fiscal Year 2012 2013 2014 Product (Ingredient) Use Approval Date Sales - 594.6 568.1 Acute Exacerbations of Chronic R&D Expenditure - 525 627 Zabofloxacin 2015.03.20./Korea Obstructive Pulmonary Disease Capital - 925.7 1,077.9

62 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 63 Main Products Ingredient Code Use Stage of Development Ph II completed(Korea) Product (Ingredient/Formulation) Use Exporting Countries Remarks Herbal extract DA-9801 Diabetic neuropathy Ph II completed(USA) 1. Growtropin II ®inj/AQ/cartridge Brazil, Iran, Peru, Bio- Human growth hormone Herbal extract DA-9803 Alzheimer's disease Non-clinical(Korea) (somatropin/injection) Colombia, Mexico pharmaceutical Herbal extract DA-9805 Parkinson's disease Non-clinical(Korea) Turkey, Thailand, Bio- Recombinant Follicle Controlled Ovarian Hyper-stimulation 2. Eporon®inj./PFS (erythropoietin/injection) Renal anemia treatment Chile, vietnam, DA-3801 Launched(Korea) pharmaceutical Stimulating Hormone in Assisted Reproductive Technology Pakistan Recombinant Follicle Ovulation induction in anovulatory DA-3801 NDA submitted(Korea) 3. Atorvastatin Hyperlipidemia treatment Japan APIs Stimulating Hormone women Recombinant human DA-3803 Infertility Ph III completed(Korea) 4. Cycloserine Tuberculosis treatment India APIs Chorionic Gonadotropin PEG-G-CSF(Pegylated- 5. Terizidone Tuberculosis treatment South Africa APIs Granulocyte-Colony DA-3031 Neutropenia NDA approved(Korea) Stimulating Factor) 6. Closerin® (Cycloserine/Capsule) Tuberculosis treatment Europe Ethical drug G-CSF(Granulocyte-Colony- DA-3030 Diabetic neuropathy Ph II completed(Korea) Stimulating Factor) Brazil, Turkey, 7. Zydena® (Udenafil/Tablet) Erectile Dysfunction Russia, Malaysia, NCE Interferon- DA-3051 Multiple sclerosis Ph III planned(Brazil) India Trastuzumab biosimilar DMB-3111 Breast cancer Ph I completde(Japan) 8. Monotaxel®inj. Recombinant Factor Anti-Malignant tumor Drug EU approval Ethical drug DA-3808 Hemophilia A Non-clinical(Korea) (Docetaxel anhydrous/Injection) biosimilar Etanercept biosimila DMB-3853 Rheumatoid arthritis Non-clinical(Korea) 9. Bacchus® Energy Drink Cambodia - (Taurine, Royal Jelly and others/Drink) Adalimumab biosimilar DMB-3113 Rheumatoid arthritis Non-clinical completed(UK) Glyco-engineered DA-3880 Anemia of chronic renal failure Ph I completde(EU) Darbepoetin- biosimilar New anti-VEGF mAb DA-3131 Age-related macular degeneration Non-clinical completed(Korea) R&D Pipeline

Ingredient Code Use Stage of Development Launched(Korea) Udenafil DA-8159 Erectile Dysfunction Ready to NDA(USA) Udenafil DA-8159 Benign Prostatic Hyperplasia Ph II completed(USA) New Active Substances

Udenafil DA-8159 Pulmonary Arterial Hypertension Ph II (Korea) Product (Ingredient) Use Approval Date/Country Launched(USA) Tedizolid DA-7218 Infection: ABSSSI Zydena(Udenafil) Erectile Dysfunction Dec. 2005/Korea NDA approved (EU) Tedizolid DA-7218 Pneumonia: HA/VAP Ph III (Global) Jun. 2014/USA Sivextro(Tedizolid) Infection: ABSSSI Apr. 2015/Korea Evogliptin DA-1229 Type2 diabetes NDA submitted(Korea) 5-Hydroxytryptamine4 Irritable Bowel Syndrome- DA-6886 Ph I completde(Korea) agonist Constipation M3 receptor antagonist DA-8010 Overactive bladder Non-clinical(Korea) SARM(selective androgen DA-4210 Sarcopenia Non-clinical(Korea) receptor modulators) GPR119 agonist DA-1241 Type 2 diabetes Non-clinical(Korea) Launched(Korea) Herbal extract DA-9701 Functional dyspepsia Ph II planned(USA)

64 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 65 Main Products Dongsung Bio Pharm Product (Ingredient/Formulation) Use Exporting Countries 1. Dong Sung Cheong Ro Hwan (In 1 pill Creosote 44.4mg, Cyperus rhizome powdered 16.6mg, Dyspepsia, watery stool, U.S.A Coptidis rhizoma powder 22.2mg, Glycyrrhiza powder 22.2mg, vomiting and diarrhea Citrus unshii pericarpium 22.2mg)

2. Dong Sung Cheong Ro Hwan (Sugar Coated Tablet) Dyspepsia, watery stool, (In 1 tab. Creosote 22.5mg, Pulvis phellondendri corticis 33.75mg, U.S.A vomiting and diarrhea Company Profile Pulvis geranil herbae 25mg)

Company introduction Parodontopathy, 3. Teethrol (In 1 tab. Zea mays L. extract 35mg) U.S.A Gingivitis, Parodontosis Founded in 1957, Dongsung pharmaceutical has led 60 years to be a mid-size pharmaceutical. We have taken the lead for the 4. Teethran periodontal disease, modernization of pharmaceutical industry by establishing KGMP (In 1 cap. Tocopherol acetate 50% 10mg, Carbazochrome 2.0mg, pyorrhea alveolaris U.S.A factory and central research center with high end facility in Asan, Lysozyme chloride 30.0mg, Ascorbic acid coated 96% Type SC (erythema, swelling, Chungnam. We have international competitiveness by producing high 156.3mg ) hemorrhage, pus etc.) quality medical product through strict quality control and the high 5. Livermarine quality hair dye through accumulated new technology. chronic liver disease, fatty Representative (In 1 cap. Carduus marianus L. seeds extract 200mg, Calcium liver, liver cirrhosis, toxic liver U.S.A Lee Yang-Gu Company philosophy pantothenate 8mg, Cyanocobalamin 1.2 , Nicotinamide 12mg, disease Pyridoxine hydrochloride 4mg, Thiamine nitrate 4mg ) Headquarter Address 'Health from Nature', the health and beauty searched in the nature, 683, Dobong-ro, Dobong-gu, Seoul, means the realization of health and beauty through value discovery Improvement of muscle 6. EMG Republic of Korea from nature and coexistence with nature. spasm that runs out of U.S.A (In 1 cap. Tocopherol acetate 500mg, Magnesium oxide 250mg) magnesium Foundation Date Dongsung pharmaceutical are dedicating to nature friendly products November. 25,1957 development in the various fields of pharmaceuticals, cosmetics, Organic brain dysfunction Research Focus hair dye and photodynamic therapy under the corporate philosophy accompanying athymia OTC 'Health from Nature'. symptoms such as tinnitus, 7. GinKolin (In 1 cap. Ginko leaf extract 120mg) headzche, memory U.S.A We will realize the product which can contribute the national health Total Staff impairment, attention 342 persons with the vision orienting 100 years corporate and the material impairment, depression, founded in the nature as a future growth engine. vertigo Representative Phone Corporate motto 82-2-6911-3600 keratodermia tylodes Web Dongsung pharmaceutical makes harmony, sincerity and creativity palmaris progressive (housewife`s eczema), dongsung-pharm.com as corporate mottos which have been the foundation of corporate 8. You Green F (In 1g, Urea 250mg) U.S.A management by progressively succeeding them up to now from the keratodermia, ichthyosis, Contact Person company foundation. senile xeroderma, lichen Ji Sun Na pilaris, atopic dermatitis Contact Phone Construction feeling of eye, 82-2-6911-3673 9. Syan Bone defectiveness, (In 1 Cap. Retinol palmitate 2mg, Ergocalciferol 200IU, Copper Night blindness, U.S.A Contact E-mail Chlorophyll 0.3mg, Snake oil 296.7mg) Rickets prevention, [email protected] Financial Figures Vitamin A and D supplies

Summary (1 Million Won) Problems with the circulation Fiscal Year 2015 2016 2017 10. Vaso-Q of the blood : decreasing (In 1 cap. Crataegus oxyacantha fruit dried extract 50mg, Garlic of memory, enervation, and Sales 74,660 79,720 84,700 U.S.A oil 150mg, Ginkgo Biloba Leaf Extract 5mg, Melissa leaf extract concentration becomes R&D Expenditure 4,078 3,201 4,000 10mg ) worse, dizziness, chronicity Capital 124,116 125,386 126,000 tiredness

66 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 67 Main Products Elyson Pharmaceutical Co. Ltd. Product (Ingredient/Formulation) Use Exporting Countries Remarks 1. Niferon CR tablet 40mg (Nifedipine) Hypertension - -

2. Molsiton tablet 2mg/4mg (Molsidomine) Anti-anginal Drug - -

3. Oxiklorin tablet 100mg/150mg/200mg/300mg Rheumatoid arthritis, Malaria - - (Hydroxychloroquine sulfate) and malaria prophylaxis

Company Profile Hypertension, angina, Treatment of stable chronic 4. Conbloc tablet 1.25mg/2.5mg/5mg/10mg Elyson Pharm was founded in 2011 as thinking patient very first and heart failure with reduced - - (Bisoprolol fumarate) conducting research and development for improvement of national systolic left ventricular health and the quality of life. function

Elyson Pharm as a company specialized in cardiovascular disorders, 5. Nebistol tablet 2.5mg/5mg Essential Hypertension, - - strives to develop new global medicine by constant investment to (Nebivolol hydrochloride) Chronic heart failure R&D, and we do our best for national health with all of one heart of passion. Representative Eul Won Dhong Headquarter Address R&D Pipeline 2F Kyungpoong building, 18, Nonhyeon-ro Compound Name Code Use Stage of Development 64-gil, Gangnam-gu, Seoul, Korea Nebivolol+Rosuvastatin EL-1401 Hypertension+Hyperlipidemia phase III Foundation Date Oct. 2011 Research Focus Cardiovascular disease Total Staff 35 persons Representative Phone 82-2-6342-7001 Web www.elyson.co.kr Contact Person Jae Jin Jung Contact Phone 82-2-6342-7001 Contact E-mail [email protected] Financial Figures

Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 8,601 9,544 14,000 R&D Expenditure 689 870 900 Capital 1,000 1,000 1,000

68 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 69 GC Pharma

Company Profile GC Pharma (formerly known as Green Cross Corporation) is a 1995 China Growth biopharmaceutical company that delivers life-saving and life- sustaining protein therapeutics and vaccines. Headquartered in South GC China is established to support increased demand for albumin and future growth in China. Korea, GC Pharma is the largest plasma protein product manufacturer 2008 GreenGene Approved in Asia and has been dedicated to quality healthcare solutions more GreenGene, GC Pharma’s first recombinant factor VIII product for haemophilia A was granted marketing authorisation in than half a century. Green Cross Corporation updates its corporate Korea. brand as GC Pharma in early 2018. Green Cross Corporation remains the company's registered, legal name. 2012 Rare Treatment Option Representative Eun-Chul Huh 1971 Korea’s First Human Plasma Fractionation The KFDA granted marketing approval for HUNTERASE, the world’s second therapy for the treatment of Hunter syndrome. Headquarter Address GC Pharma is the first company in Korea to begin fractionating 2014 Another Flu Vaccine Milestone : Green Cross’s manufacturing site in Hwasun, Korea reaches 100 million doses of 107, Ihyeon-ro 30beon-gil, Giheung-gu, plasma proteins from human plasma on an industrial scale. cumulative GCFLU, flujab, production in only five years of operation. Yongin-si, Gyeonggi-do, Republic of Korea 1974 Pioneering Haematology 2015 Expanding Plasma Business Foundation Date GC Pharma starts to produce Antihaemophilic factor (AHF) and the To support global demand of plasma products, Green Cross establishes a manufacturing site in Thailand for the Thai Red 1967 resulting therapies are provided free to Korean patients. Cross. Research Focus 1982 First IV Immunoglobulin New Flu Vaccine Biological Products GC pharma launches IV-Globulin in Korea, the county’s first purifies GCFLU QUARDRIVALENT, the only locally produced seasonal influenza vaccine in Korea, achieves MFDS approval. Total Staff immunoglobulin product for intravenous infusion 2,000 persons 2017 Capacity for the Future 1983 Hepatitis B Triumph Representative Phone GC Pharma announces major global business expansion plans in Canada. A new biotech facility will help meet future 82-31-260-9300 After a 12 year research and development, GC Pharma launches demand for plasma-derived products. Hepatitis B vaccine, HEPAVAX. Web http://www.globalgreencross.com 1993 New Varicella Vaccine Introduced http://www.greencross.com SUDUVAX is introduced as the world’s second varicella vaccine Contact Person option. Byung Lim Lee Contact Phone 82-31-260-9300 / 0848 Contact E-mail Financial Figures [email protected] [email protected] Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 912,911 1,033,114 1,098,479 R&D Expenditure 92,509 101,893 96,814 Capital 58,433 58,433 58,433

70 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 71 Main Products R&D Pipeline

Product (Ingredient/Formulation) Use Exporting Countries Remarks Compound Name Code Use Stage of Development · A-/Hypogammaglobulinemia Fibrinogen (Factor I) GC5112A Congenital fibrinogen deficiency Pre-clinical · Combined therapy with antibiotics Asia, Middle-East, for severe bacterial or viral infections Plasma Plasma-derived Factor VIII GC5111A Hemophilia A Pre-clinical 1. Human Intravenous Immunoglobulin Central & South · Idiopathic thrombocytopenic purpura Derivatives America · Guillain-Barre syndrome Anti-TFPI antibody MG1113A Hemophilia A & B Pre-clinical · Kawasaki syndrome Tuberculosis vaccine GC3107A Tuberculosis Clinical Phase I For hypoalbuminemia and shock Factor Xa inhibitor GC2107 Anti-thrombotics Clinical Phase I in acute hemorrhage from loss of Asia, Middle-East, Plasma 2. Human Albumin Solution albumin (burns, nephrotic syndrome, Central & South Derivatives EGFR target anti-cancer GC1118A Colon Cancer Clinical Phase I etc.) and low synthesis of albumin America (hepatic cirrhosis, etc.) Anthrax vaccine GC1109 Anthrax Clnical Phase II For the treatment of hemophilia A Asia, Middle-East, Plasma Tetanus, diphteria and pertussis vaccine GC3111A Tetanus, diphteria and pertussis Clnical Phase II 3. Human Blood Coagulation Factor VIII with supplies of blood coagulation Central & South Derivatives factor VIII America Hunter Syndrome treatment GC1111B Hunter Syndrome Clnical Phase II

For the prevention and control of Asia, Middle-East, Recombinant Prevention of HBV recurrence after 4. Recombinant Coagulation Factor VIII bleeding episodes and preoperative Central & South Hepariris B Immunoglobulin GC1102 Clnical Phase II Product liver transplantation management in hemophilia A America Allogenic NK cell MG4101 Hepatocellular Carcinoma Clnical Phase II · For prophylaxis of hepatitis B after exposure to HBsAg IVIG GC5101B Severe infection/PID Clinical Phase III · For prophylaxis of hepatitis B in Asia, Middle-East, Plasma 5. Human Hepatitis B Immunoglobulin neonates Central & South IVIG GC5107B Severe infection/PID Clinical Phase III Derivatives · For prevention of recurrence of America hepatitis B in patients with liver Seasonal influenza vaccine GC3106A Seasonal influenza Clinical Phase III transplants Recombinant Factor VIII GC1101D Hemophilia A Clinical Phase III For the prophylaxis of tetanus and Varicella vaccine MG1111 Varicella Clinical Phase III the reduction of tetanus symptoms Asia, Middle-East, Plasma 6. Human Tetanus Immunoglobulin by providing passive immunization Central & South Derivatives Fc-optimized monoclonal antibody MGAH22 Breast cancer Clinical Phase III against infection caused by America Clostridium tetani

Asia, Middle-East, 7. Split Virion Inactivated Influenza For the prophylaxis against influenza Central & South Vaccines Vaccine America

Asia, Middle-East, 8. Live Attenuated Varicella Vaccine For the prophylaxis against varicella Central & South Vaccines America

For treatment (Enzyme Replacement Asia, Middle-East, Recombinant 9. Idursulfase beta Therapy) of Hunter Syndrome Central & South Product (Mucopolysaccharidosis II) America

For decrease the duration of severe Asia, Middle-East, neutropenia for patients receiving Recombinant 10. PEG-GCSF Central & South cytotoxic chemotherapy for solid Product America tumor and malignant lymphoma

72 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 73 technology. - 2007: Received approval for the HCC immunotherapy “Immuncell-LC” from MFDS. Green Cross Cell Corporation - 2012: Completed phase III clinical trials for HCC and glioblastoma. 3) Diverse Pipelines of Business - Build infrastructure through networking with major university hospitals and cancer-related research centers. - Green Cross - linked synergies expected.

Executives Profile Company Profile Duckjoo Lee, President & CEO. 1. Business • MD, Ph.D. R&D, manufactures and distributes cell therapy products, • Studied for Master’s degree from Public Health, University of Minnesota. licensing business for cell therapy products, research services, cell • Former Doctor, Ajou University Hospital Family Physician. cryopreservation, etc. Joon Hee Han, CFO. 1) Cancer Immunotherapy Business - The company developed "Immuncell-LC" which is one of the most • MBA. effective cancer immunotherapy. • Former Managing Director, Green Cross BT, CANADA. Representative - The products has been approved by KFDA(Korea Food and Drug • Former Director Corporate Strategy, Green Cross Holdings Corp. Duckjoo Lee, President & CEO Administration) in 2007 for the indication of the reduction in the Jong Seong Ahn, Director, Operations. Headquarter Address recurrence of Liver cancer. • Ph.D in Biotechnology. 153-769, 6th floor, 278, Beotkkot-ro, 2) Cell Bank Business • Former Director, the production sector of Green Cross LabCell. Geumcheon-gu, Seoul, Korea - Future resource with high potential as a cell therapy. Gyouchul Jung, Director, R&D. Foundation Date 3) Entrusted Business (CMO service) Sep. 17, 1992 - Various services based on superior technologies and know-how • MD. Research Focus as a leader in the cell therapy market. • Former Vice President, Green-Cross Lab. Medical Center. - A company specialized in cell therapies with boundless potential Manufacture and distribute Anti-Cancer Kiwon Kang, Director of Commercial Operations. cell-therapy products in this area. - Advanced technologies for the development and production of • Former Director, Marketing, Green Cross Corp. Total Staff cell therapy products. Hee-jung Wang, BOD member. 160 FTE 2. Competitive Edge Representative Phone • MD, Ph.D. Liver Transplantation Specialist. • Current President, Ajou University 82-2-2101-0600 1) Industry Leader - Cell expansive Technology. Hospital Cancer Center/Transplant Center. Web - Leader of personalized medicine through the development of safe http://eng.greencrosscell.com cancer immunotherapy. Contact Person - Disastrous medical expenses for serious diseases (2013-2014). Main Products daehwan kim 2) Continuous R&D Investment, Commercialization Product (Ingredient/Formulation) Use Remarks Contact Phone - 2006: Awarded a patent on immune cell cryopreservation 82-2-2101-0702 Clinical Trial Results Adjuvant therapy for patients Publications of our clinical results in global top-tier Contact E-mail Financial Figures whose tumor has been removed oncology journals [email protected] after curative resection for Summary (1 Million Won) Hepatocellular Carcinoma 1. Liver cancer Immuncell-LC Fiscal Year 2015 2016 2017 (Surgical resection, Radio Gastroenterology(May 27, 2015) Sales 10,418 11,909 19,539 Frequency Ablation, Results of phase 3 clinical trial Percutaneous Ethanol Injection • Recurrence Free Survival increased by 1.5 times R&D Expenditure 610 1,230 2,173 Therapy) • Risk of recurrence decreased by 37% Capital $5,400,000 $5,400,000 $5,400,000 • Risk of death decreased by 79%

74 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 75 Product (Ingredient/Formulation) Use Remarks 2. Brain tumor Immunotherapy(March 30, 2017) GUJU PHARM. CO. LTD. Adjuvant therapy for patients Review of phase 3 clinical trial whose tumor has been removed • Progression Free Survival increased by 1.5 times after curative resection for • Disease control rate increased by 30% Hepatocellular Carcinoma Immuncell-LC (Surgical resection, Radio 3. Pancreatic cancer Frequency Ablation, Cancer Immunology, Immunotherapy(Jun 12, 2014) Percutaneous Ethanol Injection Results of phase 2 clinical trial led by researchers Therapy) • Disease control rate increased by 25% Company Profile • Improvement of Quality of Life GUJU PHARM. CO. LTD. is a specialized pharmaceutical manufacturer considering human life the most important value in the world. R&D Pipeline Focus Area : Chronic metabolic disease Compound Name Code (ClinicalTrials.gov Identifier) Use Stage of Development NCT01890291 Liver cancer Launch

NCT00807027 Glioblastoma Phase III Representative CIK(Cytokine- NCT02856815 Liver cancer, Mid stage Phase II (IIT) Kim Woo Tae Induced Killer cell) NCT01897610 Liver cancer, Terminal stage Phase II (IIT) Headquarter Address + aTc(CTL)(Activated River Tower officetel 12F, 50, Beodeunaru- Tc cell) - Liver cancer, Liver Transplantation Phase II (IIT) ro, Yeongdeungpo-gu, Seoul, South Korea NCT03220984 Colorectal cancer Phase II (IIT) Foundation Date NCT01802138 Neuroblastoma Phase I (IIT) 23rd of Dec. 1974 Research Focus Final Product (Medicine) New Active Substances Total Staff 270 persons Product (Ingredient) Use Approval Date Representative Phone Immuncell-LC Liver cancer Aug, 2007 82-2-2672-1122 Representative Fax 82-2-2679-7569 Others Web http://www.gujup.co.kr/ Business Strategy Contact Person Kim Jeoung Seob - Target Indication (Liver cancer) Contact Phone • Market Exclusivity -> To maximize Profit & MKT Share 82-2-2672-1122, Ext. 400 • Fast Track Pathway -> To sustain minimized Payback Period Financial Figures Contact E-mail • CMO Utilization -> Risk mitigation Summary (1 Million Won) [email protected] Fiscal Year 2012 2013 2014 - Other applications (Various cancers) Sales 56,592 59,253 57,137 • Continuous R&D and Addition of new Indications (Brain tumor, Pancreatic cancer) R&D Expenditure 1,795 1,856 2,091 • Other Collaboration with Partners Capital 13,189 14,788 15,960

76 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 77 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks Hana Pharm Co., Ltd 1. Clif cap.(Cefaclor) Antibiotics - -

2. Atorix Tab.(Atorvastatin Calcium hydrate) Treatment for Hyperlipidemia - -

3. Unazol cap.(Fluconazole) Antifungal agents - -

4. Bronkid syrup.(Hederae Helix Fluid) Expectorants - -

5. Rabiem Tab. (Rabeprazole Sodium) Proton pump inhibitor - - Company Profile Since founded in 1996, Hana Pharmaceutical Company has been 6. Neocatin tab.(Acetyl Carnitine HCl) Cholinergic drugs - - keeping steady product development and pharmaceutical synthesis, and now it is ready to advance to take-off stage. 7. Neotidine tab.150mg(Ranitidine HCl) H2-blocker - - With our specialized products such as anesthetics (Propofol, 8. Anicid cap.(Omeprazol) Proton pump inhibitor - - sevoflurane, isoflurane) and narcotics (Oxycodone, fentanyl, 9. Talimed Tab.(Talniflumate) NSAID - - morphine), we will continue our effort to become as a world-class global pharmaceutical company. Representative 10. Diacerhein Cap.(Diacerhein) Treatment of Osteoarthritis - - Younha Lee Headquarter Address 16F, 218 Narae B/D, Teheran-ro, Gangnam-gu, Seoul, Korea Foundation Date 1996 Research Focus Synthesis of API, Pharmaceutical Product Manufacturing, Selling and Exporting Total Staff +530 Representative Phone 82-2-577-7667 Web www.hanaph.co.kr Contact Person Gemma Kim Contact Phone 82-2-559-5778 Contact E-mail Financial Figures [email protected] Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 108,255 125,156 140,155 R&D Expenditure 3,308 4,159 4,164 Capital 35,385 56,923 90,939

78 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 79 Main Products Product (Ingredient/Formulation) Use Exporting Countries HanAll Bio Pharma Thailand, Yemen, 1. Propofol Inj. Anesthetics Vietnam, Dominican republic

2. Sevoflurane Sol. Anesthetics Yemen, Taiwan, Dominican republic

3. Isoflurane Sol. Anesthetics Yemen, Dominican republic

4. Atracurium Besylate Inj. Muscle relaxants Thailand, Philippines Company Profile 5. Nalbuphine HCl Inj. Analgesics Philippines HanAll is a top 20 Korean-based R&D pharmaceutical company established in 1973. Our company initially started R&D with the 6. Bupivacaine HCl + Dextrose Inj. Anesthetics Yemen, Philippines development of over 30 different combinations of cardiology products 7. Midazolam Inj. Benzodiazepines Yemen through its innovative and proprietary XC Hybrid Combination formulation technology. With the acquisition of Nautilus Biotech and 8. Nitroglycerin Inj. Vasodilators Mongolia strengthened bio-therapeutics pipeline, we are currently developing engineered protein therapeutics via amino acid replacement Non-cardioselective beta 9. Labetalol Inj. Chile engineering and mAb fragment via domain engineering which blockers Representative will provide superior PK/PD profile. We also focus on the treating Mr. Sung-Wuk Kim / CEO 10. Ramosetron HCl Inj. Antiemetics Taiwan autoimmune disease with bio-therapeutics. Headquarter Address Not only do we focus on bio-therapeutics, but also strive to develop Jamshil I-Space 6F, 11-10 Sincheon-dong, new chemical entities for the treatment of cancer due to high global Songpa-gu, Seoul, Korea needs. It is important to provide effective and safe anti-neoplastic Foundation Date agents with minimized adverse drug events which can significantly R&D Pipeline 1973. 11. 20 increase patient's quality of life. Recently, preclinical and clinical data are emerging for a beneficial effect of Metformin which may affect Compound Name Code Use Stage of Development Research Focus cancer cell's proliferation and apoptosis. Hence, we are presently Bio-therapeutics (Biobetter & antibodies), - HNP-2001 Anesthetics Phase III developing new chemical entity of biguanide derivatives as an CV Combinations, AMPK activator, Ant- effective and safe anti-neoplastic agent. - HNP-2006 Contrast media Preclinical Atopic dermatitis. Total Staff - HNP-7060 Anti-pain Formulation 446 persons - HNP-7076 Rheumatoid arthritis Formulation Representative Phone 82-2-2204-1753 Representative Fax 82-2-414-8046 Web www.hanall.co.kr

Financial Figures

Summary (1 Million Won) Fiscal Year 2008 2009 2010 Sales 91,900 98,700 106,900 R&D Expenditure 10,831 10,928 10,651 Capital 18,500 18,500 18,500

80 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 81 Main Products Product (Ingredient) Use Exporting Countries HANDOK Inc. 1. Reposporen inj.(Cefazedone) Antibiotics - 2. Tomiporan inj.(Cefbuperazoen Sod.) Antibiotics - 3. Normix tab.(Rifaximin) Antibiotics - 4. Hanall Glimepiride tab.(Glimepiride) Antidiabetes Vietnam 5. Glucodown OR tab.(Metformin HCl) Antidiabetes - Company Profile 6. Hanall tramadol inj.(tramadol HCl) NSAIDS - HANDOK, a leading innovation-driven pharmaceutical/health-care 7. Levod tab.(Levosulpiride) Prokinetic agent - company in Korea, develops, manufactures and distributes healthcare 8. Hanall Fluconazole cap.(fluconazole) anti-fungal drug - solutions to improve the health and quality of human life. Handok 9. Lenvard tab.(Rebamipide) antiulcer agent - has a core business focus in diabetes, cardiovascular, muscular skeletal, psychoneurotic disease, human vaccines, medical devices, 10. Hanall finasteride tab. 5mg(Finasteride) 5alpha-reductase inhibitor Vietnam, Philippines diagnostics and consumer health.Handok, founded in 1954, grew as a joint venture with Hoechst/Aventis/Sanofi from 1964 to 2012. Handok has also established strategic collaborations in several areas Representative with multiple multinational pharmaceutical companies. Young-Jin Kim Chairman & CEO R&D Pipeline Headquarter Address 132, Teheran Street, Gangnam-Gu, Seoul, Ingredient Use Stage of Development 135-755, Korea KOR Phase 2 completed HL009(Adenosylcobalmin) Atopic dermatitis US phase 2 IND approved Foundation Date 1954. 4. 27 KOR Phase 1 completed HL008(amlodipine, losartan) Hypertension US IND preparation Research Focus KOR Phase 3 preparation Oncology, Diabetes & Metabolic HL040(losartan, atorvastatin) Hypertension, Hyperlipidemia US IND preparation disorders, CNS, CV, Orphan disease, Eye HL156(Biguanide derivative NCE) Anti-cancer Lead optimization disorders, Quality of life products HL032(oral hGH) Growth hormone deficiency KOR Phase 1 ongoing Total Staff 913 persons HL143(sc IFN) Hepatitis C US Phase 1 on-going Representative Phone HL036(anti TNF-alpha) Rheumatoid arthritis Lead optimization 82-2-527-5114 HL161(FcRn) Autoimmune disease Lead optimization Web http://www.handok.co.kr/english/ company/company.asp Contact Person So-Hyun Kwon New Active Substances Contact Phone 82-2-527-5316 Financial Figures Product (Ingredient) Use Approval Date Contact E-mail Summary (1 Million Won) Spelear(Fudostein) antitussive agent 2005-01-19 [email protected] Fiscal Year 2015 2016 2017 Sales 358,477 396,253 424,903 R&D Expenditure 18,805 18,149 26,855 Capital 316,424 318,324 319,915

82 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 83 Main Products Others

Product (Ingredient/Formulation) Use Exporting Countries Remarks We are the best partner to bring your novel drugs to the Korean market. 14 countries 1. Amaryl M Innovation and partnership belong to Handok's core values, and we strive every day to bring Innovative new products to (Taiwan, Indonesia, The first fixed dose combination of (Glimepiride+Metformin/ Anti-diabetic drug patients, wherever they may have been discovered. With a history as a joint venture, Handok knows how to value partnership Philippines, Hungary, glimepiride and metformin HCl in Korea Tablet) as a way of growing business for both parties involved. Handok offers its partners core competencies in areas that critical for Russia, Dubai, etc) successful drug development and commercialization. 6 countries 2. Amaryl Mex (Singapore, Hungary, Applied by DRM technology (Dual Release Excellence in clinical development and management (Glimepiride+Metformin/ Anti-diabetic drug Croissy, Philippines, Micro-coating Technology) Sustanined–release Tablet) Our Clinical Research Center is recognized for performing quality clinical trials, pharmacoeconomic studies, data management Kazakhstan, etc.) and biostatistics. The center meets global standards and has been participating in global clinical trials with multinational 3. Tenelia M partners. Applied by DRM technology (Dual Release (Teneligliptin+Metformin/ Anti-diabetic drug - Micro-coating Technology) Sustanined–release Tablet) Optimized market access through regulatory and pricing expertise

Osteoarthritis, Handok was the first pharmaceutical company in Korea an international pharmacoeconomic team. It has been successful in arthritis, 5 countries Korea’s No. 1 pain relief OTC product achieving shorter registration and launch timelines, as well as optimizing pricing fir partners' products in the Korean market. Humeroscapularis (Singapore, Ketotop relieves pain and reduces 4. Ketotop (Stiff shoulder), Malaysia, Vietnam, inflammation and Ketotop plaster is (Ketoprofen/Plaster) Maximize returns though strong sales and medical marketing capability Muscular pain, Kazakhstan, designed to penetrate deeply into the site Peritendinitis Myanmma, etc.) of pain and works for 12hours We provide maximum return through scientific and ethical marketing practices and top-tier sales force productivity. Handok also (Tendinitis) has a high reputation among key opinion leaders in Korea.

5. Ready-Q ; Drink and Delicious hangover remedy contains Hangover Remedy 1 country (Taiwan) World-class manufacturing capabilities Chew(Gummy) curcumin, an extract from Tumeric Handok offers high-quality manufacturing and QC capability for multiple dosage forms with the highest standard if production Innovative and best way to consume facilities in Korea to meet partners' manufacturing needs in Korea and other export markets. Theracurmin, Curcumin made as small 6. Ulgeum Theracurmin - - particles to be soluble and absorbed well into body Rigorous company-wide compliance program Handok believes that adherence to ethical practices is essential for continuous growth and long-term success or the company and its partners' business. We were the first company to introduce a strict company-wide compliance program in Korea.

Internal research expertise to support your program R&D Pipeline Handok has expertise in small molecules, biologics, and drug delivery system and is seeking collaborations on innovative early- Compound Name Code Use Stage of Development stage research programs to build its future pipeline. - HL2356 Growth Hormone Deficiency Phase II

- HL5101 Cancer Preclinical development

- HL3501 Glaucoma Discovery

- HL1550 Diabetes + Hyperlipidemia Preclinical development

- DENEX Resistant Hypertension Phase I

84 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 85 Main Products Hankooksinyak Pharm. Co., Ltd. Product (Ingredient/) Use Exporting Countries 1. Chunsim heart disease, hypotension, etc. -

2. Keopoongshibodan stroke -

3. Woohwangchongshim-won stroke, atherosclerosis, hypertension, etc. Japan

4. Mankyungdan stroke, sciatica, etc -

Company Profile 5. Mesima gastrointestinal cancer Japan We have a lot of specialized technologies in the natural medicine field, such as Korean traditional medicines. Since our modern Korean 6. Yukmihwan urinary difficulty - traditional medicines, resulting in many accomplishments in the 7. Ickbodan fortifying, kidney-essence - biotechnology sector. Those accomplishments includes development of anticancer substances as well. In 1984, we produced and supplied 8. Shinbanwan diabetes - successfully Korean traditional medicine solutions(i.e., Galgeuntang, Sipjeondaebotang, Sosihotang etc.) to the market. In 1992, we saw 9. Oakbihwan constipation - another success for development of the anticancer substance having 10. Chongwidan stomach catarrh, indigestion - Representative a brand of MESIMA. Han Sang Wook Headquarter Address 805-15, Joongsan-Ri, Yangchon-myeon, Nonsan, Chungnam Prov., Korea R&D Pipeline

Foundation Date Ingredient Use Stage of Development 1961. 2. 27 Korean medicine GST anti-atopic dermatitis Evaluation of GST Research Focus Korean traditional herbal medicine Total Staff 260 persons Representative Phone New Active Substances 82-41-740-8900 Product (Ingredient) Use Approval Date Representative Fax 82-41-740-8849 MESIMA Immuno-stimulating drug 1990.2.28 Web www.hsp.co.kr

Financial Figures

Summary (1 Million Won) Fiscal Year 2008 2009 2010 Sales - 20,384 21,687 R&D Expenditure - - 646 Capital - - 2,100

86 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 87 Main Products HANLIM PHARM. CO., LTD. Product (Ingredient/Formulation) Use Exporting Countries 1. Dages Cap. (Pepsine, Papain, Diastase, Cellulase, Alimentary Drug China Pancreatin, Pancrelipase, UDCA)

Hemostatics, Anticoagulants 2. Heparin Inj. (Heparin Sod.) Vietnam, Singapore and related agents Company Profile 3. Easy-Drops Eye Drops Ophthalmic Drugs USA, Cambodia, Nigeria With the corporate mission of "Protecting the precious human life 4. Numaren Eye Drops USA, Myanmar, Cambodia,Vietnam, Ophthalmic Drugs from various forms of disease", HANLIM has consistently endeavored (Hydropropylmethyl cellulose, Dextran 70) Hongkong to manufacture high quality pharmaceutical products. Also, we 5. Posod Eye Drops continue to make a great investment in new medicine development Ophthalmic Drugs Vietnam, Singapore, Hong Kong, Nigeria (Potassium Iodide, Sodium Iodide) and reorganizing manufacturing facilities. 6. Quinovid Ophthalmic Ointment (Ofloxacin) Ophthalmic Drugs Vietnam

7. Quinovid Ear Drops (Ofloxacin) Ophthalmic Drugs Vietnam Representative Allergy&ENT Disease Mr. Jae-Yoon Kim 8. Desona Nasal Spray (Budesonide) Cambodia, Vietnam, Mongol, Guatemala Mr. Jung-Jin Kim Related agent Headquarter Address 9. Peptazole Inj. Alimentary Drugs Vietnam 42, Seocho-Daero 52-Gil, Seocho-Gu, (Pantoprazole Sod. Sesquihydrate) Seoul, Korea Hemostatics, Anticoagulants 10.Protamine Sulfate Inj. (Protamine Sulfate) Azerbaijan Foundation Date and related agents Sep. 1974 Research Focus Pharmaceutical R&D Pipeline Total Staff 635 persons Compound Name Code Use Stage of Development Representative Phone - HL-MSC Systemic lupus erythematosus Phase 1 82-2-3489-6000 - HL301 Bronchitis Phase 3 Web http://www.hanlim.com - HL217 AMD Phase 1 Contact Person - HL237 Rheumatoid Arthritis Phase 1 Ms. Jung-Hwa Yang - HL235 Osteoporosis Lead mol Contact Phone 82-2-3489-6214 - HL-PIF Mixed hyperlipidemia Phase 3 Contact E-mail Financial Figures - HL151 Allergic rhinitis pruritus Phase 3 [email protected] Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 130,702 148,629 169,096 R&D Expenditure 11,148 17,255 14,465 Capital 146,882 171,100 196,100

88 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 89 Main Products Hanmi Pharm. Co., Ltd Product (Ingredient/Formulation) Use Exporting Countries 1. Amosartan (amlodipine+losartan) Hypertension Southest Asia 4counties, Latin America 15countries 2. Rosuzet (Rosuvastatin+ezetimibe) Hyperlipidemia WW 16 countries including Brazil 3. Duted (Dutasteride) BPH Japan 4. Amodipin (Amlopidine camsylate) Hypertension Philippines, Mexico 5. Esomezol (Esomeprazole strontium) GERD, Gastric ulcer U.S.A Company Profile 6. Pidogul (Clopidogrel napadisilate) Antithrombotic Hongkong Established in 1973, Hanmi Pharmaceutical now is the No.1 R&D focused pharmaceutical company in Korea with highest R&D investment for many years. R&D Pipeline

Hanmi Pharm. Co., Ltd. is a Korea-based pharmaceutical company, Compound Name Code Use Stage of Development fully integrated with strong focus in R&D which is strategically LAPSGCSF; Eflapegrastim - Neutropenia Phase 3 designed in 3 major fields: 1) Biologics: LAPSCOVERY platform applied long-acting pipelines. Key targeting areas are diabetes, LAPSGLP-1; Efpeglenatide - Diabetes, obesity Phase 3 Foundation Date obesity, NASH, and rare diseases / PENTAMBODY platform applied LAPShGH; Efpegsomatropin - GHD Phase 2 bispecific antibody pipelines. Key targeting areas are targeted 2010. 7. 5 HM12460A / immuno-oncology and autoimmune disease; 2) NCE: Mainly oncology LAPSInsulin/ LAPSInsulin Analog Diabetes Phase 1 HM12470 Research Focus and auto-immune disease targeted pipelines; and 3) Fixed-dose New Biologics, New Chemical Entities combination programs. The company has worked closely with global LAPSGLP/GCG HM12525A Diabetes, obesity Phase 1 Total Staff partners on various co-developments and collaborations. Hanmi LAPSInsulin/LAPSGLP-1 combination HM14220 Diabetes Pre-Clinical continues to further expand through "Open Innovation Strategy" by 2,195 persons LAPS finding potential partners for innovative solutions. Triple Agonist HM15211 Obesity, NASH Pre-Clinical Representative Phone LAPS Focus Area : Innovative R&D - Diabetes, Obesity, NASH, Oncology, Glucagon Analog HM15136 Congenital Hyperinsulinism Pre-Clinical 82-2-410-9114 (회사 소개용 사진 배치; 주력 제품 or 본사 및 공장 조감도 등 ) Autoimmune diseases, Rare diseases * 공장 조감도 LAPSASB HM15450 Mycopolysaccharidosis Pre-Clinical Representative Fax LAPS 82-2-410-9179 GLP-2 Analog HM15910 Short Bowel Syndrome Pre-Clinical Web Oraxol™; (Paclitaxel+HM30181A) - Breast cancer Phase 3 (회사 소개용 사진 배치; 주력 제품 or 본사 및 공장 조감도 등 ) www.hanmipharm.com * 공장 조감도 Olita™ (Olmutinib) - NSCLC Phase 3 Contact Person Poziotinib - Breast cancer, NSCLC Phase 2 Steven Cho BTK Inhibitor HM71224 Rheumatoid arthritis Phase 2 * 주력제품 Contact Phone Oratecan™; (Irinotecan+HM30181A) - Solid tumors Phase 1 82-2-410-0462 RAF inhibitor HM95573 Solid tumor Phase 1 Contact E-mail [email protected] Src kinase/tubulin dual inhibitor KX2-391 Solid tumor Phase 1 FLT3 Inhibitor HM43239 AML Pre-Clinical GMB Stem Cell Therapy HM21001 Glioblastoma Pre-Clinical Financial Figures PENTAMBODY - Solid tumor Pre-Clinical

* 주력제품 Summary (1 Million Won) Fiscal Year 2015 2016 2017 New Active Substances Sales 1,317,535 882,725 916,586 R&D Expenditure 187,159 162,594 170,676 Product (Ingredient) Use Approval Date/Country Capital 25,577 26,088 27,909 Olita tab(Olmutinib) NSCNC 2017 NOV. /South KOREA

90 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 91 Main Products Han Wha Pharma Co., Ltd. Product (Ingredient/Formulation) Use Exporting Countries Remarks 1. Antibio Probiotics Vietnam -

2. Ramnos Probiotics Malaysia -

3. Muteran Mucolytics - -

4. Wingli-M Anti-diabetics Indonesia Under registration

Company Profile 5. Winexge Anti-hypertension Indonesia Under registration Han Wha Pharma(HWP) is a pharmaceutical company based in Seoul, Korea. HWP is well established in development, manufacture, 6. Telmiam Anti-hypertension - - distribution, marketing/sales and export of pharmaceutical and healthcare products. HWP is recognized to doctors and pharmacists as a specialized company that has ethical products in certain therapeutic areas such as alimentary, cardiovascular, obstetrics/ gynecology, neuro-muscular, and respiratory system. Aiming to R&D Pipeline become a global enterprise, HWP has introduced global marketing Compound Name Code Use Stage of Development Representative techniques through an organic partnership with several overseas - YJP-14 Cardiovascular agent Phase 2 Kyoungrak Kim companies. As a result, HWP has continued making record growth in Headquarter Address sales by successfully launching new products in the domestic market - YJP-40 Respiratory agent Phase 3 76 Hwarang-ro 32-gil, Seongbuk-gu, to meet customer needs based on market research. In sales activities, - YJC-50018 Anti-rheumatoid arthritis Preclinical Seoul, 02789, KOREA HWP has grown into a most trusted company among customers by successfully supplying high-quality and superior medicines to Foundation Date hospitals and clinics. HWP has expanded its business area to dietary July 4, 1976 supplements. HWP family consists of NaturaLife focused on nutrition Research Focus supplements for domestic market and NaturaLife Asia for exporting Respiratory diseases etc. business to Asian territory. Total Staff Focus Area : Gastro-intestinal system, Respiratory system, Obstetrics/ 300 persons Gynecology etc. Representative Phone 82-2-959-3161 Representative Fax 82-2.959-3621 Web www.hwpharm.com Contact Person Jinbo Kim Contact Phone 82-2-959-3161 Financial Figures Contact E-mail Summary (1 Million Won) [email protected] Fiscal Year 2015 2016 2017 Sales 57,887 65,146 62,719 R&D Expenditure 154 597 380 Capital 3,436 3,436 3,436

92 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 93 Main Products Hawon Pharmaceutical Corporation Product (Ingredient/Formulation) Use Exporting Countries 1. Fazidone Inj. 1g,2g - urinary tract infection, cholangitis, intrauterine - (Cefazedone sodium 1g,2g) infection, adnexitis - pneumonia, bronchitis and breathing device nfection - ear, nose and throat nfection - nephritis and urinary tract infection 2. Hawon Ceftriaxone Inj. 1g,2g - sepsis Mongolia (Ceftriaxone Na 1g,2g) - bone and joint infection Company Profile - skin, laceration and soft tissue infection - peritonitis, cholecystitis, cholangitis Hawon believes that "To contribute to the health and happiness of - meningitis people through developing good medicines". We will keep the level of global standards of competition and place high priority on R&D for - Respiratory Infections devised out new products and raw materials of new brand. 3. Ciploxacin Inj. 200mg (Ciprofloxacin 2mg) - ENT infections, Oral, Teeth, jaw infections - - kidneys, urinary tract infection Focus Area : Antibiotic Drug etc 4. Myal Inj. (Sodium hyaluronate/10mg) - Osteoarthritis of the knee, shoulder treatment - - perceived exercise barrier 5. Coxicam Cap. (Meloxicam 7.5mg) - Symptomatic treatment of rheumatoid arthritis Vietnam Representative - Symptomatic treatment of poker back Kooh, Dae-ho - upper airway infection : otitis media, tonsillitis, Headquarter Address pharyngitis 6. Furoxetil Tab.(Cefuroxime axetil 300.72mg - lower respiratory tract : acute bronchitis and chronic #135-080, 2~4F Time bldg, 312 Nonhyun- - ro, Kangnam-gu, Seoul, Korea (cefuroxime axetil(as cefuroxime) 250mg)) bronchitis, pneumonia - urogenital system infection : nephropyelitis, cystitis, Foundation Date urethritis 4th May 1981 - Ulcer Research Focus - Gastric mucosal lesions in the following diseases Natural Medicine 7. Remist Tab. (Rebamipide 100mg) (erosion, bleeding , redness, swelling) improvement of - acute gastritis, acute exacerbation of chronic gastritis Total Staff group 158 persons - Acute or recurrent vaginal candidiasis - Hand, nail fungus, athlete's foot (foot ringworm), Representative Phone 8. Fronan Cap. (Fluconazole 50mg) - 82-70-8260-6030 tinea corpus, wanseon (groin ringworm), Skin and skin fungal infections, including candida eorureogi Representative Fax - Reduced risk of myocardial infarction 82-2-554-4557 - Reduced risk of stroke 9. Lipitrol Tab. (Atorvastatin calcium 10.35mg) - Web - Vascular regeneration and reduce the risk of chronic stable angina http://www.hawonpharm.co.kr - Functional due to poor digestion digestive symptoms 10. Mosadin Tab. (Mosapride citrate 5.29mg) - Contact Person (heartburn, nausea, vomiting) R&D Department Contact Phone 82-70-8260-6030(#3) Financial Figures Contact E-mail Summary (1 Million Won) [email protected] Fiscal Year 2012 2013 2014 Sales 6,190,651 5,865,021 5,320,896 R&D Expenditure 78,894 35,727 49,028 Capital 5,777,685 5,254,988 5,915,659

94 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 95 Main Products Humedix Co., Ltd Product (Ingredient/Formulation) Use Exporting Countries 1. Sodium Hyaluronate Remedies for Arthritis Worldwide (Sodium Hyaluronate/Powder)

2. High Hyal Plus Inj. Remedies for Arthritis Worldwide (Sodium Hyaluronate/Injection)

3. High Hyal Inj. Remedies for Arthritis Worldwide Company Profile (Sodium Hyaluronate/Injection) We, humedix, have platform technology for application of 4. High Eye Inj. (Sodium Hyaluronate/Injection) Ophthalmological surgical aids Worldwide biocompatible polymers just like hyaluronic acid and PEG. And then, we are trying to research and develop the improvement of drugs with biocompatible polymers. We've rapidly grown up recently due to our products developed with hyaluronic acid and have been listed in korean stock R&D Pipeline market(KOSDAQ), Compound Name Use Stage of Development Representative Chung, Bong-Yeol Focus Area : application of biocompatible polymer as hyaluronic acid cross-linked hyaluronic acid improvement of osteoarthritis pre-clinical and PEG etc. Headquarter Address conjugated Vit. D derivative whitenning pre-clinical Unit 603 Mega Valley, 268, Hagui-ro, Dongan-gu, Anyang-si, Gyeonggi-do, scFv macular degeneration pre-clinical Korea Foundation Date 2003 Research Focus Biomaterials & Applications Total Staff 79 persons Representative Phone 82-70-7492-5618 Representative Fax 82-31-421-5623 Web www.humedix.com Contact Person Lee, Jong-Oh Contact Phone Financial Figures 82-70-7492-5609 Summary (1 Million Won) Contact E-mail [email protected] Fiscal Year 2012 2013 2014 Sales 11,704 23,544 29,200 R&D Expenditure 1,916 1,832 2,602 Capital 2,042 2,304 3,158

96 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 97 Main Products HUONS CO., LTD. Product (Ingredient/Formulation) Use Exporting Countries Remarks Temporary improvement of 1. Hutox Inj. 100units (Botulinum Toxin Type A) moderate to severe glabellar Worldwide - wrinkles 2. Elraive premier (Sodium hyaluronate + Lidocaine) HA Dermal Filler Worldwide - 3. High Hyal Plus Inj. (Sodium Hyaluronate) Osteoarthritis treatment Worldwide - 4. Lidocaine / Articaine with Epinephrine Inj. Dental Anesthetics Worldwide - Company Profile 5. Dermashine Balance Skin hydro-lifting Worldwide - Huons has existed for more than 50 years, and grown to a competent global company, producing original and effective essential medicine 6. Derma Akne Acne treatment Worldwide - and medical products, through continual challenges and innovations Treatment and Prevention of 7. Vitamin D Inj. (Chloecalciferol 200,000IU) Worldwide - over 50 years. Vitamin D deficiency Huons is putting a ceaseless effort for human healthy life based on ANDA the advanced manufacturing technologies and production facilities. 8. Sodium chloride inj. Diluent Worldwide Approval in US FDA Our goal is to achieve 1 billion USD in 2020 and aiming to be the 9. Honey bush Inner beauty Worldwide - Representative TOP TEN global company in the industry. Huons is trying to develop 4 KEY AN, UM cores businesses in order to be the successful model of cooperation case. Our 4 main values are research and development, management Headquarter Address of distribution, manufacturing production and developing a global R&D Pipeline 902-c, 253 Pangyo-ro, Bundang-gu, business. Seongnam-si, Gyeonggi-do, Korea Compound Name Code Use Stage of Development Foundation Date - HU007 Dry eye syndrome Phase II July 30, 1965 - HU002 Fatty liver Phase II Research Focus NCEs, Biologics and Generics - HU014 Glabellar wrinkle Phase I/II - HU024 Dry eye syndrome Pre-Clinical Total Staff 570 persons - HU036 Auto-immune disease Discovery Representative Phone - HU035 Atopy Discovery 82-2-854-4700 - HU017 Inflammatory bowel disease Discovery Web www.huons.com Contact Person New Active Substances Han Seok, Ko Contact Phone Product (Ingredient) Use Approval Date/Country March, 2015/ Korea 82-2-854-4700 Clacier Eye drop (Cyclosprine 0.05%) Dry eye Syndromes (Modified generic) Contact E-mail [email protected] Financial Figures

Summary (1 Million Won) Others Fiscal Year 2015 2016 2017 Sales - 167,572 - We, Huons are a new company separated from the former Huons established in 1965. The former Huons split into Huons Global R&D Expenditure - 14,003 - (a holding company) and the new Huons (operations). In assuming that Huons has not split, the sales was 21.5b(KRW) in 2015 & Capital - 95,051 - 24.5b(KRW) in 2016 based in separated income statement.

98 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 99 Main Products Hyundai Pharm Product (Ingredient/Formulation) Use Exporting Countries Remarks Acute, chronic respiratory disease, 1. Surfolase Capsule acute, chronic bronchitis, bronchial China IND submission (Acebrophylline 100mg) asthma, paranasal sinustis, dried rhinitis

Preparation 2. Minoxyl solution 5% Hong Kong, Vietnam, Approval Main pattern baldness Company Profile (Minoxidil 5g/100mL) Cambodia, Myanmar Submission Approval We, Hyundai Pharm. with corporate philosophy in "Contribute to public health promotion" which embodies humanistic philosophy Approval 3. Hyundai Moolpas-F Solution Hong Kong, USA, in improving public health and quality of life and CEO's philosophy Antiinflammatory analgesic, pernio Registration (Methyl salicylate, dl-camphor, etc) Mongolia focused in transparent enterprise spirit, implements organization's Approval vision and value and actively handle fast changing business are in 4. Bumooly-S Solution Eczema, dermatitis, erosion, miliaria, order to have a new leap forward in 21st century. (Diphenhydramine HCl, Dibucaine rhus dermatitis, pruritus, pernio, USA Approval Focus Area : Caridovascular, CNS, Oncology support, Women's Health HCl, etc) insect bite, hives Care, Respiratory Representative 5. Varosc Tablet Approval Hypertension, coronary artery disease Vietnam, Cambodia Lee, Han Koo (Amlodipine besylate 5mg) Approval Headquarter Address 6. Olanpin Tablet Treatment of schizophrenia, bipolar Approval Hong Kong, Macao Hyundaipharm Bldg, Bongeunsa St 135, (Olanzapine 5mg, 10mg) disorder Preparation Gangnam-Gu, Seoul, Korea Treatment of episodes of major Approval Foundation Date 7. Mirtapin Tablet (Mirtazapine 15mg) Hong Kong, Macao depression Preparation 1965 Research Focus 8. Mirap SR tablet (Pramipexole HCl) Idiopathic parkinson's disease Thailand Submission Pharmaceutical products, Health food drinks, Medical equipment & device Total Staff over 400 Representative Phone 82-2-2600-3951 Representative Fax 82-2-2693-7628 Web www.hyundaipharm.co.kr/english Contact Person Yuna Chae Contact Phone Financial Figures 82-2-2600-3883 Summary (1 Million Won) Contact E-mail [email protected] Fiscal Year 2012 2013 2014 Sales 101,116 106,627 107,837 R&D Expenditure 8,083 8,368 8,243 Capital 14,000 14,000 14,000

100 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 101 Main Products ICURE Pharmaceutical Inc Product (Ingredient/Formulation) Use Exporting Countries Remarks Treatment of mild to moderate dementia of the 1. Rivaderm Patch (Rivastigmine) - - Alzheimer and Parkinson` disease

2. Exoderm Patch (Nicotine) Nicotine replacement therapy - - Company Profile 3. NSAIDs Plaster (Ketoprofen/ Diclofenac Sodium, Relief for Rheumatic arthritis Russia, Hong Kong, Icure Pharmaceutical Inc. is a privately held specialty drugs company diethylammonium/ Flurbiprofen/ - pain Bolivia, India with its HQ located in Seoul, R&D Center in Pyeongtack-si and KGMP Indomethacin /Felbinac/ approved manufacturing facility in Anseong-si in Korea. Icure's Loxoprofen) business strategy is to develop innovative transdermal drug delivery systems for local, systemic and device aided delivery of drugs. Icure 4. Lidogesic Cataplasma (Lidocaine) Local anesthetics - - is developing the transdermal formulations that enhance therapeutic Treatment of bronchial value of the drugs by reducing side effects, enhancing efficacy and asthma and chronic 5. Tulobuterol Patch (Tulobuterol) - - promoting patient compliance. obstructive pulmonary Representative disease (COPD) Young Kweon Choi The company has successfully developed and commercialized several pharmaceutical plasters and patches for the treatment dementia 6. Teeth whitening strips Headquarter Address Teeth whitening treatment Taiwan, Finland - associated with Alzheimer Disease, rheumatic arthritis pain, nicotine (Hydrogen perxide) 7, Saimdang-ro 1-gil, Seocho-gu, Seoul replacement therapy. 137-87, Korea Anti wrinkles, Whitening, 7. Cosmetics Patch and Facial mask - These products have been licensed to several leading Korean Moisturizing Foundation Date Pharmaceutical firms for sales in Korea. Several countries May 29, 2000 Anti wrinkles, Whitening, Focus Area : Central nervous system, Respiratory, Nicotine 8. Skin care Product - Moisturizing Research Focus Replacement Therapy, Pain management, Skin care TDDS(Transdermal Drug Delivery System) Total Staff 93 persons R&D Pipeline Representative Phone 82-2-6959-6909 Compound Name Code Use Stage of Development Representative Fax Donepezil Patch - Treatment of mild to moderate Clinical study phase 1 82-2-6959-8509 dementia associated with Alzheimer`s disease and Ropinirole Patch - Formulation phase Web Parkinson`s disease www.icure.co.kr Fentanyl Patch - Relief for Severe cancer pain BE Study phase Contact Person Tom Chung Prevention for nausea and Granisetron Patch - vomiting caused by cancer - Contact Phone chemotherapy 82-70-5038-3399 Financial Figures Contact E-mail Summary (1 Million Won) [email protected] [email protected] Fiscal Year 2012 2013 2014 Sales 9,122 9,347 14,930 R&D Expenditure 309(3%) 372(4%) 305(2%) Capital 10,111 12,930 14,997

102 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 103 Main Products IKSU PHARMACEUTICAL CO., LTD. Product (Ingredient/Formulation) Use Exporting Countries Remarks valetudinarianism, asthenia, reduced stamina, Achieved the first 1. Iksu gongjindan pill/liquid dizziness by aggravated liver functions, - liquid production in headache, chronic fatigue, emmeniopathy the world

Cerebral apoplexy (total paralysis, hemiplegia, 2. Yongpyo wonbang speech defect, coma, lethargy condition, woohwang chungsimwon facial paralysis), hypertension, palpitation, - - Company Profile pill/liquid anxiety neurosis, acute & chronic convulsion, autonomic imbalance, insensibility With 50-year history Iksu Pharm. Co., Ltd. has made continuous growth on herb medicine in a half century history. Iksu Pharm. which Cerebral apoplexy (total paralysis, hemiplegia, has developed ‘Gohowhan’, a neuralgia, arthritis treatment medicine, 3. Yongpyo speech defect, coma, lethargy condition, Korean wonder drug ‘Woowhangchungshimwon.’, and ‘Gongjindan’ woohwangchungsim won facial paralysis), hypertension, palpitation, Vietnam - known as the best royal tonic medicine with its distinguished Korean pill/liquid anxiety neurosis, acute & chronic convulsion, herbal medication technology, is raising its public trust such as autonomic imbalance, insensibility receiving license of Gongjindan, Banhasashimtang and Cheers liquid Following symptom of the person with released by its technology knowhow. stuffiness of epigastrium, nausea, anorexia, Representative Achieved the first soft stools or diarrhea : acute&chronic gastric By releasing various products through dosage form change with 4. Iksu banhasasimtang liquid - liquid production in Yong-Jin Chung catarrh, fermental diarrhea, dyspepsia, gastric securing of GMP and quality management system for excellent the world Headquarter Address medical suplies manufacturing we continue development of high ptosis, gastraneuria, weak stomach, hangover, heartburn, stomatitis, nervousness 2~4F, Iksu Building., 315, Gucheonmyeon- quality liquid herb medication medicine. Iksu Pharm. also completed ro, Gangdong-gu, Seoul, 134-050, Korea license registration of Gongsjindan liquid, fresh blood peritomy liquid, Maldigestion, vomiturition, thirst, headache 5. Cheers liquid - - Foundation Date Banhasashimthag liquid, Engyosan liquid and Daesenggi liquid first in caused by heavy drinking 1970 domestic. Common cold, coryza, headache, pain of 6. Iksu galgeuntang liquid - - Research Focus shoulder and hands Herbal medicine Insomnia, unrest, anxiety, thirst, palpitation, 7. Yongpyo ansin pill/liquid - - Total Staff neurasthenia, shortness of breath, amnesia 121 persons 8. Iksu gohohwan pill Neuralgia, arthralgia, myalgia - - Representative Phone 82-2-416-1116~7 9. Iksu samsoeum liquid Headache, fever, cough caused by cold - -

Web valetudinarianism, asthenia, reduced stamina, www.iksu.co.kr 10. Hwangjinhwan gold pill dizziness by aggravated liver functions, - - Contact Person headache, chronic fatigue, emmeniopathy Yong Kim valetudinarianism, asthenia, reduced stamina, Contact Phone 11. Hwangjejinsangbo liquid dizziness by aggravated liver functions, - - 82-2-416-1115 headache, chronic fatigue, emmeniopathy Contact E-mail loss of appetite, stomach swelling, [email protected] Financial Figures 12. Wisokchung Q indigestion, overeating, dyspepsia, nausea, - - vomiting Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 14,300 17,800 21,100 R&D Expenditure - - - Capital - - -

104 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 105 R&D Pipeline Compound Name Code Use Stage of Development Antlers and 5 other ingredients IK-101 Improve Liver Function Under registration ILDONG Pharmaceutical

Corni and 5 other ingredients IK-102 Improve Liver Function Under registration

Rehmannia glutinosa and 5 other IK-103 Improve Liver Function Under registration ingredients

Angelica root and 5 other ingredients IK-104 Improve Liver Function Under registration Company Profile Ginseng and 5 other ingredients IK-105 Improve Liver Function Preclinical ILDONG Pharmaceutical, as one of the leading pharmaceutical Peony and 1 other ingredients IK-106 Pain relief Formulation companies in Korea, strives to create a healthier and happier future for mankind with developing, manufacturing and distributing the Asparagus tuber and 15 other IK-301 Atopic Dermatitis Phase II finest pharmaceutical products. ingredients With latest research facilities and passionate professionals, we have Antlers and 2 other ingredients IK-401 Immunity Improvement Formulation concentrated on new drug development project targeted at resistant bacteria, malignant tumor, and Alzheimer’s disease, and pushed Foundation Date forward our production of outstanding quality APIs, generic drugs, Mar. 14th, 1941 IMDs, OTC(Over-The-Counter) products as well as nutraceuticals. ILDONG Pharmaceutical has been successful for a few decades in Research Focus OTC Market with several power brands. Representatively, ILDONG’s prescribed drugs, OTC, probiotics, nutrient Multi-vitamin brand ARONAMIN ranked no.1 sales OTC brand in food Korean OTC market in 2016. Total Staff ILDONG succeeded in developing a chronic hepatitis B treatment 1,401 persons BESIVO in 2017 and it has been approved as a new drug from Representative Phone MFDS(KFDA). ILDONG also has strengthen the competitiveness 82-2-526-3114 in Ethical market with many original brand-name drugs through technical and marketing partnership with global pharmaceutical Web companies and outstanding quality generic drugs by own synthetic https://www.ildong.com technology. Contact Person Nathan Ahn(Sales) / Sungsang Seo(IR) Contact Phone 82-2-526-3500(Sales) 82-2-526-3500(IR) Contact E-mail [email protected](Sales) [email protected](IR)

Financial Figures

Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 458,600 479,900 461,200 R&D Expenditure 50,900 53,800 50,000 Capital 25,068 17,845 19,629

106 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 107 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks Ilsung Pharmaceuticals Asia / Central 1. Biovita Probiotics FDF America

2. Aronamin series Vitamin complex Asia FDF

3. Capecitabine Anti-cancer Asia / Pakistan FDF

4. Pemetrexede Anti-cancer Asia / CIS FDF Company Profile 5. Fursultiamine Active vitamin Japan / Asia API ILSUNG Pharmaceuticals is one of the well-known pharmaceutical companies in Korea. ILSUNG has been focused on antibiotics, Asia / CIS / Central 6. Levofloxacin Antibiotics FDF anesthetics and contrast media and is expanding to GI, CV, CNS and America other areas. ILSUNG is famous for its in-licensing activities with 7. Ceftriaxone Antibiotics Asia / CIS FDF global partners such as GSK (UK), Bracco (Italy), Abbott / Baxter (USA), Ono / Teijin (Japan). ILSUNG is selling various kinds of the branded 8. Besifovir Hepatitis B Asia FDF products such as Augmentin, Suprane, and Rytmonorm. In addition to this, ILSUNG is interested in exporting business for contrast media 9. Telmisartan/Rosuvastatin Cardiovascular Asia FDC Representative and CMO business for antibiotics based on well organized KGMP Suk Keun Yoon 10. Rosuvastatin/Ezetimibe Cardiovascular Asia FDC manufacturing facilities approved by PMDA for contrast media and Foundation Date antibiotics. FEB 15th 1061 Focus Area : Antibiotics, Anesthesia, Contrast Media, GI, CV, CNS Research Focus R&D Pipeline Antibiotics, Anesthesia, Contrast Media Compound Name Code Use Stage of Development Total Staff 245 persons Toosendanin (botanical drug) ID 1201 Alzheimer's disease Phase 2 Representative Phone PARP inhibitor (compound name has not anticancer (target indication Phase 1 IDX 1197 82-2-3271-8705 been disclosed) will be determined after P1) (Single Ascending dose) Representative Fax HIF modulator(compound name has not anticancer (target indication 82-2-718-7239 IDF-11774 Preclinical been disclosed) will be determined after P1) Web Lucentis bio-betters IDB0062 Macular Degeneration Preclinical www.ilsung-ph.co.kr

Avastin bio-betters IDB0072 anticancer Preclinical Contact Person Ji Young Lee Contact Phone 82-2-3271-8824 New Active Substances Contact E-mail [email protected] Product (Ingredient) Use Approval Date/Country Financial Figures Besivo (Besifovir) Hepatitis B virus Nov. 1, 17 / S.Korea Summary (1 Million Won) Fiscal Year 2012 2013 2014 Sales 77,161 62,807 62,829 R&D Expenditure 1,903 1,402 1,213 Capital 318,059 322,744 328,683

108 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 109 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks IL-YANG PHARM. CO., LTD. 1. Raypam Injection(Iopamidol) CT Contrast Media - -

2. Sevoprane Inhalation (Sevoflurane) Anesthesia - -

3. Augmentin Antibiotics - - (Amoxicillin + Clavulnate)

Company Profile With the company`s slogan, 'Respect humanity', 'Promote human's health' and 'Improve welfare', IL-YANG PHARM. CO., LTD., has R&D Pipeline tried its utmost to manufacture superior medicines for the last half a century. In addition, IL-YANG has put forth its strength for Compound Name Code Use Stage of Development the construction of the country with healthy people under the Iohexol - CT Contrast Media - banner of "Challenging the limitations of the medical practice and pharmaceutical dispensing for one hundred years". On the basis of Iopromide - CT Contrast Media - the most advanced medical practice and pharmaceutical dispending Representative Ioversol - CT Contrast Media - and a solid business footing in the Korean market, IL-YANG has Dong Yeon KIM, Ph.D exported a variety of pharmaceuticals to approximately 30 countries Iomeprol - CT Contrast Media - Headquarter Address in the world including the USA and Europe. And also IL-YANG has opened an era of local production, by establishing 2 Joint Ventures in Meglumine Gadoterate - MRI Contrast Media - 110, Hagal-ro, Giheung-gu, Yongin-si, Gyeonggi-do, 17096, Republic of Korea China; YangZhou-IlYang and TongHua-IlYang. Gadobutrol - MRI Contrast Media - Foundation Date July 1st , 1946 Research Focus Gastroenterology, Oncology, Virology, Vaccine Total Staff 621 persons Representative Phone 82-31-281-7851 (Headquarter) 82-2-570-3700~7 (Seoul) Web www.ilyang.co.kr Contact Person Young Hwi KO Contact Phone 82-2-570-3804 Financial Figures Contact E-mail [email protected] Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 186,285 261,614 290,000 R&D Expenditure 15,007 14,646 16,000 Capital 48,727 48,727 48,727

110 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 111 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks

Product (Ingredient/Formulation) Use Exporting Countries Remarks 26. Alvorin Tab / Levocetirizine Antihistamine - Generic New 27. Epinastine Tab / Epinastine HCI Antihistamine, Antiallergy - Generic 1. Supect Cap / Radotinib 1st and 2nd line of CML-CP - Drug 28. Kukuratum Syrup / Pelagonium Gastric Ulcer, Duodenal Ulcer, Acute laryngitis - Generic New sidoides 2. Noltec Tab / Ilaprazole Erosive Esophagitis, H.pylori Ecuador, Cambodia Drug 29. Ambosol Inj / Amino acid Amino acid - Generic Eradication 3. Il Yang Flu Vaccine Pre-filled 30. Ibandronsan Tab / Ibandronic Acid Osteoporosis - Generic Syringe inj / Trivalent purified Influenza Vaccine - Generic CVA, Cardiac infarction, 31. Clopidogrel Tab / Clopidogrel - Generic inactivated influenza virus antigen Peripheral artery disease 4. Teratect Pre-filled Syringe inj / Non-insulin dependent 32. Glimed Tab / Glimepiride - Generic Quadrivalent purified inactivated Influenza Vaccine - Generic diabetes, mellitus influenza virus antigen Neurogenic bladde,r Nervous 33. Finasterid Tab / Finasteride - Generic 5. Rosatan Tab / Losartan potassium Hypertetion - Generic pollakiuria Pyelonephritis, Cystitis, 6. Nizaractine Cap / Nizatidine H2-blockers - Generic 34. Cefadroxil Cap / Cefadroxil - Generic Urethritis 7. Neusilin A Tab / Magnesium Antacid, Absorbent - Generic Aluminum Silcate 35. Nofaxin Tab / Levofloxacin Antibiotic - Generic 8. Andilac-S Cap / Lactobcillus 36. Aldrin Tab, Susp / Almagate Antacid action Vietnam, Cambodia, Mongolia, Etc Generic Digestive - Generic Acidophillus 37. Noigel Susp / Aluminium Habitual constipation, Antacid action Vietnam, Cambodia, Mongolia, Etc Generic 9. Mutacil Powder / Psyllium husk - Generic magnesium silicate irritable bowel syndrome 38. Norumo Susp / Boehmite Antacid action Cambodia, Etc Generic 10. Motive Tab / Mosapride Cirtate Anticonvulsive - Generic 39. Shumecton Susp / Dioctahedral Antidiarrhotica Cambodia, Etc Generic 11. Etive Tab / Itopride HCI Anticonvulsive - Generic smectite 40. Alluphose Plus Susp / Colloidal 12. Montidin Tab / Levosulpiride Anticonvulsive - Generic Antacid action Cambodia, Etc Generic Aluminum phosphate 12. Telmisartan Tab / Telmisartan ARB - Generic Symptoms due to insufficient 41. Azintal Forte Tab / Azintamide Vietnam Generic 13. Betaprol Tab / Bisoprolol -blockers - Generic bile secretion 42. Ginkgo Biloba Leaf Ex Cap / 14. AmBP Tab / Amlodipine Mesylate Circulatory Improvement Vietnam Generic CCB - Generic Ginkgo biloba leaf extract Monohydrate 43. Alled Tab / Cetirizine HCI Allergin rhinitis Mongolia Generic 15. Furix Tab / Furosemide Diuretics - Generic 44. Alcom Tab / Flubendazole Anthelmintics Mongolia Generic 16. Indapam Tab / Indapamide Diuretics - Generic 45. Epiderm Cream / Triamcinolone Dermatologicals Cambodia, Singapore Generic 17. Atrovastatin Tab / Atorvastatin Hyperlipidaemic - Generic Acetonide 18. Pista Tab / Pitavastatin Hyperlipidaemic - Generic 46. Aminopi Tab / Thiamine Vitamin, Mineral & Nutrition - Generic 19. Actigli Tab / Piolitazone HCI Hypoglycemic agent - Generic 47. Jointap Plus Cap / Sodium Vitamin, Mineral & Nutrition - Generic 20. Hinechol Tab / Bethanechol chondrotin sulfate Autonomic nervous system - Generic Chloride 48. Poweramin Softcap / L-leucine Vitamin, Mineral & Nutrition - Generic genitourinary, Urinary 49. Wonbi-D / White Ginseng Extract Health Drink Malaysia, Mauritius - 21. Poverin Tab / Propiverine HCI frequency, urinary - Generic 50. Sol+(Ginseng energy) / Guarana Afghanistan, Mongolia, USA, incontinence Energy Drink - powder Pakistan, Etc 22. Sildenafil Tab / Sildenafil citrate Erectile dysfunction - Generic Guatemala, Singapore, South Africa, 23. Arthalgyl Inj / Aspirin lysine Fever reducer, Pain reliever - Generic Taiwan, Malaysia, USA, Bangladesh, Vietnam, Spain, Syria, Iran, Egypt, Improvement of brain 51. D.A.H.G (API) / Dried Aluminum 24. Nutrix Tab / Acetly-L-Carnitine - Generic Antacid Raw Material India Ney Oh, China, Cambodia, - metabolism Hydroxide Gel Costa Rica, Colombia, Thailand, Motion sickness, Vomiting, 25. Bonaring A Tab / Dimenhydrinate - Generic Tunisia, Pakistan, the Philippines, Nausea, Meniere’s disease Australia, Hong Kong

112 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 113 Product (Ingredient/Formulation) Use Exporting Countries Remarks Taiwan, Malaysia, the US, Spain, Singapore, Indonesia, Thailand, ISU Abxis Co., Ltd. 52. Magnesium Hydroxide Gel (API) Antacid Raw Material Pakistan, Australia, Hong Kong, - Bangladesh, Guatemala, New Zealand, Syria, Egypt, 53. Almagate (API) / Aluminum Antacid Raw Material China - Magnesium Hydroxide Carbonate Taiwan, Malaysia, the US, Spain, Singapore, Indonesia, Thailand, 54. Magnesium Aluminum Antacid Raw Material Pakistan, Australia, Hong Kong, - Company Profile Metasilicate (API) Bangladesh, Guatemala, New Since 2001, ISU Abxis has established its own platform technologies Zealand, Syria, Egypt, and product pipelines with a desire of being an axis of all therapeutic Bangladesh, Bolivia, Switzerland, antibody industry as its name stands (ABXIS=AntiBody + aXIS). 55. Magaldrate (API) Antacid Raw Material Taiwan, Spain, Ecuador, Egypt, India, - Beginning with the successful development and market-launch of Chile, Pakistan Korean first therapeutic antibody in 2006. Consequently in 2013 and Vietnam, Taiwan, United States, 56. Dried Aluminium Phosphate (API) Antacid Raw Material - 2014, ISU Abxis launched two biotherapeutics for orphan diseases of Singapore, China Gaucher and Fabry disease. ISU’s three products, supplied to over 30 57. Hydrotalite (API) / Aluminum Antacid Raw Material Germany, Indonesia - countries including Turkey, Iran, Mexico and Algeria, are available as Magnesium Hydroxycarbonate Representative the only alternative against the reference drugs worldwide. Moreover, Mr. Seok Joo Lee ISU ABXIS GMP which is for drug substance has been inspected under PIC/S guideline and successfully registered, and application of R&D Pipeline Headquarter Address Global R&D Center C-5F, 22 variation for DS manufacturing site addition were approved by MFDS Compound Name Code Use Stage of Development Daewangpangyo-ro, 712 beon-gil, (Ministry of Food and Drug Safety). ISU Abxis will grow its advanced Ilaprazole - N.E.R.D Phase III Bundang-gu, Seongnam-si, Gyeonggi-do, technology based business for difficult-to-treat and orphandisease market both domestically and worldwide. Radotinib - Chronic Myeloid Leukemia Phase III 13488, Korea - IY-7640 Anti-viral Phase I Foundation Date March 28, 2001 Flu Vaccine - Pediatric Quadrivalent Flu Vaccine Phase III Research Focus Oncology, Metabolic disorder New Active Substances Total Staff Product (Ingredient) Use Approval Date/Country 150 persons Dec. 2007 / China, Oct. 2008 / Korea, Representative Phone Noltec (Ilaprazole) Anti-Ulcer Agent Oct. 2016 / Ecuador, Jan. 2017 / Cambodia 82-31-696-4700 Supect (Radotinib) Anti-CML Agent Jan. 2012 / Korea Web http://www.abxis.com Others Contact Person Mira PARK OUT-LICENSING BUSINESS Contact Phone IL-YANG PHARM CO., LTD. is seeking for a partner in every continent to License out new chemical entity developed by IL-YANG's 82-31-696-4645 very own technology and R&D. IL-YANG is fully focusd on promoting "ILAPRAZOLE (Proton Pump Inhibitor)" and "RADOTINIB (Tyrosine Financial Figures Kinase Inhibitor)" as well as "INFLUENZA VACCINE (Trivalent/Quadvalent)" with other biological products globally with mutual Contact E-mail business relationships. [email protected] Summary (1 Million Won) IN-LICENSING BUSINESS Fiscal Year 2015 2016 2017 IL-YANG PHARM CO., LTD. is dedicated to realize the true value of the products which compliance to IL-YANG's own vision and Sales 11,471 19,055 30,051 strategy. IL-YANG is actively engaged in the In-Licensing business to introduce innovative products from all nations to Korea. R&D Expenditure 5,339 5,344 4,831 ILYANG and Licensor will synergistically maximize the effect of registration, marketing, distribution and sales regarding the product. Capital 9,791 9,875 9,875

114 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 115 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks JEIL Pharmaceutical Co., Ltd. 12 countries The first therapeutic Adjunct to Percutaneous including Algery, antibody developed in 1. Clotinab®(Abciximab) Coronary Intervention (PCI) Turkey, Columbia, Korea and the world’s Venezuela and etc. second Abciximab

20 countries The first drug for GD Enzyme Replacement Therapy including Mexico, Sri developed in Korea 2. Abcertin®(Imiglucerase) (ERT) for Gaucher disease Lanka, Iran, Russia and the world’s second (GD) Company Profile and etc. Imiglucerase We, Jeil pharma have started global business by supplying Penicillin The first drug for FD APIs to a Japanese renowned company and also wide range of Enzyme Replacement Therapy Launched only in developed in Korea plaster products to South East Asian countries in the late 1990s. 3. Fabagal®(Agalsidase beta) (ERT) for Fabry disease (FD) Korea in 2014 and the world’s second Agalsidase beta Our factory has passed the strict standard of PMDA, Japan and also has PICS GMP as Korea has enrolled a member of PICS. As for API facilities, we have 5 dedicated factories such as Cephalosporin injection, Cephalosporin Oral, Caba-penem, Cytotoxic anti-cancer Representative and General APIs. R&D Pipeline Suk Je Sung In finished dosage as well, we have installed dedicated production lines such as Caba-penem injection and Cytotoxic Anti-cancer Compound Name Code Use Stage of Development Headquarter Address 343, Sapyeong-daero, Seocho-gu, Seoul, products. Besides these, we produce many kinds of generics to meet Recombinant Factor IX ISU304 Hemophilia B Phase I 06543, Korea the need of our customers around the world. In 2016, our overseas sales turnover exceeds 60 million US dollarsand more than 50 Novel drug (mAb) ISU104 Solid tumor Phase I Foundation Date countries, we are supplying our products. 1959 Paroxysmal nocturnal Eculizumab ISU305 Phase I (2018) We, Jeil pharma will keep expanding our market with best quality hemoglobinuria (PNH) Research Focus of products and contribute to the enhancement of global citizens' Cardiovascular, Gastrointestinal, but no health. Non Small Cell Lung Cancer, Nivolumab ISU106 Non-clinical study (ready) limitation Melanoma Total Staff Trastuzumab ISU103 Breast cancer Non-clinical study (ready) 945 persons Representative Phone 82-8-529-7451~65 (546) Web www.jeilpharm.co.kr Contact Person Pil Joong Kim Contact Phone 82-2-529-7451~65 (520) Contact E-mail Financial Figures [email protected] Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 594,716 617,280 640,000 R&D Expenditure 20,299 22,313 23,000 Capital 7,425 7,425 7,425

116 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 117 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks JINYANG PHARM. Co., Ltd. 1. Cefditoren (Ingredient) Antibitotics Japan - 2. Cefcapene (Ingredient) Antibitotics Japan - 3. Epinastine (Ingredient) Allergy Japan - 4. Meropenem (Ingredient) Antibitotics Japan - Vitenam,Thailand, 5. Meropenem (Formulation) Antibitotics - Azerbaijan Company Profile 6. Imipenem (Formulation) Antibitotics Vietnam, Thailand - Since Jin Yang Pharm. Co., Ltd. was established in 1971, we have 7. Entecavir (Formulation) Anti Viral Japan, Hong Kong - been trying to stay ahead of the pharmaceutical industry in Korea with our full automatic production system in the most modern and up- to-date manufacturing facility. In 2017, new manufacturing facility which is designed to export our products to advanced countries including U.S. & Europe (cGMP/ R&D Pipeline EU-GMP standard) was completed and PIC/s GMP was approved. Compound Name Code Use Stage of Development Representative It is capable of manufacturing oral formulations over 500 million JPI-289 JPI-289 Stroke Phase 2A Jae-Joon, Choi Tablets(Capsules) per year by using state-of-the-art technologies & equipments. JPI-547 JPI-547 Cancer Phase 1 Headquarter Address We have also been leading the development of the pharmaceutical JP-1366 JP-1366 GERD Phase 1 231, Hyoryeong-ro, Seocho-gu, Seoul, Korea industry in Korea through cooperation with the global pharmaceutical JP-2266 JP-2266 Type 1 Diabetes Mellitus Pre-clinical companies. Foundation Date JCT1-PD JCT1-PD Parkinson’s disease, AMD Pre-clinical July 01, 1971 For more than forty years, based on the principle of honesty and Fixed dose combination drug sincerity, all the staffs and employees of our company have been Tamsulosin/Solifenacin JLP-1207 Phase 3 Research Focus for BPH putting all their efforts into building a better world with the aim of Capsule, Tablet, Dry Syrup developing good quality drugs for health and happy life of the people Fixed dose combination drug Metformin/Rosuvastatin JLP-1310 Phase 3 for diabetes / dyslipidemia Total Staff and with the faith of managing the company in a profound respect 217 Employee for humanity. We promise to be a company that keeps on doing Fixed dose combination research and development for the improvement of life quality of the Telmisartan/Amlodipine/Rosuvastatin JLP-1401 drug for hypertension / NDA Representative Phone people and clients can give their confidence to our company. We will dyslipidemia 82-2-3470-0372 contribute to healthy life of the people by bending over backwards to New salt form drug for Varenicline JLP-1603 NDA help you not to lose your healthy body and happy life. smoking cessation aid Web http://www.jinyangpharm.com/ Clinical trial study UNI-DEB (Medical Device) JLM-1401 Liver Cancer (TACE) (Pivotal study) Contact Person Chang Hwan, Lim Contact Phone 82-2-3470-0361 Others Contact E-mail [email protected] Financial Figures Jeil is partnered with many multinational companies like Pfizer, Takeda, Daiichi Sankyo and etc. We are currently promoting Pfizer's Lipitor, Takeda‘s Nesian, and Daiichi Sankyo's Cravit in Korea, so we have a very good Summary (1 Million Won) understanding of various market and plenty of sales marketing experience. Fiscal Year 2015 2016 2017 We seek new opportunities through in licensing as well as co-promotion. If you are interested in entering the Korean market, Sales 40,100 36,100 46,000 partnering with us will be a great opportunity to both of us. R&D Expenditure 2,172 1,390 1,600 Capital 6,000 6,000 6,000

118 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 119 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks JW Pharmaceutical Corporation 1. CLIVIX (Clopidogrel bisulfate/Tab.) Anti-coagulants - - 2. ESZOL (Esomeprazole/Cap.) GERD - - 3. ATORAN (Atorvastatin/Tab.) Hyperlipidemia - - 4. Acechol (Choline Alfoscerate/Soft Cap.) Neuropsychiatric system - - 5. ELBUNAL (Erdosteine/Cap.) Respiratory system - - Company Profile 6. BESDIPINE (Amlodipine besylate/Tab.) Anti-hypertensives - - Since its foundation, JW Group has led the hospital market based on 7. HYALLON (Hyaluronate sodium/Inj.) Osteoarthritis - - respect for life and the pioneering spirit, and is now being reborn as a 8. ALBIJIN (Pot.bismuth citrate, Ranitidine Digestive system - - global healthcare company to lead the industry into the 21st century. hydrochloride,Sucralfate hydrate/Tab.) Based on leading competitiveness in the ethical drug market, JW 9. MOGATON (Itopride HCl/Tab.) GI-regulator - - Pharmaceutical has built up strong sales network across the country 10. RAMISTA (Rebamipide 100mg/Tab.) Digestive system - - and superior pipelines in I.V solutions, antibiotic, cardiovascular, gastrointestinal, nephrology, anticancer and neuropsychiatry. And 11. ROSUVATIN 10mg (Rosuvastatin Ca./Tab.) Anti-hyperlipidemics - - Representative now, it is pioneering the rapidly growing new field such as diabetes 12. JINFLAG (Sarpogrelate HCl/Tab.) Anti-coagulants - - Mr. Kyung Ha Lee / CEO and so on. It has been striving to produce and provide innovative new 13. OCTIRAN 40mg (Octylonium bromide/Tab.) Digestive system - - technologies and services heading for healthy lives of human beings Headquarter Address on the basis of its founding spirit of "Respect for life". 14. DAPID (Indapamide/Tab.) Anti-hypertensives - - 698, Shindaebang-dong, Dongjak-gu, 15. KAZATAN (Losartan potassium/Tab.) Anti-hypertensives - - Seoul, 156-757 16. MIARYL (Glimepiride/Tab.) Anti-diabetics - - Foundation Date 1945. 17. BANDRON Osteoporosis treatment - - (Ibandronate sodium monohydrate/Inj.) Research Focus 18. ACTOGREEN (Pioglitazone HCl/Tab.) Anti-diabetics - - Anti cancer, Formulation research 19. SIMECOPAN Total Staff Digestive system - - (Simethicone, Alverine citrate/Soft Cap.) 1,872 persons 20. TRIMA (Trimebutine maleate 200mg/Tab.) Digestive system - - Representative Phone 82-2-8406-777 Representative Fax 82-2-841-1213 Web R&D Pipeline http://www.jw-pharma.co.kr/ Compound Name Code Use Stage of Development Atrovastatin Calcium - Antilipidemic Agents BE study Choline Alfoscerate - Nootropics % Neurotonics Formulation Study Antithrombotics & Antiplatelet Financial Figures Clopidogrel bisulfate / Aspirin - Formulation Study Agents Summary (1 Million Won) Linagliptin - DPP-4 Inhibitors Formulation Study Fiscal Year 2008 2009 2010 Sitagliptin - DPP-4 Inhibitors Formulation Study Sales 437,648 455,147 443,276 Empagliflozin - SGLT Formulation Study R&D Expenditure 19,942 22,173 24,231 Capital 23,033 23,774 24,487

120 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 121 Main Products Product (Ingredient/Formulation) Use Exporting Countries KMS Pharm Co., Ltd. Japan, China EU (Spain, Germany) South-East Asia (Hongkong, Indonesia, Malaysia, 1. Carbenem Antibiotics Infection by Gram Mongol, Parkistan, Philippines, Syria, Thailand, (Imipenem/Cilastin) - positive bacteria Vietnam, Yemen, Nigeria, India, Bangladesh etc.) CIS (Russia, Kazahstahn, Belarus, etc.) Latin America (Brazil, Mexico, Argentina etc.) Company Profile Supply electrolytes and trace 2. I.V Solutions South-East Asia (Vietnam, Cambodia, etc.) elements Future oriented pharmaceutical manufacturer producing and distributing finished medicines such as tablets and capsules to the 3. Antifungal Agents Japan domestic and overseas hospitals, pharmacies, etc. under KGMP Infection by fungi (Itraconazole,ketoconazole) South-East Asia (Indonesia, Parkistan etc.) based on PIC/S GMP guidelines.

4. Other antibiotics Japan Various infection (Cefmetazole, amikacin) South-East Asia (Vietnam etc.)

Care for various cancer 5. Anticancer drugs South-East Asia including hematological Foundation Date (Cytarabine,Alkyloxan,5-FU) (Turkey, Malaysia, Bangladesh etc.) cancer July 1997 Research Focus Finished medicines Total Staff R&D Pipeline 60 persons Compound Name Code Use Stage of Development Representative Phone 82-31-215-5456 Phase I clinical trial approved by FDA in April, WnT - Hematological Malignancy 2011 Web www.kmspharm.com Lucentis bio-betters - Metastatic Colorectal Cancer Pre-clinical study for IND application Contact Person BUSH-Tab® Tech (Formulation research) Jong Ho, Kim Montelukast - Anti-Asthma To be launched in January, 2012 Contact Phone 82-31-215-5456(ext. 403) Contact E-mail [email protected] New Active Substances

Product (Ingredient) Use Approval Date/Country 100mg: 6th, May, 1993 Q-ROXIN (Balofloxacin) Antibiotics 200mg: 7th, Jul., 1995 Financial Figures Zepeed (Avanafil) Erectile Dysfunction 17th, Aug., 2011 Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 9,500 11,000 12,900 R&D Expenditure 270 321 380 Capital 1,200 1,200 1,200

122 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 123 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks Kolmar Korea Co.,Ltd. Cambodia, Myanmar 1. Levocetirizine dihydrated 5mg Tab Anti-histamines - Hongkong, Mongolia

2. Tramadol hci 37.5mg / Vietnam, Cambodia Anti-inflammatory - Acetaminophen 325mg Tab Hongkong

Vietnam, Cambodia 3. Levosulpiride 25mg Tab Indigestion - Hongkong Company Profile 4. Losartan potassium 50mg Tab Hypertension Vietnam - Since founded in 1990 as a joint venture company with Nihon(Japan) Kolmar, Kolmar has grown to the biggest Korean Pharmaceutical 5. Rebamipide 100mg Tab Gastric ulcer Vietnam - contract manufacturer. 6. Felodipine 5mg Tab Hypertension Cambodia - Kolmar Korea has extended our business to pharmaceutical business from 2002. And provide specialized production system with total 7. Levodropropizine 60mg Tab Antitussives & Expectorants Hongkong - outsourcing service on development and production of pharmaceutical 8. Streptokinase / and quasi-drug. Enzymes Ecuador - Streptodornase 10mg Tab Representative Kolmar Korea has provided customized contract manufacturing Cho Hong Koo service with customers who want to outsource their pharmaceutical Headquarter Address products, cosmetics and healthcare foods to be more competitive and 245 Sandan-gil, Jeonui-myeon, Sejong to develop new formulations feasible in the market. city, Korea Focus Area : CMO (Contract Manufacturing Organization), Generic Foundation Date drug. 1990.05.15 Research Focus 42 (Pharmaceutical division) Total Staff 650 persons Representative Phone 82-2-3485-0497 Representative Fax 82-2-515-1532 Web http://www.kolmarpharm.co.kr Contact Person Mr.M.S.Pyo Contact Phone 82-2-3485-0397 Financial Figures Contact E-mail Summary (1 Million Won) [email protected] Fiscal Year 2012 2013 2014 Sales 177,779 267,881 439,080 R&D Expenditure 7,418 11,997 17,200 Capital 9,742 9,742 10,550

124 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 125 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks Kolon Pharma 1. Painless Tablet Anti inflammatory Philippines EU-GMP 추진품목

2. Hiforge Tablet Hypertensive Ajerbaijan -

3. Cerephone Dry Syrup Anti-biotic Vietnam -

4. Azithrobiotic Dry Syrup Anti-biotic Vietnam -

5. Romaryl Cream Anti-fungi HongKong - Company Profile KOLON Pharma is focusing on developing and distributing high- 6. Levocetirizine HCl Tab. Anti-histamine The Philippines - quality over the counter pharmaceuticals, prescription medications 7. Minoxidil solution Male pattern alopecia Japan - (mainly respiratory and dermatology) and sports nutrition products in Korean market with a vision of expanding globally. KOLON PHARMA is now working on expanding our business through the open R&D process in Oncology, CNS and Hepatology areas as well as focusing on developing of new drugs by using Incrementally Representative Modified Drug(IMD) technique. R&D Pipeline Woosok Lee Compound Name Code Use Stage of Development Headquarter Address Tadalafil - Eretile dysfunction BE 13 Kolon-ro, Gwacheon, Gyeonggi, Korea

Amlodipine + Olmesartan - Hypertension BE Foundation Date September, 1958 Celecoxib - Antiinflammatory BE Research Focus Atorvastatin Calcium - Hyperlipidemia BE Respiratory, Dermatology

Entecavir - Treatment of HBV BE Total Staff 453 persons Representative Phone 82-2-2120-8300 Web http://www.kolonpharma.co.kr Contact Person Narae Song Contact Phone 82-2-2120-8533 Contact E-mail [email protected] Financial Figures

Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 73,500 81,600 100,200 R&D Expenditure 1,478 1,494 1,600 Capital 6,000 6,000 6,000

126 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 127 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks Korea Arlico Pharm Co.,Ltd. 1. Foster HFA (Beclomethasone Dipropionate, Asthma, COPD - No.1 in MDI Market Formoterol Fumarate / inhalation) 2. Topisol Milk Lotion (Methyl Prednisolone aceponate/ Topical Corticosteroids - No.1 in Topical Steroid Market Topical Lotion) World’s No.1 Surfactant Company Profile 3. Curosurf Neonatal Distress One of the leading product s in - (Poractant Alfa/Oral Solution) Respiratory syndrome hospital -Accounting for 63% of the About 20 years, we Korea Arlico Pharm have been poured our energy Korean market into helping people to live healthier and happier based on the belief 4. COMY Syrup that life is precious and nature is the source of all life. Nasal & Sinus -Ranked No.1 in pediatric (Pseudoephedrine, - Congestion decongestion and rhinitis market Chlorphenylephrine/Oral Solution) We value our quality through KGMP validation for better circumstance. 5. INVOSSA-K Inj. The World's first cell-mediated Osteoarthritis - (1: hChon J, 2: hChonJb#7) gene therapy In the year 2010, we had 30% increase from 2009 and keep growing Disposable sachet its sale record in 2011 and exports to 4 Countries as for April. 2011. 5. APNIBEN Q Soln Cold sores/ Stomatitis - The only mouthwash type Ranked Representative (Diclofenac/Gargle Solution) Hang Gu Lee We Awarded a million dollars "Export top" by Korea International No 1. in Somatitis Tx Market Trade Association in 2013. 6. BICOGREEN S Tab Headquarter Address Ranked No 1. in Constipation (Bisacodyl, Sennoside, Sod. Constipation - And we went public on February 12, 2018. Market Korea Arlico B/D, 7-21,Baumoe-ro Docusate) 27-gil, Seocho-gu, Seoul, 06752, Republic In the near Future, we hope to find more countries to have a strong of Korea partnership. Foundation Date R&D Pipeline OCT. 01, 1992 Compound Name Code Use Stage of Development Research Focus beclomethasone dipropionate + Tablets, Ointments, Creams, Gels KPC-7001 Asthma COPD Pre-registration formoterol + CHF-5992 Total Staff beclomethasone dipropionate + KPC-7002 Asthma COPD Pre-registration 200 persons formoterol high dose Representative Phone Oseltamivir Capsule/Dry Powder for KPC-1023 Influenza Launched 82-2-585-0004 suspension Bepotastine Dry Syrup/SR tablet KPC-2003/2004 Rhinitis Phase 1 Web www.arlico.co.kr Bepotastine + Montelukase KPC-2007 Rhinitis Phase 1 Contact Person Undisclosed KPC-9007 Psoriasis registration SEUNG CHAN HAN Sinecatechins KPC-7104 Warts Pre-registration Contact Phone 82-2-520-6945 Contact E-mail Financial Figures New Active Substances [email protected] Summary (1 Million Won) Product (Ingredient) Use Approval Date/Country Fiscal Year 2015 2016 2017 Morniflu Tab(Monriflumate) NSAIDs 2004.06.09. / Italy Sales 32,985 48,214 71,346 Remicut Cap(Emedastine Difumarate) Anti histamine, For allergic Rhinitis 1994.04.31. / Japan R&D Expenditure 1,770 1,358 1,925 Brexin Tab (Piroxicam beta cyclodextrine) NSAIDs 1992.01.22. / Italy Capital 1,112 1,216 3,211

128 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 129 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks Korea Otsuka Pharmaceutical Co.,Ltd. 1. Thioct HR Tab. Relief and treatment of Vietnam, Mongol - (Thioctic Acid 600mg / Solid oral) diabetic multiple neuritis

2. Acrasone Cream 10g (Betamethasone Dipropionate Anti-inflammatory action and Vietnam, Tanzania, - 0.64mg, Clotrimazole 10mg, good antifungal action Hongkong Gentamicin Sulfate 1mg) Company Profile Hypertension Renal disease 3. Cozasartan Tab. in diabetic patient with - - Established in 1982, Korea Otsuka Pharmaceutical Co.,Ltd. is a joint- (losartan potassium 50mg) hypertension stock company that provides excellent and innovative medicines as part of its mission of contributing to the Korea healthcare industry. Duodenal ulcer, gastric ulcer, 4. Curazol Cap. (Omeprazole 20mg) Ecuador - We have large-scales production facilities in Korea for the consistent reflux esophagitis etc., production of finished goods from synthesis of life. Moreover our products have help treat patients in Korea and improve quality of life. Moreover our products been exported Europe, Asia and the Middle East contributing to the taken an active part in international Representative Others clinical studies, and strived to expand our business starting with the Moon Sungho healthcare business in 2012. Headquarter Address Our ultimate goal is to become a global pharmaceutical company competing against current multi-national companies. Focus Area : CNS, Neurology, Cardiology, Gastroenterology 226 Yeoksam-ro, Gangnam-gu, Seoul, We will vigorously continue to improve our products. Korea Foundation Date July 9,1982 Total Staff 340 persons Representative Phone 82-2-3287-9000 Representative Fax 82-2-3287-9019 Web http://www.otsuka.co.kr Contact Person Kim Taejin Contact Phone 82-2-3287-9124 Contact E-mail [email protected] Financial Figures

Summary (1 Million Won) Fiscal Year 2012 2013 2014 Sales 11,517,041 12,124,578 12,100,153 R&D Expenditure 402,665 213,818 177,080 Capital 17,356,368 17,457,246 18,287,237

130 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 131 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks KOREA PHARMA CO., LTD. Hong-Kong, Philippines, 1. ABILIFY Tab. Anti-psychotic agent - Thailand, Indonesia

2. ABILIFY ODT Anti-psychotic agent OPEL(Europe) -

Hong-Kong, Philippines, 3. PLETAAL Tab. Anti-platelet agent - Thailand, Vietnam, Malaysia Company Profile 4. PLETAAL SR Cap Anti-platelet agent - - Korea Pharma Co., Ltd.(KP) established in 1974, have acquired KGMP Philippines, Thailand, 5. MUCOSTA Tab. Anti-ulcer agent - as we have safe and stabilized production systems. KP maintain the vietnam, Cambodia, Malaysia production process to assure the efficacy, safety and stability of all 6. SAMSCA Tab. Aquaretic agent Philippines, Thailand - our products such as oral solid forms, oral liquid forms, topical liquid forms, ointment etc. We have built up perfect Q.C. systems, and we 7. Meptin Tab. Anti-asthmatic agent - - are supplying our products to the domestic markets, and exporting to over 16 countries to be widely recognized the manufacturing and 8. Meptin swinghaler Anti-asthmatic agent Philippines, Indonesia - technological achievements in the world. Representative Anti-asthmatic agent Philippines, Thailand, Focus Area : CNS Drug, Colon Cleansing Agent, Alimentary 9. OBUCORT swinghaler - Jae Don Park (Inhalation) Indonesia Preparation etc. Headquarter Address 10. Mikelan Tab. Anti-arrhythmic agents - - 87, Jeyakgongdan 3-gil, Hyangnam-eup, Hwaseong-si, Gyeonggi-do, Korea HSCT (hematopoietic stem cell 11. Busulfex IV transplantation)Conditioning - - Foundation Date agent Sep. 03, 1974

12. Lorelco Tab. Anti-hyperlipidemic agent - - Research Focus Developing innovative new medicines Total Staff 242 persons Representative Phone 82-2-558-1277 Representative Fax 82-2-558 1678 Web www.koreapharma.co.kr Contact Person Jin Wook Lee Contact Phone 82-70-4742-8845 Financial Figures Contact E-mail Summary (1 Million Won) [email protected] [email protected] Fiscal Year 2012 2013 2014 Sales 44,744 50,046 54,829 R&D Expenditure 1,010 1,350 1,453 Capital 3,300 4,200 4,200

132 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 133 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks Korea Prime Pharm. Co., Ltd. 1. VASTIA Tab. 5mg/10mg Central nervous system agent Hong Kong - (Donepezil HCl 5mg, 10mg)

2. ALBIX Tab. 10mg Central nervous system agent Hong Kong - (Memantine HCl 10mg)

3. KOTASE Tab. Anti-tumefacient enzyme (Bromelaine 40mg & Crystalline Myanmar, Vietnam - preparation Company Profile Trypsin 1mg) KOREA PRIME PHARM. CO., LTD. is specializes in manufactures and 4. BAB Chewable Tab. sales of pharmaceutical drugs(ETC) and Hospital doctors prescribe (Hydrous dibasic calcium phosphate Alimentary preparation Myanmar - medications, and going to achieve higher growth rate of 30% per year 100mg, Calcium lactate 25mg, rather than the average growth rate of the pharmaceutical industry. Vitamins, etc.) Furthermore, domestic pharmaceutical companies are noticed 5. AMOROLFINE Nail Lacquer Topical antifungal agent for - - to a big change by Korea-US FTA agreement recently. Therefore, (Amorolfine HCl 5g) onychomycosis Our c35,145ompany cope with the policy changes of the domestic pharmaceutical industry and the opening of the global pharmaceutical 6. CRICOLON Tab. Representative (Dibasic Sodium phosphate Kim Dae Ik market, and we think to develop new products as a top priority Tablet type colon cleansing anhydrous 398mg, Monobasic - - in order to grow as a global company, and are focusing on doing agent Headquarter Address Sodium phosphate business making new drugs(improved new drugs, Biomedicine, drug monohydrate1,102mg) 8F, Daein B/D, 158-3, Daein-dong, Dong- formulation development, and so on) by R&D cooperation. gu, Gwangju, Korea 7. RISDON Tab. 1mg/2mg In particular, our company awarded "2009, Korea Health Industry Central nervous system agent - - Foundation Date (Risperidone 1mg, 2mg) Award", and "Grand Prize"in the part of independent medium venture 1995. 5. 31 company. With this opportunity, we will increasingly continue to 8. PAROXETINE Tab. 20mg work hard with the responsibility of the development of domestic Central nervous system agent - - Research Focus (Paroxetine HCl 22.8mg) Medicine pharmaceutical health industry. Total Staff 253 persons Representative Phone 82-2-848-8487 Representative Fax 82-2-848-8489 Web http://www.koreaprime.co.kr/english/ main.htm

Financial Figures

Summary (1 Million Won) Fiscal Year 2008 2009 2010 Sales 35,145 43,544 60,233 R&D Expenditure - - - Capital 1,950 2,150 2,150

134 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 135 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks KOREA UNITED PHARM.INC. 1. Denical Tab. (Calcium lactate pentahydrate 271.8mg, Calcium Glluconate In case of calcium shortage/supply Vietnam, Cambodia - 240mg, Precipitated Calcium Carbonate 240mg, Dried Crgocalciferol 0.118mg) Pharyngolaryngitis, acute bronchitis, tonsillitis, 2. Throgin Tab. bacterial pneumonia, otitis media, sinusitis, Vietnam, Cambodia - Company Profile (Roxithromycin 150mg) periodontitis, etc. · Establishment Date : Dec. 3, 1987 Respiratory tract infection, infections in ear, nose, 3. Rocin Tab. throat, mouth and tooth, renal and urinary tract Vietnam, Cambodia - · Business Activities : Manufacture, Marketing & Sales of (Ciprofloxacin 250mg) infection, etc. Pharmaceuticals and Other Healthcare Products 4. Anflaim Tab. respiratory tract infections, urinary tract infections, Vietnam, Cambodia - · Number of registered products : about 307 items (Ofloxacin 100mg) dermatological infections, gynecological infections · Number of employees : 810 (Feb. 28, 2017) hyperlipidemia, prophylactic use in 5. Simbidan Tab. hypercholesterolaemic patients with ischaemic Vietnam - · Investment in R&D : 12.8% of net sales (2016) (Simvastatin 20mg) heart disease Representative · Sales : $160M (2016) 1. Anti-inflammation and analgesia in the Duk-young Kang · Growth Rate from 2015 to 2016 : 9.2% following diseases and symptoms : Chronic Headquarter Address rheumatoid arthritis, osteoarthritis, low back pain, 25-23, Nojanggongdan-Gil, Jeondong- · Incrementally Modified Drug : Clanza®CR, Clavixin®Duo Cap, scapulohumeral periarthritis and neck-shoulder-arm Myeon, Sejong, Korea 6. Loxorofen Tab. syndrome. Cilostan®CR, Kalomin®Tab, Losasc®Tab5/50, Losasc®Tab5/100, Gastiin®CR, Levotics®CR (Loxoprofen sodium 68.1mg) 2. Anti-inflammation and analgesia after operation, Vietnam, Cambodia - Foundation Date (60mg as anhydrous) trauma or tooth extraction. Dec. 03, 1987 KUP is an export-oriented company. KUP is aiming to be not only 3. Anti-pyresis and analgesia in the following a local leader but also global leading company by offering wide range of diseases : Acute upper respiratory tract Research Focus generics as well as differentiated products, incrementally modified drugs. inflammation(including acute upper respiratory tract Drug delivery system inflammation accompanied by acute bronchitis) - Novel Controlled Release Formulation KUP has broad and well balanced portfolio of 307 products and Rheumatoid arthritis, osteoarthritis, (degenerative - Novel Fixed Dose Combination exports 416 different items to 32 countries through global marketing, arthritic disease), sciatic neuralgia, amenorrhoeic and overseas manufacturing facilities in USA, Vietnam, and has 7. Talpain Tab. Total Staff pain, pain caused by trauma, inflammation and Vietnam, Cambodia - business alliances with oversea companies. Especially, KUP (Talniflumate 370mg) 810 persons pain after surgery, tendosynovitis, sprain, adnexitis, established manufacturing facility in Alabama, US for manufacturing pharyngitis, tonsillitis, otitis, sinusitis Representative Phone and distrubuting drugs and health functional foods in 2003. This Duodenal ulcer, gastric ulcer, Gastric oesophageal 82-2-512-9982 facility have allowed KUP to expand markets in US, Japan, and 8. Exad Cap. (Nizatidine 150mg) Vietnam, Cambodia - reflux disease Web Europe with know-hows of FDA regulatory processes. Alleviation of the following symptoms due to http://www.kup.co.kr functional dyspepsia: abdominal fullness, epigastric 9. Borad Tab. (levosulpiride 25mg) Vietnam, Cambodia - discomfort, and stomach soreness, belching, Contact Person nausea and vomiting Jihyun Ahn 10. Apepsia-m Tab. Following diseases and dyspepsia in case of Contact Phone (Domperidone maleate drug administration nausea, vomiting, anorexia, Vietnam, Cambodia - 82-2-558-8612 12.72mg) abdminal Distension, abdominal pains, flatulence, Financial Figures (10mg as Domperidone) etc. Contact E-mail [email protected] Summary (1 Million Won) Fiscal Year 2015 2016 2017 R&D Pipeline Sales 162,039 176,905 - Ingredient Use Stage of Development R&D Expenditure 16,434 17,456 - Sildenafil citrate Treatment for erectile dysfunction. Bioquivalence Test completion Capital 227,804 234,220 -

136 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 137 KUP invested in Research&Development. KUP invested about 12% of net sales and 10% of total employees in R&D continuously. KUP is Korea Vaccine successful developing innovative drugs and commercializing them. As a result, KUP has launched several IMDs including Clanza®CR Tab., Calvixin®Duo Cap., Cilostan®CR Tab., Kalomin®Tab., Losasc®Tab5/50, Losasc®Tab5/100, Gastiin®CR Tab., Levotics®CR Tab.. In addition, KUP has well balanced R&D portfolio including differentiated products of anti- neoplastic, Anti-hypertensive, and Antithrombotic Drugs. KUP has been acknowledged at home and abroad. KUP was Company Profile nominated as Forbes’ ‘Asia’s 200 Best Under A Billion’ over two Specializing in production of infectious disease preventive consecutive years. KUP is one and only pharmaceutical company in Korea medicine(Vaccine) and disposable medical devices, Korea Vaccine nominated by the Forbes magazine as one of the ‘Asia’s 200 Best Under has contributed to people's health since 1954. A Billion’ over two consecutive years (2009~2010). KUP was awarded the Best Drug Research Award in Korea for Cilostan®CR Tab in 2015. Focus Area : Pediatric vaccine and disposable medical supply.

Main Products Representative Product (Ingredient/Formulation) Use Exporting Countries Remarks Deok-Ho Choi · Improved dosing Headquarter Address 1. Clanza®CR Tab. Pain caused by rheumatism regimen from b.i.d. to Ukraine, Vietnam, 128, Mongnae-ro, Danwon-gu, Ansan-si, (Aceclofenac 200mg / Controlled (Antiinflammatory Analgesic q.d. Philippines Gyeonggi-do, South Korea Release Formulation) drug) · Less side effects of gastrointestinal Foundation Date · Improved dosing 1956.01 2. Cilostan®CR Tab. Ischemic symptoms, regimen from b.i.d to Research Focus (Cilostazol 200mg / Controlled Thrombosis (Antithrombotic - q.d. Vaccines Release Formulation) drugs) · Reduced side effects of headache & tachycardia Total Staff 3. Clavixin®Duo Cap. 260 persons Acute coronary syndrome · Improved patient (Clopidogrel 75mg and Aspirin - (Antithrombotic drugs) compliance 100mg / Fixed Dose Combination) Representative Phone 82-31-495-6397~8 4. Kalomin® Tab. (Pelargonium Sidoides(as dry Upper respiratory tract · Improved patient 82-2-443-1961~5 - extract) 20mg / New Dosage infections (Antitussive) compliance for adults Representative Fax Formulation) 82-2-2249-0363 5. Losasc® Tab5/50, 5/100 (Amlodipine 5mg and Losartan · CCB+ARB in ONE tablet Web Hypertension 50mg / Amlodipine 5mg and - · Patent protected unique www.koreavaccine.com (Anti-hypertensive drugs) Losartan 100mg, Dual Layer Anti- formulation Contact Person Oxidant) Sungbae Ha Gastrointestinal symptoms 6. Gastiin®CR Tab · Improved dosing associated with functional Contact Phone (Mosapride 15mg / Controlled - regimen from t.i.d. to Financial Figures dyspepsia(brash, nausea, Release Formulation) q.d. 82-2-443-2008 vomiting) Summary (1 Million Won) Contact E-mail · Just one tablet, twice a Fiscal Year 2012 2013 2014 daily [email protected] 7. Levotics®CR Tab. Sales 115,774 100,700 133,200 Antitussive - · Performed clinical trial (Levodropropizine 90mg) lll phase of 8 university R&D Expenditure 179 236 206 hospitals Capital 46,790 55,646 63,256

138 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 139 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks KOREAN DRUG CO., LTD. 1. Freeze-dried BCG Prevention of Tuberculosis - Global distributorship vaccine(percutaneous)

2. Kovax Polio PF. Prevention of Poliomyelitis - -

Prevention of Thphoid 3. Typhoid Kovax Inj. - - bacillus Company Profile 4. Kovax Influ PF (Influenza Vaccine) Prevention of Influenza - - We manufacture, distribute, export and import more than 180 5. IL-YANG Flu Vaccine (Influenza Prevention of Influenza - Global distributorship medicines, health functional foods and cosmetics. Also, do contract Vaccine) manufacturer of specific dosage forms, supplies medicines and 6. Vari-L Vaccine Inj. Prevention of Varicella - Global distributorship diverse products. We have always been eager to be the most reliable and trustworthy Prevention of pharmaceutical company that can bring the highest value to the 7. CD.JEVAX Inj. Japanese - Global distributorship society, clients and employees since our establishment in 1980. Encephalitis Virus Representative We started the progressive sales of our OTC products and we become Sang Hun, Park a famous local brand in Korea with the launch of our brand Haben®, Headquarter Address a common cold remedies. Also, another brand called Santamon®, 34, 28 Gil, Nonheyon-ro, Gangnam-gu, an anti-anemic, had a very good reception in the market. These Seoul, Korea achievements made us an important place in the OTC market and we earned the affection and respect of the Korean society. Foundation Date January, 1980. Later on, after continuously developing and researching new drugs day and night and start the incrementation of our sales in the ETC Research Focus market with notorious and innovative products. Central Nervous System drugs Nowadays, we are developing and doing research in Lifestyle Total Staff modification products, such as Vitamins, Omega 3 and nutrients, 255 persons essentials for patients and human’s healthy lifestyles. Representative Phone 82-2-529-6100 Web www.nicepharma.com Contact Person Eun Young, Park Contact Phone 82-2-529-6100 (Ext. 313) Contact E-mail [email protected] Financial Figures

Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 47,390 55,308 59,000 R&D Expenditure 2,405 3,278 3,600 Capital 5,500 5,500 5,500

140 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 141 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks KUKBO SCIENCE 1. Neuromed Alzheimer's dementia China - (Oxiracetam/Tablet, Syrup, Injection) 2. Gabatin Vietnam, Myanmar, Epilepsy, Neuropathic pain - (Gabapentin/Tablet, Capsule) Cambodia 3. Neurocept (Donepezil/Tablet) Alzheimer's dementia Vietnam - 4. Lukema Asthma, Allergic rhinitis Vietnam - (Montelukast/Tablet, Chewable tablet) Company Profile Schizophrenia, Bipolar 5. Zypeace OD (Olanzapin/OD Tablet) Vietnam - We, KUKBO SCIENCE LTD., have produced public health insecticides disorder and rodenticides and made effort to make eco-friendly products over Singapore, Vietnam, 6. Allertec (Cetrizine/Tablet) Allergic rhinitis, Skin itching - 47 years under 'Human Living, Human Environment' as company Cambodia philosopy. 7. Isotren (Isotretinoin/Soft capsule) Severe acne Vietnam, Cambodia - KUKBO SCIENCE. LTD is the biggest pest control company in South of 8. Plamed (Clopigorel/Tablet) Atherosclerotic symptoms Vietnam - Korea. We have exported our products about 20 countries around the world. Representative R&D Pipeline HO-YOUNG AHN Compound Name Code Use Stage of Development Headquarter Address 49, SANDAN-RO, HEUNG DEOK-GU, Crude extract KDC14-1 Osteoporosis Phase I CHEONGJU-SI, SOUTH OF KOREA Crude extract KDC14-2 Anti-thrombosis Research Foundation Date Crude extract KDC14-3 Brain disease Research 1983.02.10 Crude extract KDC14-4 Inflammatory bowel disease Pre-clinical Research Focus Crude extract KDC14-6 Atopy treatment Pre-clinical MANUFACTURING Total Staff 73 persons New Active Substances Representative Phone 010-6844-1527 Product (Ingredient) Use Approval Date/Country Web Neuromed Tablets (Oxiracetam) Alzheimer's dementia 1992-03-11/Korea WWW.KUKBOSCIENC.CO.KR Ribecca Cream (Difluprednate) Eczema, dermatitis 1995-01-05/Korea Contact Person SOPHIA KIM Other Contact Phone 010-3845-0842 Contact E-mail [email protected] Financial Figures

Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 9,517 9,713 9,192 R&D Expenditure 510 686 524 Capital 2,300 2,300 2,300

142 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 143 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks Kukje Pharma Co., Ltd. Thailand, Oman, 1. Cleanbait power 35g Pest control Qatar, Russia, Hong - (Hydramethylnon 2%) kong etc

2. Coumafen Jordan, Philippine Pest control - (Flocoumafen 0.005%) etc

Vietnam, Chile, 3. Delta zone MC Company Profile Pest control Spain, South Africa, - (Deltamethrin 2.5%) UAE etc Kukje took its first step as a prescription drug manufacturer 57 years ago. It is now Korea’s representative pharmaceutical company and continues further growth in becoming a global leader that will help render people around the world healthier. Kukje is committed to its vision of developing prescription drugs to prevent diseases as well as render your lives more meaningful and beautiful.

Representative Mr. Nam Tae-Hoon Headquarter Address 96-8, Yatap-ro, Bundang-gu, Seongnam- si, Gyeonggi-do, Republic of Korea Foundation Date Jul. 27, 1959 Total Staff 500 persons Representative Phone 82-31-781-9081 Web www.kukjepharm.co.kr Contact Person Mr. H. J. Lee Contact Phone 82-70-7461-7314 Contact E-mail [email protected]

Financial Figures

Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 111,651 114,992 122,291 R&D Expenditure 3,438 4,424 6,511 Capital 16,607 16,607 17,397

144 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 145 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks Kwang Dong Pharmaceutical Co.,Ltd. 1. Cefminox Sod. Inj. 1g/0.5g Antibiotics China -

2. Ceftazidime Inj. 1g Antibiotics Vietnam -

3. Lincomycin Hcl. Inj.600mg Antibiotics Vietnam -

4. Spectinomycin Hcl Inj. 2g Antibiotics Iran - Company Profile 5. Amlodipine Tab.5mg Hypertension Cambodia - Primary Logo Secondary Logo Kwang Dong Pharmaceutical Co., Ltd. has tried its utmost to 6. Cefotetan Inj. Antibiotics UAE - manufacture superior medicines for the last half a century since it took the first step to supply medicines in Korea,abarrenlandforth emedicalindustryin1960’s. Kwang Dong has been advancing in to a top-ranking pharmaceutical company in the world through thee establishment of the most advanced factories in Pyungtaek City. We have been enjoying an excellent reputation in technology over R&D Pipeline Primary Signature Secondary Signature forty years because of the goods quality and dependability of our Compound Name Code Use Stage of Development Representative goods. We are one of leading pharmaceutical manufacturer in Korea Soo Boo Choi Nizatidine&Irsogladine Cap. - Gastritis Phase 3 is completed having GMP factory for ETC, OTC, drink and nutrition supplement. Headquarter Address So, we have been exporting to our pharmaceutical products (Finished Cyclosporin eye-drop - Dry Eye syndrome Phase 3 is ongoing 1577-4, Seocho-dong, Seocho-gu, Seoul, products) to sell all over the world. Rebamipide eye-drop - Dry Eye syndrome nonclinical trial is ongoing Korea Foundation Date October. 16, 2012 Research Focus Pharmaceutical Other Total Staff Our product line with certified PIC/s GMP is fully equipped with high performance modern technology such as high-quality lyophilizer 749 persons for producing Cephalosporin Injections. Approximately 150 kinds of medicines including ophthalmic products, antibiotics, GI products, Representative Phone CV products, NSAIDs and etc. are produced and sold as of now and, at the same time, we are constantly expanding the CMO 82-2-6006-7258~9 business. Representative Fax 82-2-6006-7024 Web www.ekdp.com

Financial Figures

Summary (1 Million Won) Fiscal Year 2008 2009 2010 Sales 276,173 276,585 289,435 R&D Expenditure 6,500 6,630 6,150 Capital 52,400 52,400 52,400

146 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 147 Main Products Product (Ingredient/Formulation) Use Exporting Countries Kyongbo Pharmaceutical Co., Ltd. Advanced prostate cancer in combination with LHRH 1. Bicalude Tablet (Bicalutamide 50mg) Vietnam, Nigeria analogue therapy or surgical castration 2. Lenara Tablet (Letrozole 2.5mg) Breast cancer - 3. Kwangdong Woohwang Stroke, Hypertension, Palpitation, Mental anxiety, Acute. Vietnam Chungsimwon 4. Sedera ODF (Sildenafil citrate 50mg) Treatment of erectile dysfunction - 5. Cool strip ODF (Cetylpyridinium Preventive treatment of pharyngitis, amygdalitis, Company Profile - chloride 1.5mg) stomatitis Kyongbo Pharm. has committed Contract Manufacturing Analgesia, anti-inflammatory : arthrosis deformans, 6. KD-Fen Plaster(Diclofenac Organization(CMO) business with sufficient technical and marketing tenontothecitis, tennis elbow, myalgia, post traumatic Hong Kong Diethylammonium 120.0mg) resources. As one of major manufacturers of APIs and finished pain dosages in Korea, we will put utmost efforts along with the best 7. Clisia Solution(Clindamycin staff of R&D and quality assurance to be a global pharmaceutical phosphate 1.188g/100mL ( 1g as acne vulgaris Hong Kong, Cambodia manufacturer. Our modern facilities and infrastructure guarantee Clindamycin) that our products meet superior quality in accordance with cGMP 8. Beaurasen Injection(placenta 100mg, standards. menopausal disorder Malaysia, Hong Kong Benzyl Alcohol 0.03mg) Representative Focus Area : General API, Anti-Cancer API, Cephalosporins API, 9. Kwangdong Ceftriaxone Sodium Inj. Treatment of community-acquired or mild to moderate Taewon Kang Afghanistan, Vietnam Carbapenem API (Ceftriaxone Sodium1g) health care-associated pneumonia Headquarter Address 1. after 5-FU therapy recurrent, progressive metastatic 174, SIROK-RO, ASAN-SI, rectal cancer, colon carcinoma CHUNGCHEONGNAM-DO, 336-020, 2. combined treatment with 5-FU or Leucovorin, KOREA progressive metastatic rectal cancer, colon carcinoma 10. Iritesin Injection(Irinotecan 20mg) Georgia without other therapy Foundation Date 3. gastric cancer (incapable surgery or requrrent) Mar., 31, 1987 4. small cell lung cancer Research Focus 5. progressive small cell lung cancer GENERIC Total Staff 352 persons R&D Pipeline Representative Phone Category Product Name Development Phases Indicant dosage form Development Type 82-2-365-2301 License in from Representative Fax KD501 Clinical test Phase II dementia oral Elcomscience (Kor) Central Self developed 82-2-2175-2388 Nervous Web dementia, System www.kbpharma.co.kr KD103 Developing Alzheimer's considering Self developed disease Contact Person Richard Kim Metabolic KD101 Pre clinical obesity oral Self developed disease Contact Phone Financial Figures 82-2-2175-2387 License in from Endocrine Summary (1 Million Won) KD802 Pre clinical short stature Injection Genexine (Kor) / Contact E-mail System Fiscal Year 2012 2013 2014 joint research [email protected] Sales 152,822 162,238 170,278 Digestive antinauseant Ramosetron ODF IND oral / film Self developed R&D Expenditure 4,408 4,724 5,357 trouble medicine Capital 10,758 10,758 10,758

148 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 149 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks Kyowa Hakko Kirin Korea Co., Ltd. 1. ATORVASTATIN Hypolipidemic Japan -

China, Japan, South 2. CEFTIZOXIME Anti-Biotic - east Asia(SEA)

EU, Japan, SEA, 3. CEFTRIAXONE Anti-Biotic - Russia etc Company Profile 4. CLARITHROMYCIN Anti-Biotic Japan - Korean affiliate of Kyowa Hakko Kirin Co., Ltd., Japan 5. PRANLUKAST Anti-asthmatic Japan - A global specialty pharmaceutical company mainly focused on 6. Loxoprofen Anti-inflammatory Turkey - Hemato-oncology, Nephrology, Immunology and CNS area with world leading high technology on antibody. 7. SULBACTAM -lactamase inhibitor Japan, Russia - Focus Area : Hemato-oncology, Nephrology, Immunology and CNS 8. Cefroxadine Anti-Biotic Japan - area

9. Cefotaxime Anti-Biotic Russia, SEA etc - Headquarter Address 5th Floor, Samwon Tower, Yeoksam-dong, 10. Clopidogrel Anti-platelet Japan - 124, Teheran-ro, Gangnam-gu, Seoul, Korea Foundation Date May 24th, 1991 R&D Pipeline Research Focus Hemato-oncology, Nephrology, Compound Name Code Use Stage of Development Immunology, CNS Tenofovir Disoproxil - HBV Pilot scale Total Staff 74 persons Duloxetine HCl - Antidepressant Pilot scale Representative Phone Ezetimibe - Hyperlipidemia Pilot scale 82-2-3471-4321 Cinacalcet HCl - Hyperlipidemia Completed Process validation Representative Fax 82-2-3471-4322 Dabigatran Etexilate - Anticoagulant Pilot scale Web Vildagliptin - Diabetes Pilot scale www.kyowa-kirin-korea.com Sitagliptin Phosphate - Diabetes Pilot scale Contact Person Mr. Sang Heon Lee Memantine HCl - Alzheimer'S Disease Completed Process validation Contact Phone 82-2-2181-2926 Financial Figures Contact E-mail [email protected] Summary (1 Million Won) Fiscal Year 2012 2013 2014 Sales 41,919 47,768 50,528 R&D Expenditure 1,097 1,925 3,623 Capital 2,000 2,000 2,000

150 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 151 Main Products Compound Name Code Use Stage of Development

Product (Ingredient/Formulation) Use Exporting Countries Remarks - KHK4577 Atopic Dermatitis PII

1. Neulasta (Peg filgrastim) Neutropenia - - - KHK7580 Secondary Hyperparathyroidism PII

2. Grasin (Filgrastim) Neutropenia - - Bardoxolone Methyl RTA402 CKD in Patients with Type 2 Diabetes PII

3. Nesp (Darbepoetin alfa) Anemia - - X-linked Hypophosphatemic Rickets(XLH)inpediatricpatients PII 4. Regpara (Cinacalcet HCl) Secondary Hyperparathyroidism - - X-linked Hypophosphatemic - KRN23 Rickets/Osteomalacia(XLH)inadultpatients PI 5. Renagel (Sevelamer HCl) Hyperphosphatamia - - X-linked Hypophosphatemic Rickets/Osteomalacia(XLH)inadultpatients PI 6. Nplate (Romiplostim) Idiopathic Thrombocytopenic Purpura - - - KHK2823 Cancer PI 7. Mitomycin-C (Mitomycin) Cancer - - - KHK2898 Cancer PI 8. Leunase (L-asparaginase) Cancer - - - KHK4083 Autoimmune diseases PI

KHK2804 - Cancer PI CEP37250

- KHK6640 Alzheimer's Disease PI R&D Pipeline Tivozanib KRN951 Cancer PI Compound Name Code Use Stage of Development Idiopathic Thrombocytopenic Purpura Launched Romiplostim AMG531 Aplastic anemia PII

Leukemia/Lymphoma Launched Cutaneous T-cell Lymphoma PIII Peripheral T-cellLymphoma PII Mogamulizumab KW0761 Adult T-cell Leukemia/Lymphoma PII Solid Tumor PI Asthma PI

Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency Launched Antithrombin Gamma KW3357 Disseminated Intravascular Coagulation, PI Congenital Antithrombin PI

Granisetron - Chemotheraphy induced Nausea and Vomiting Launched

Tivantinib ARQ197 Hepatocellular Cancer PIII

Benralizumab KHK4563 Asthma PIII

Brodalumab KHK4827 Psoriasis PIII

Istradefylline KW6002 Parkinson's Disease PIII

Mesalazine Z206 Ulcerative Colitis PIII

- ASKP1240 Organ Transplant Rejection PII

- BIW8962 Cancer PII

152 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 153 Main Products Kyung Dong Pharm. Co., Ltd. Product (Ingredient/Formulation) Use Exporting Countries Remarks 1. Clopidogrel bisulfate (API) - Japan -

2. Roxatidine acetate HCl (API) - Japan, China -

3. Aclovir Inj (Acyclovir) - Pakistan, Chile -

Pakistan, Yemen, Vietnam, 4. Ceftisone Inj.(Ceftriaxone sodium) - - Company Profile Philippines, Afghanistan Kyung Dong Pharm. Co., Ltd. established a GMP factory in 1987 to 5. Ducas Tab. (Tripotassium bismuth dicitrate) - Vietnam - manufacture medical products with good quality. 6. Rebamide Tab.(Rebamipide) - Philippines - Since we were approved as a designated KGMP company in 1991, we have been producing more than 80 items including tablets, 7. Cozoltec Tab. (Cetrizine HCl) - Pakistan, Vietnam, Cambodia - capsules, injections, and solutions. We have approved BGMP manufacturer since 2001 and also have the cGMP and EU-GMP grade facilities for general finished product and R&D Pipeline Representative API. Compound Name Code Use Stage of Development Ryu Deokhee Bucillamine (API) - Antirheumatic Process Validation Headquarter Address 9F, Kyungdong B/D, 1926 Imidafenacin (API) - Urinary antispasmodic Process Validation Nambusunhwan-ro, Gwanak-gu, Seoul, Korea Risperidone (API) - Antipsychotic Process Validation Foundation Date Escitalopram (API) - Antidepressant R&D Sep. 1975 Ambrisentan (API) - Pulmonary hypertension R&D Research Focus Circulatory system, Digestive system Pilsicainide (API) - Antiarrhythmic R&D Total Staff Istradefylline (API) - Antiparkinson R&D 618 persons Suplatast (API) - Antiallergic R&D Representative Phone 82-2-570-6135 Clopidogrel Camsylate (Finished Product) - Antiplatelet KFDA Approved

Web Esomeprazole base (Finished Product) - Anti-peptic ulcer KFDA Approved www.kdpharma.co.kr (Finished Product) KD3003 Anti-rheumatic Preclinical Research Contact Person Nam, Gwi Hyun (Finished Product) KD4001 Anti-diabetic Preclinical Research

Contact Phone Amlodipine+Valsartan+Rosuvastatin Anti-hypertensive and Anti- KD5001 Clinical Research 82-2-570-6168 (Finished Product) hyperlipidemic Contact E-mail Financial Figures Varenicline Besylate (Finished Product) KD8001 Smoking cessation treatment Clinical Research [email protected] Summary (1 Million Won) Fiscal Year 2015 2016 2017 Other Sales 151,893 158,599 175,500

R&D Expenditure 4,390 4,580 5,600 Competitive strong power of Products and Good profit structure by 1st generic development through R&D and patent research. Capital 13,575 13,575 13,575

154 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 155 Main Products Kyung Nam Pharm. Co, Ltd Product (Ingredient/Formulation) Use Exporting Countries Remarks 1. Lemona pulvis (vitamin B,C) vitamin America, Hong Kong, Mongolia -

2. KN vitamin C Tab. (vitamin B,C) vitamin - -

3. Lemo vita C Tab. (vitamin B,C) vitamin America, Hong Kong, Mongolia -

Company Profile 4. Jahasaengryeok (Human Placenta) Tonic nutrition Hong Kong, Mongolia - KyungNam Pharmaceutical has been representing the domestic vitamin C market by its steady seller ‘Lemona’ which has been relieve menopausal 5. Plagensia inj. (Human Placenta) - - receiving constant love for 28 years since the first release in 1983. As symptoms proving its popularity, it has been awarded “Brand Award of the Year for four consecutive years hosted by the Korean Consumers’ Forum 6. PM Solution (Salicylic Acid) athlete's foot treatments - - and shown 73 percent of overwhelming public support in vitamin C product field in 2011. In addition, KyungNam has been occupying the 7. Minol troche relieve Throat - - unrivaled No.1 title in the Human placenta market, which is the origin (Cetypyridinium Chloride) inflammation Representative of the life energy. Mr. Hee-Cheul Lee / CEO Moreover, KyungNam has been leading the general medicines market Headquarter Address through its product such as PM, a typical athlete‘s foot medicine, and 17F, Keumkang Tower B/D, 889-13, Dachi- Minol Troche, a sore throat drug. dong, Gangnam-gu, Seoul, 135-918 Foundation Date Jun 1, 1957 Research Focus Vitamin & Human Placenta Total Staff 244 persons Representative Phone 82-2-3490-5105 Representative Fax 82-2-3490-5129 Web http://www.kyungnampharm.co.kr http://www.lemona.co.kr

Financial Figures

Summary (1 Million Won) Fiscal Year 2008 2009 2010 Sales 43,701 46,869 45,983 R&D Expenditure - - 337 Capital 11,192 14,692 15,350

156 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 157 Main Products Medica Korea Co., Ltd. Product (Ingredient/Formulation) Use Exporting Countries Remarks Singapore, 1. Nimegen Soft Cap.10/20mg Cystic acne and acne Hong kong, Myanma, - (Isotretinoin 10,20mg) conglobata treatment Vietnam

2. GREEN PAM Cap. Supplementary treatment of Vietnam - (Thymomodulin 80mg) bacterial and viral infections.

Treatment of osteoarthritis Company Profile 3. POINTY Cap. (Diacerhein 50mg) Vietnam - disease Established Doing-IlPharmaceutical Co., Ltd., in 1976. Acquired and 4. Allutec Tab. Rhinitis, Conjunctivitis, Hong kong, renamed Medica Korea in 2000 - (Cetirizine Hydrochloride 10mg) Eczema, Dermatitis, etc Cambodia Manufacturing one hundredand twenty pharmaceutical products under the control of KGMP (Korea Good ManufacturePractice). Focus Area : Skin Diseases Target country : Philippines, Vietnam, Cambodia, Hongkong, Representative Singapore, Myanma, etc. R&D Pipeline Chani Jeong Compound Name Code Use Stage of Development Headquarter Address Nimegen Soft Cap. 10mg Cystic acne and acne - Approved 7F, Diplomatic center 2558, (Isotretinoin 10mg) conglobata treatment Nambusunhwan-ro, Seocho-gu, Seoul, Asthmatic bronchitis, Chronic Republic of Korea SALBUTRON SR Cap.4mg - bronchitis, emphysema Approved (Salbutamol sulfate 8mg) Foundation Date disease May 20th, 1976 Hypertension, Meniere’s Research Focus disease, Buerger’s disease, NEWBORN Tab. 25 I.U. ETC, OTC Drugs - menopausal disorder, Approved (Kallidinogenase 25 I.U.) circulatory disturbance of Total Staff chorioretinal disease 165 persons MUCOSTEN INJ. 10% Acute Chronic & Asthmatic Representative Phone - Approved (Acetylcysteine 100mg/mL) bronchiti disease 82-70-4018-8000 CALDIOL Soft Cap.20 Chronic renal failure, Representative Fax - Approved 82-2-585-9689 (Calcifediol 20 ) Metabolic bone disease Web http://www.medicakorea.com/ Contact Person Lee Won Jung Contact Phone Financial Figures 82-2-70-4018-8052 82-2-70-4018-8053 Summary (1 Million Won) Contact E-mail Fiscal Year 2015 2016 2017 [email protected] Sales 30,637 36,858 36,858 [email protected] R&D Expenditure 696 612 463 Capital 3,560 3,560 3,560

158 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 159 Main Products MG Co., Ltd. Product (Ingredient/Formulation) Use Exporting Countries Remarks Under registration in Iran, 1. MG TNA inj. IVH for NPO inpatients Vietnam Kazahstan, Syria, Thailand, Malaysia and Kenya

Mongolia, Vietnam, Under registration in Iran, 2. MG TNA-peri inj. IVH for NPO inpatients Philippines, Kazahstan, Syria, Thailand, Myanmar Malaysia and Kenya Company Profile Under registration in Syria, 3. MG Combi-peri inj. IVH for NPO inpatients Mongolia MG Co., Ltd. is a pharmaceutical company that specializes in Kazahstan manufacturing parenteral & enteral nutrition solution to play a big role in nutrition infusion therapy and its related areas. 4. Lipid LCT inj. 10% / 20% Supply EFA & Calory Mongolia Under registration in Iran It is mandatory for patients to provide proper nutrition to treat the Under registration in overseas 5. FOMS TNA inj. IVH for NPO inpatients - disease and recover their health, especially for: surgical patients who countries are incapable of taking nutrition, patients with hypoproteinemia and Under registration in overseas malnutrition, patients with wasting disease caused by burn or gash, 6. FOMS TNA-peri inj. IVH for NPO inpatients - countries Representative and patients with immunosuppression. Under registration in overseas Chul-Soo, Shin (Mr.) With a long-term experience and accumulated technology, for the 7. FOMS Lipid inj. 20% Supply EFA & Calory - countries Headquarter Address first time in Korea, we succeeded in localization of a 3-chamber bag 27, Yongso 2-gil, Gwanghyewon-myeon, product, MG TNA with 2-chamber bag products, MG COMBI, and Jincheon-gun, Chungcheongbuk-do, South Lipid LCT etc. Furthermore, we recently developed the new products, Korea FOMS TNA and FOMS Lipid, which are the combination of fish oil, olive oil, MCT oil and soybean oil. R&D Pipeline Foundation Date September 16, 2003 We, MG Co., Ltd., promise our effort and endeavor to provide the best Compound Name Code Use Stage of Development quality products in nutrition therapy and always hold an outstanding Selenium for injection - Supply for Selenium Formulation Research Focus position to take care of human health in the 21st century. Nutrition infusion therapy products Zinc for injection - Supply for Zinc Formulation Total Staff IVH for NPO pediatric 87 employees TPN solution for pediatric patients - Review the formular inpatients Representative Phone Dextrose, Amino acids, Lipid 82-2-2057-1002 - IVH for NPO inpatients Review the formular (New formular for 3-chamber bag) Web www.medi-green.co.kr Dextrose, Amino acids, Lipid, Vitamins, Elements etc. - IVH for NPO inpatients Review the formular Contact Person (The first 4-chamber bag product) Seong-Un, Jeong (Mr.) Contact Phone 82-2-2057-1002 Contact E-mail Financial Figures [email protected] Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 14,480 17,623 20,220 R&D Expenditure 714 823 640 Capital 9,873 11,111 18,670

160 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 161 Main Products MOTHER'S PHARMACEUTICAL CO., LTD. Product (Ingredient/Formulation) Use Remarks 1. RAYBON Tab. (Angelica·Chaenomeles·Ledebouriella·Dipsac Relaxation on Golgwan Georgian ETC us·etc Soft Ext. 405.4mg) 2. STOEM Tab. (Artemisia Asiatica 95% Ethanol ext. 60mg) Chronic gastritis, acute gastritis improvement ETC The above-mentioned · duodenal ulcer, gastritis, 3. RACETINEM Tab. (Ranatidine hydrochloride 84mg, Sol drip-Ellison syndrome, reflux esophagitis, pre- Tripotassium dicitrato bismuthate 100mg, sucralfate anesthesia medication (prevention of Mendelson's ETC Company Profile hydrate 300mg) syndrome), postoperative ulcer, nonsteroidal anti- inflammatory analgesia (NSAID) MOTHER'S PHARMACEUTICAL CO., LTD. is a manufacturing plant 4. ITANDOL Tab.(Titrated extract of zea mays L. Unsaponifiable Gingivitis after periodontal treatment, secondary OTC of tablets, hard capsules authorized from Korea Food & Drug fraction 35mg) treatment of moderate periodontitis Administration. We took over a pharmaceutical company, which had 5. URUQBAC Tab.(Anhydrous dibasic calcium phosphate manufactured oriental medicine more than 35 years. We have even 100mg, Coated ascorbic acid 10 4.17mg, Benfotiamine expanded our business areas to chemical medicine based on natural 50mg, Biotin 0.2mg, Calcium pantothenate 30mg, product research experience. We have been rapidly developing to Cholecalciferol granule 4mg, Choline bitartrate 50mg, 0.1% 1. Supply of vitamin (D, B1, B2, B6, C) OTC become the best pharmaceutical company. Cyanocobalamin 50mg, Folic acid 0.4mg, inositol 50mg, Magnesium oxide 100mg, Nicotinamide 50mg, Pyridoxine Representative hydrochloride 50mg, Riboflavin 50mg, Ubidecarenone Jwa-Jin Kim 10mg, Ursodeoxycholic acid 30mg, y-oryzanol 5mg) Gingivitis after periodontal treatment, Headquarter Address 6. Etantan-Plus Cap. (Ascrobic acid 150mg, Carbazochrome adjuvant treatment of gingivitis and moderate OTC 703-ho, 1-dong, (Lotte Itcastle,) 98, Gasan 2mg, Dried vitamin E 50% 10mg, Lysozyme chloride 30mg) digital 2-ro, Geumcheon-gu, Seoul, Korea periodontitis 7. KERASIDIL Cap. (Calcium pantothenate 60mg, Keratin Foundation Date 1. Damaged hair, poor growth of infectious nails 20mg, L-cystine 20mg, Medicinal yeast 100mg, OTC 2. Assistive treatment of hair loss July 20th, 2011 p-aminobenzoic acid 20mg, Thiamine nitrate 60mg) Research Focus - Constipation - Relieving the following symptoms of Novel drug 8. Bicarine-M EntericCoated Tab. (Bisacodyl 7mg, Docusate constipation: loss of appetite (loss of appetite), OTC sodium 20mg, Sennae folium Powder 100mg) Total Staff abdominal distension, intestinal fermentation, 99 persons hemorrhoids Representative Phone 9. Ranitis Tab. (Aluminum magnesium hydroxide 100mg, 82-2-2026-8890 Aluminium magnesium silicate 125mg, Magnesium oxide Stomach pain, heartburn, indigestion, nausea OTC 50mg, Ranitidine hydrochloride 31.5mg) Web 10. UruqbacClassic Tab. (Anhydrous dibasic calcium www.mtspharm.com phosphate 100mg, Coated ascorbic acid 10 4.17mg, Contact Person Benfotiamine 50mg, Biotin 0.2mg, Calcium pantothenate 30mg, Cholecalciferol granule mg, Choline bitartrate Ye Rin Kim 1. Supply of vitamin D, B1, B2, B6, C 50mg, Cyanocobalamin(1000) 50mg, Folic acid 0.4mg, OTC 2. Supply of zinc Contact Phone Magnesium oxide 100mg, Nicotinamide 50mg, Pyridoxine 82-70-7457-8812 hydrochloride 50mg, Riboflavin 50mg, Ubidecarenone 10mg, Ursodeoxycholic acid 10mg, Zine oxide 21.2mg, Contact E-mail y-oryzanol 5mg) [email protected] Financial Figures

Summary (1 Million Won) R&D Pipeline Fiscal Year 2015 2016 2017 Compound Name Code Use Stage of Development Sales 16,898 24,234 33,000 R&D Expenditure 500 600 1,000 - MTS-F1 - Candidate Capital 2,000 2,000 2,000 - MTS-N1 - Candidate

162 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 163 Main Products Myung In Pharm. Co., Ltd. Product (Ingredient/Formulation) Use Exporting Countries Remarks 1. Igatan-F Cap. Gum disease - -

2. Disgren Cap. Anti-thrombosis China -

3. Silvercept Tab./OD Tab. Dementia - -

4. Q-Rokel Tab./XR Tab. Schizophrenia Peru -

Company Profile 5. Rispen Tab./OD Tab. Anti-psychotic - - Established in 1985, Myung In is a distributor as well as a contract manufacturer with exceptional expertise in the development of small 6. Superpirin Cap. Anti-thrombosis - - molecule, conventional and specialized solid dosage forms including 7. Newpram Tab. Depression&Bipolar disorder - - pellets and bi-layer tablets, and sterile products including liquid/ lyophilized vial and liquid ampoule. 8. Zanapam Tab. Tranquilizer - -

A research-driven pharmaceutical company, Myung In has ranked 9. Proctin Cap. Depression&Bipolar disorder Singapore - first among locals in the field of central nervous system in Korea. 10. Q-Pam Tab./Oral soln./Inj. Epilepsy - - Representative Myung In also collaborates with many global partners to successfully Hang Myung Lee launched their products in Korea, getting them to be blockbusters. Headquarter Address Myung In will continue to expand and invest in facilities to provide Myung-In Bldg, 95, Banpo-daero, Seocho- high quality medicines to patients as well as to meet the growing gu, Seoul, Korea 06657 market demand. R&D Pipeline Foundation Date Focus Area : anti-thrombotic, anti-hypertensive, anti-psychotic, anti- April.1.1985 depressant&bipolar disorder, anti-insomnia, ADHD, anti-convulsant, Compound Name Code Use Stage of Development anti-parkinson, anti-dementia Research Focus Mirtazapine 7.5mg - Depression Approved New Drugs Introduction, Incrementally Betahistine HCl - Vertigo(Off-label:Obesity) Approved Modified Drugs development, New technology export, Overseas CMO Levetiracetam Inj. - Epilepsy Approved business Waiting for approval from Paliperidone - Schizophrenia Total Staff MFDS 430 persons Waiting for approval from Representative Phone Aspirin/Clopidogrel (75mg/75mg) - Anti-thrombosis MFDS 82-2-587-9060 Representative Fax 82-2-585-0352 Web http://www.myunginph.co.kr New Active Substances

Contact Person Product (Ingredient) Use Approval Date/Country Hee Soo Kim Financial Figures Disgren(Triflusal) Anti-thrombosis 1993.12.13 Contact Phone Summary (1 Million Won) 82-2-587-9060 Fiscal Year 2015 2016 2017 Narcaricin Tab.(Benzbromarone) Anti-gout 1995.03.27 Contact E-mail Sales 140,000 148,000 159,000 [email protected] R&D Expenditure 5,400 6,500 9,000 Capital 5,600 5,600 5,600

164 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 165 Main Products Myung Moon Pharm. Co., Ltd. Product (Ingredient/Formulation) Use Exporting Countries Remarks 1. Kimite Patch (Scopolamine 1.5mg) Motion sickness Vitenam, China, Hong-Kong -

2. Dobutamine Inj. Cardiac stimulants Vietnam, Pakistan, Nigeria - (Dobutamine HCl 280.3mg/5ml)

3. Inopan Inj. Cardiovascular drug Vietnam, Pakistan, Nigeria - (Dopamine HCl 200mg/5ml) Company Profile 4. Ketocin Inj. Nonsteoidal Anti- Vietnam, Philippines, Rep. of - In 1983, Myungmoon Pharm. Co., Ltd. was established for the (Ketorolac tromethamine 30mg/1ml) inflammatory drug Dominica improvement of national health. It is achieving remarkable 5. Bupivacaine HCL Heavy Inj. 0.5% Vietnam, Nigeria, Rep. of development via research and development, production, and sales Local Anesthetics - based on its founding principle: Advancement, Harmony, and (Bupivacaine HCL 21.12mg/4ml) Dominica Creation. 6. Pyrinol Tab. Parasympathomimetics Chile, Malaysia - Myungmoon Pharm. Co., Ltd. is an acknowledged manufacturer to (Pyridostigmine Bromide 60mg) produce the finished medicines; Injection, Tablet, Capsule, Patches, 7. Levonia Tab. Contraceptive Vietnam, Mexico - Representative Solution and Creams. (Levonorgestrel 1.5mg) Mr. Lee, Kyu Huok / CEO Nowadays, Myungmoon Pharm. Co., Ltd. produces more than 250 8. Tipem Inj. specialized and general medicines and has more than 400 specialized Antibiotics Vietnam - Headquarter Address (Imipenem 500mg, Cilastatin 500mg) Myungmoon B/D, 946-18 Dogok-dong, and generalmedicine licenses to be able to manufacture. Myungmoon Pharm. Co., Ltd. is focusing on our research and development efforts 9. Esgen Vaginal Cream Gangnam-gu, Seoul Hormons Guatemala - so that Myungmoon Pharm. Co., Ltd. is launching more than 20 new (Estropipate 1.5mg/g) Foundation Date products every year. September, 1983 10. Neocoline Inj. 500mg parkinson diease Uzbekistan, Vietnam - Myungmoon Pharm. Co., Ltd. established the new plant for API in (Citicoline 500mg/2ml) Research Focus 2008. Myungmoon Pharm. Co., Ltd has Gabapentin(USP) and the Medicines, Bio-Product other 8 API products now, however, Myungmoon Pharm. Co., Ltd. Total Staff would have many new API products in the foreseeable future. 450 persons To gain a foothold on biomedicine products, outsourcing strategies Representative Phone are preceding the use of trusted clinical agency CRO and production R&D Pipeline 82-2-6711-2000 agency CMO, and Myungmoon Pharm. Co., Ltd has already started to develop human growth hormones through a bio-venture corporation. Ingredient Use Stage of Development Representative Fax Within 2 or 3 years, Myungmoon Pharm. Co., Ltd. should be launching Sonatropin-PEG conjugate (Bio-Product) GROWTH Hormone Finished Process(Lab Scale) 82-2-572-5137 bio-similar, including EPO and the processing of the complement Erythropoietin(Bio-Product) Erythrogenesis Finished Process(Lab Scale) Web of plants for biomedical products as well as the development of advanced medical bioethics, including monoclonal antibodies. www.mmpharm.co.kr Flumanzenil Inj. 0.5mg Antidote for Midazolam Launching on April, 2012 Myungmoon Pharm. Co., Ltd. is sharply developing to be a professional and global treatment company in the world. Valsartan 160mg, 80mg Hypertension Launching on April, 2012 Lansoprazole 30mg Antipeptic ulcer drug Launching on August, 2012

Financial Figures Sildenafil 100mg Erectile dysfunction Launching on August, 2012

Summary (1 Million Won) Raloxifene 60mg Osteoporosis Launching on July, 2013 Fiscal Year 2008 2009 2010 Sales 77,390 92,246 100,914 R&D Expenditure 1,401 1,741 1,789 Capital 5,100 5,293 5,500

166 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 167 Main Products Pharmbio Korea Co., Ltd Product (Ingredient/Formulation) Use Exporting Countries Remarks 1. Picolight (Sodium Picosulfate, Magnesium Discussing out-licensing Pre-colonoscopic preparation - Oxide(light), Citric Acid(anhydrous)/ in Vietnam, etc. Powder)

2. Urocitra-K Discussing out-licensing Uric acid lithiasis Myanmar (Potassium citrate/Tablet) in Vietnam, etc. Company Profile 3. Urocitra-C Discussing out-licensing Pharmbio Korea Co., Ltd. is an emerging, innovative company (Potassium Citrate, Citric Acid Uric acid lithiasis - in Cambodia, etc. established in 1999, specializing in registration, ex/importing, Hydrate/Powder) manufacturing, and marketing of innovative pharmaceutical products in Korea. It is one of the most influential companies in many 4. Endonse (Pronase B/Powder) Pre-endoscopic preparation - - therapeutic areas. 5. Ribon Discussing out-licensing Postmenopausal (Risedronate Sodium Hydrate / - in Singapore, Hong Kong, Focus Area : Urology, gastroenterology, neurosurgery, orthopedics, osteoporosis general surgery, immunology, etc. Tablet) etc. Representative 6. Gagron Bong Kil, Nam (Pentasan Polysulfate Sodium / Interstitial Cystitis - - Calsule) Headquarter Address A-7F, Samho Bldg, 83 Nonheyon-ro, 7. Movilax Seocho-gu, Seoul 137-940, South Korea (Polyethylene Glycol3350, Chronic constipation - - Electrolytes/Powder) Foundation Date May 1st, 1999 8. Zinkistin Zinc deficiency - - Research Focus (Zinc Histidine Dihydrate / Capsule) 25 9. Acupan casule Discussing out-licensing pain controller - Total Staff (Nefopam Hydrochloride / Capsule) in Nigeria, etc. 170 persons Representative Phone 82-2-587-2551~4 Representative Fax 82-2-529-7454 Web www.pharmbio.co.kr Contact Person Jun Sang, Nam Contact Phone 82-10-4558-8033 Financial Figures Contact E-mail Summary (1 Million Won) [email protected] Fiscal Year 2012 2013 2014 Sales 32,700 39,300 44,200 R&D Expenditure 1,500 2,700 3,300 Capital 20,680 34,065 40,020

168 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 169 Main Products PMG Pharm Product (Ingredient/Formulation) Use Exporting Countries Remarks 1. Layla Tab (12 Herbal extracts 405.4mg) Osteoarthritis - -

2. Rudia Cap 50mg (Diacerein) Osteoarthritis - -

3. Duroc Tab 100, 200, 300 400mg Rheumatoid arthritis - - (Hydroxychloroquine sulfate)

Company Profile 4. Tarsin Cap 0.5, 1mg (Tacrolimus) Rheumatoid arthritis - - PMG Pharm has been a leading pharm in the market for treatments 5. Rheumakin Tab 10, 20mg (Leflunomide) Rheumatoid arthritis - - of rheumatoid arthritis, osteoarthritis, anti-osteoporosis and related 6. Admin Forte Tab diseases and its main business has been focused on the development VitD deficiency - - (Cholecalciferol, VitD 1000IU) of DMARDS, DMOADS and NSAIDs etc. At 13 Mar 2012, a Layla Tab has been registered as a new treatment for the osteoarthritis. 7. Indometa Cap 25mg (Indomethacin) NSAID - - Layla is consisted of 12 medicinal plants which has been recognised 8. SynflexSafe Tab as traditional herbal medicines for arthrosis. PMG Pharm is ready to NSAID - - expand its business by licensing out Layla. (Naproxen/Esomeprazole 500/20mg) Representative Mr. Young Chin Chun 9. Morix Cap 7.5mg (Meloxicam) NSAID - - Headquarter Address 10. Laxib Cap 100, 200mg (Celecoxib) NSAID - - 21 Sinangbukro 4-gil, Sangnok-gu, Ansan- si, Gyeonggi-do, South Korea 11. Droban Tab 150mg (Ibandronate) anti-osteoporosis - - 12. Risena Tab 35, 150mg Foundation Date anti-osteoporosis - - Dec, 2001 (Risedronate Na) Research Focus DMARDS, DMOADS, NSAIDS Total Staff 89 persons R&D Pipeline Representative Phone Compound Name Code Use Stage of Development 82-31-439-5470 PMG1001 - Osteoarthritis In-vitro test Web www.pmgpharm.co.kr Contact Person Ki-Tae Han Contact Phone New Active Substances 82-31-439-5470 Product (Ingredient) Use Approval Date/Country Contact E-mail [email protected] Financial Figures Layla Tab(12 Herbal extracts 405.4mg) Osteoarthritis 2012.03.13/Korea

Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 29,131 32,695 38,000 R&D Expenditure 1,147 1,335 1,500 Capital 2,319 2,636 2,636

170 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 171 Main Products Richwood Pharmaceutical Co., Ltd. Product (Ingredient/Formulation) Use Exporting Countries Remarks 1. Acetracet Tab. (acetaminophen, tramadol HCl) Pain relief - -

2. Ebaco SR Cap. (pseudoephedrine, ebastin) Allergic rhinitis - -

3. Gli-M Tab. 2/500mg (glimepiride, metformin) Type II diabetes - -

Company Profile Buerger's disease, acquired 4. Limaprost 0.17mg (limaprost) - - Richwood Pharmaceutical Co., Ltd., a reliable CMO company with spinal canal stenosis global standards in pharmaceutical manufacturing, has competitive advantages such as holding specialized formulation technologies 5. Cetirizine Tab. (cetirizine) Allergic rhinitis - - using a 3-layer tablet machine and a GPCG series, a strategic partnership with CRO, and development pipelines of herbal medicine. 6. Livaduet Tab. (atrovastatine,amlodipine besylate) Hypertension - -

Representative Mr. JeongSuk Lee / CEO R&D Pipeline Headquarter Address Ingredient Use Stage of Development Danam B/D 22F, 120 Namdaemoonno 5-ga, Jung-gu, Seoul Oxycodone hydrochloride Opioid analgesic Clinical trial Foundation Date March, 1974 Research Focus Finished drug, Herbal medicine Total Staff 146 persons Representative Phone 82-2-778-2351 Representative Fax 82-2-756-5402 Web www.richwood.net

Financial Figures

Summary (1 Million Won) Fiscal Year 2008 2009 2010 Sales 25,192 32,744 41,414 R&D Expenditure 950 1,229 1,589 Capital 500 500 500

172 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 173 Main Products RP Bio Product (Ingredient/Formulation) Use Exporting Countries Remarks 1. Ginsatine Korea Ginseng Multivitamin Vietnam, Cambodia Soft gels (Korea Ginseng 100mg and multivitamins etc.)

2. Caldiol (Calcifediol hydrate 20mg) Vitamins Vietnam, Pakistan Soft gels

3. Ursa (Ursodeoxycholic acid 100mg) Hepatics China Soft gels Company Profile - RP Bio. is CMO by OEM/ODM specializing in Soft Gelatine Capsules 4. Provimin (Korea Ginseng 100mg, etc.) Vitamins Cambodia Soft gels for pharmaceutical and health functional food formulations since 1983. Initially founded as a J/V between R.P. Scherer USA and 5. Livergold-F (Milk Thistle 100mg, etc.) Hepatics Myanmar Soft gels Daewoong Pharmaceutical Co., Ltd. Korea. RP Corp. boasts high quality production as a Korean company to pass international audits. 6. Valix Vaginal (Nystatin 100kIU, etc.) Pessary Vietnam Soft gels

7. Nimegen (Isotretinoin 20mg) Acne Vietnam, Cambodia Soft gels * Infra Representative Seung-ho Han, Nam-gi Kim · KGMP approved Pharmaceutical Mfg. facility (finished dosage: Soft 8. Tak-Sen (Naproxen 250mg) Pain Reliever - Soft gels capsules) Headquarter Address 9. Whituben Q (Acetaminophen 180mg, etc.) Cold Medicine - Soft gels 315 Yeongdong-daero, Gangnam-gu, · Two KGMP approved Health Functional Food Mfg. facilities (one for Seoul, Korea soft capsules and another for tablets, powders and granules) 10. Tobicom-S (L-Citrulline, etc.) Eye - Soft gels Foundation Date Oct.1983 Research Focus Pharmaceuticals, health functional food Total Staff 330 persons Representative Phone 82-2-2002-9800 Web http://www.rpskorea.com Contact Person Hee Jeong Jang Contact Phone 82-2-2002-9819 Contact E-mail [email protected] Financial Figures

Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales - 26,013 70,000 R&D Expenditure - 250 300 Capital - 34,144 40,690

174 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 175 Main Products SamChunDang Pharm. Co., Ltd. Product (Ingredient/Formulation) Use Exporting Countries Remarks 1. Sodium Hyaluronate 0.1% Eye Drops Artificial Tears Vietnam, Myanmar -

Myanmar, Panama, 2. Tobramycin 0.3% Dexamethasone 0.1% Antibacterial Cambodia, Hong - Eye Drops Kong, Yemen

Myanmar, Panama, Vietnam, Cambodia, Company Profile 3. Fluorometholone 0.1% Eye Drops Anti-Inflammatory - China, Costa Rica, SamChunDang(SCD) Pharm. Co., Ltd. is the leading pharmaceutical Hong Kong company specialized in ophthalmic fields. We have acquired EU GMP certificate for sterile eye drops from UK MHRA(Medicines & Hong Kong, Healthcare products Regulatory Agency). Since established in 1943, 4. Mometasone furoate 0.05% Nasal Spray Nasal Spray Myanmar, Vietnam, - we have been providing a high quality pharmaceutical product for the Ecuador, Cambodia purpose of providing healthier and happier lives for everyone. We provide safety and convenience and also offer a wide range of Headquarter Address choices with multi-dose and preservative-free single dose eye drops. We have been exporting pharmaceutical products to more than 25 351, Hyoryeong-Ro, Seocho-gu,Seoul 137- R&D Pipeline 877, Korea overseas countries for more than 20 years and have been seeking to expand in to the global market with EU GMP certificated techology. Compound Name Code Use Stage of Development Foundation Date in 1943 Confidential SCD311 Artificial Tears Formulation development Total Staff Confidential SCD212 analgesics DDI (Phase I complete) 384 Employees Confidential SCD313 Artificial Tears Formulation development Representative Phone 82-2-2046-1100 Web www.scd.co.kr Other Contact Person Mr. Brian Kim Submission of EU CTD (Decentralised Procedure) UK-MHRA has confirmed the dates for submission of Dossier and allocated the DCP Contact Phone number. 82-2-2046-1250 Allocated DCP number(s) together with the PL numbers : UK/H/5793/01/DC - Olopatadineeye drops 1mg/ml, PL 43063/0002 DECENTRALISED Contact E-mail After submission of EU CTD Dossierin Aug. 2014, MHRA (UK) inspection was successfully done in 1st week of Jan. 2015. [email protected] EU GMP Certificate from MHRA, U.K was generated on Mar. 9th,2015. (Certificate No. : UK GMP 43778 Insp GMP 43778/10951938-0001)

Financial Figures

Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 100,514 111,521 120,422 R&D Expenditure 4,357 5,158 9,480 Capital 10,619 11,000 11,053

176 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 177 Main Products SAMA PHARM CO.,LTD. Product (Ingredient/Formulation) Use Exporting Countries Remarks NSAIDs 1. SETOPHENTM (Acetaminophen/ tablets ER (Fever, Pains, Headache, - - tablets & Dry syrup & suspension) Menstrual pain etc.) 2. CODENAL® Cough, sputum Hong Kong - (Dihydrocodeine, etc. / tablets & syrup) 3. ATOCK® Acute & chronic, bronchitis, - - Company Profile (Formoterol fumarate / tablets & dry syrup) Bronchial asthma 4. LIDOMEX® Eczema, Dermatitis, Prurigo, SAMA is Korea’s top leading company in Respiratory, ENT, (Prednisolone valeroacetate / topical lotion & - - Psoriasis, etc. Dermatology, and Pediatrics. Founded in 1945, it is one of the most cream) financially sound companies with a long history of achievements 5. CITUSTM Bronchial asthma, Perennial and recognitions by the Korean government. It has a GMP-certified (Pranlukast hydrate / tablets, ispersible tablets & - - allergic rhinitis manufacturing plant, and it has been accredited by Japan’s dry syrup) Regulatory Authority (PMDA: Pharmaceuticals and Medical Agency) Gingivitis glossitis, 6. TANTUM® as an “Accredited Foreign Manufacturers”. SAMA has a central R&D Pharyngitis, Laryngitis, - - (Benzydamine HCl / gargle solution & nebulizer) center and nation-wide sales force. Tonsillitis etc. Representative Jun Hur SAMA has a strong track record of new business development and Chronic inflammatory bronchial disease, acute partnership with multinational companies, with some having lasted 7. HEBRON® (Ivy leaves extract / tablets & syrup) - - Headquarter Address over 30 years. It has demonstrated capabilities in branding and inflammation of respiratory 49 Dongwha gongdan-ro, Munmak-eup, marketing to achieve #1 brand recognition and equity. tract Wonju-si, Gangwon-do 8. BEPORIN® (Bepotastin salicylate / tablets) Anti-histamines - - SAMA is also active in its own in-house R&D activities, especially Foundation Date in Respiratory and GI fields. SAMA’s CitusTM(pranlukast) tablet for Gastric ulcer, duodenal Oct. 04, 1945 adults was developed with its proprietary patent technology, which 9. GERD® (Sodium alginate / solution) ulcer, improvement of gastro - - esophageal reflux disease Research Focus dramatically lowered the dosage (112.5mg * 2cap. -> 50mg * 1tab.) Respiratory, ENT, Dermatology, Pediatrics, SAMA also successfully completed a Phase II clinical trial for the new 10. NOMA Growth promotion, nutritional (Multivitamins, Minerals / gummies & deficiency, supply for - - GI, and Orphan Diseases 4th generation LTRAs drug in collaboration with Mitsubishi Tanabe. chewable tablets) vitamins & minerals Total Staff SAMA plans to expand into other fast growing therapeutic areas via 320 persons licensing deals and its own R&D. Representative Phone Focus Area : Respiratory, ENT, Dermatology, Pediatrics, GI, and 82-2-2056-7200 Orphan diseases Representative Fax R&D Pipeline 82-2-2056-7210 Compound Name Code Use Stage of Development Web www.samapharm.co.kr SLIP SLIP Erectile dysfunction Launch Contact Person TDIQ TDIQ Erectile dysfunction Launch Soojin Lee Bronchial asthma, PRIT PRIT Launch Allergic rhinitis Contact Phone Financial Figures Bronchial Asthma, 82-2-2056-7283 SA09012 SA09012 Phase 2 Allergic rhinitis Summary (1 Million Won) Contact E-mail DRIT SA15001 Gastric ulcer, GERD Non-clinical study [email protected] Fiscal Year 2015 2016 2017 Bronchial Asthma, Sales 59,658 65,876 61,800 PRIC SA16001 Phase 1 R&D Expenditure 4,898 4,236 4,400 Allergic rhinitis Capital 140,077 148,916 156,100 HLIM SA16002 Bronchitis Phase 1

178 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 179 Main Products Samik Pharm. Co., Ltd. Product (Ingredient/Formulation) Use Exporting Countries Remarks 1. CEZAR TAB. (Losartan potassium 50/100mg) Hypertension - -

2. CEZAR PLUS TAB. (Losartan potassium 50mg, Hydrochlorothiazide Hypertension - - 12.5mg)

3. TAMITRA TAB. Cambodia, Myanmar, (Acetaminophen 325mg, Tramadol Hydrochloride NSAIDs - Company Profile Vietnam 37.5mg) Since founded in 1973, Samik has focused on our ability to improve 4. NEWSOVOMIN SYR. public health through the R&D and manufacture of a number of the Dizziness, vomiting, headache (Dimenhydrinate 20mg, Anhydrous Caffeine Mongolia - over-the-counter drugs famous for excellent efficacy and good quality caused by motion sickness. under the banner of "systemic approach to natural drugs". 10mg, Pyridoxine Hydrochloride 2.5mg) “Aiming for the best technical capability in the field of solid Cambodia, Myanmar, 5. TMD CAP. (Thymomodulin 80mg) Bacterial and viral infections. - dosage form” Vietnam

Now, Samik will establish as Total Health Company in fact as well 6. BROJE TAB. Inflammation Cambodia, Vietnam - Representative as in name by devoting itself to the development of new natural (Bromelain 40mg, Crystallized trypsin 1mg) Lee, Sae Young drugs, modified drug and to supplementing biomedicine pipeline, 7. BONOMAX TAB. (Alendronate 70mg) Osteoporosis Myanmar, Vietnam - Headquarter Address marketing its own best medicines globally in R&D and management 15F, A Tower, 11, Beobwon-ro 11-gil, as well as by continuing in development and manufacture of the 8. AMORIA CAP. (Meloxicam 7.5/15mg) NSAIDs Bolivia, Hong Kong - Songpa-gu, Seoul, 05836, Republic of therapeutic prescription only medicine based on excellent technology Korea accumulated in the natural drug manufacture industry in the mean- time. Foundation Date 1973 “Realizing Health improvement in harmony with nature” Research Focus Please give us your help and encouragement with interest and R&D Pipeline Circulatory System support continuously to us who are devoting ourselves to establish a welfare society in spite of our poor ability in contributing to Health Compound Name Code Use Stage of Development Total Staff of mankind under the banner of "realizing health improvement in 135 persons harmony with nature." Chong Myung Tang - Brain Function Formulation Development Representative Phone SIP-1101 SIP-1101 Liver Function Research 82–2-928–0661~4 SIP-1102 SIP-1102 Allergic Rhinitis Formulation Development Web www.samik.co.kr SIP-1103 SIP-1103 Dementia, Brain Function Formulation Development

Contact Person SIP-1104 SIP-1104 Hypertension Formulation Development Kim, Yu Li Contact Phone 82-2-928-0661 Contact E-mail Financial Figures [email protected] Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 33,053 38,367 40,689 R&D Expenditure 757 716 900 Capital 34,781 38,831 42,000

180 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 181 Main Products Samil Pharm. Co., Ltd. Product (Ingredient/Formulation) Use Exporting Countries Remarks 1. Ofloxacin 3mg/mL Ophthalmic Soln. Susceptible strains of the under registration Asia, Mid-East & Oint. microorganisms (Asia, Mid-East, Europe) 2. Tobramycin 3mg/mL Ophthalmic Susceptible strains of the under registration Asia, Mid-East Solution & Ointment microorganisms (Asia, Mid-East) 3. Polymyxin B sulfate 6,000IU, Neomycin sulfate 3mg (potency), conjunctivitis, blepharitis, and Asia, Mid-East under registration (Asia) Company Profile Dexamethasone 1mg / Ophthalmic keratitis Suspension & Ointment Company overview 4. Levofloxacin 5mg/mL Ophthalmic Susceptible strains of the under registration Asia · 1947 - The establishment of Samil Pharm. Co., Ltd. Solution microorganisms (Asia, Mid-East) Sjogren's syndrome, Stevens- · 1969 - Technical alliance with Boots Co. of the UK for Brufen 5. Sodium Hyaluronate 1mg/mL Johnson Syndrome, dry eye under registration Asia · 1985 - Korea stock exchange IPO (000520) Ophthalmic Solution syndrome, drug-induced, injury, (Asia, Mid-East) contact lenses · 1985 - Completion of KGMP (Korean Good Manufacturing Practice) 6. Diclofenac sodium 1mg/mL a nonsteroidal anti-inflammatory under registration Asia, Mid-East in Ansan Ophthalmic Solution product (Mid-East) Representative · 1987 - Establishment of Central R&D Center / Set up ophthalmic 7. Povidone 20mg/mL Ophthalmic under registration Kang Huh a lubricant alleviating dry eyes Asia business division Solution (Mid-East) Headquarter Address 8. Acyclovir 30mg/g Ophthalmic keratitis caused by herpes simplex under registration · 2003 - Newly established Thea business division Asia 155, Hyoryeong-ro, Seocho-gu, Seoul, Ointment virus (Asia, Mid-East) Korea · 2008 - Joint Venture contract with Allergan Inc, of USA corticosteroid-responsive 9. Fluorometholone 1mg/mL Ophthalmic under registration inflammation of outer and anterior Asia Foundation Date · 2011 - Joint Venture contract with Mon-samil LLC of Mongolia suspension (Asia, Mid-East) 07 OCT. 1947 segments of the globe · 2014 - $9 Million export contract with Iran 10. Losartan Potassium, HCTZ 50mg, Research Focus hypertension Asia - Export country : Hong Kong, Japan, Myanmar, Mongolia, 50/12.5mg, 100/12.5mg Tablets Ophthalmology, Gastro-intestinal, Philippines, USA, Vietnam, Yemen Respiratory, Circulatory, Cardiovascular, Dermatology Subsidiary company : Samil H&T Co., Ltd., Samil Medical Co., Ltd. (detistry, medical device) Total Staff 396 persons Focus Area : Ophthalmology, Gastro-intestinal, Respiratory, R&D Pipeline Circulatory, Cardiovascular, Dermatology Representative Phone Compound Name Code Use Stage of Development 82-2-520-0300 Stable pharmaceutical composition Trimebutine 1020100002507 12 JAN. 2010 comprising Trimebutine and prokinetic agent Representative Fax Pharmaceutical composition in tablet form 82-2-588-5924 Limaprost alfadex 1020100068304 15 JUL. 2010 for oral administration comprising Limaprost Web Multi layer pharmaceutical tablet with www.samil-pharm.com improved stability comprising Sulglycotide Sulglycotide 1020110013635 16 FEB. 2011 Contact Person and H2 antagonitsts and preparation method Shin-ku Kang thereof Financial Figures Pharmaceutical composition comprising Contact Phone Telmisartan 1020120079809 Telmisartan with improved stability and 23 JUL. 2012 82-2-520-0324 Summary (1 Million Won) preparation method thereof Contact E-mail Fiscal Year 2015 2016 2017 Pharmaceutical composition comprising Telmisartan & Hydrochlorothiazide 1020120114062 15 OCT. 2012 [email protected] Sales - - - Telmisartan and HCTZ R&D Expenditure - - - Capital - - -

182 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 183 Main Products Samjin Pharmaceutical Co., Ltd. Product (Ingredient/Formulation) Use Exporting Countries Remarks Singapore, 1. PLATLESS (Clopidogrel / Tablet) Antithrombotics, Antiplatelet Cambodia, - Philippines

Philippines, Vietnam, Cambodia, 2. GEWORIN Tablet Analgesics & Antipyretics OTC Mongolia, Company Profile Uzbekistan

All human beings have the right to enjoy a healthy and happy life. 3. NEUSTATIN-A (Atorvastatin / Tablet) Antilipidemic Agents Philippines -

However, the complicated social structure of modern society and 4. TRESTAN Capsule Appetite Stimulants - OTC the development of material civilization cause the advent of new diseases. 5. NEUTOIN (Donepezil / Tablet) Nootropics & Neurotonics - -

In order to protect human health from these diseases and Hong Kong, fundamentally get rid of diseases, Samjin Pharm Co., Ltd secures 6.NEUSTATIN-R (Rosuvastatin /Tablet) Antilipidemic Agents Philippines, - excellent personnel and latest equipment and continues to challenge Myanmar Representative the development of excellent pharmaceutical drug by utilizing Cambodia, Sung-Woo Lee advanced pharmaceutical information and technology. 7. BAMEDIN (Rebamipide/Tablet) Antiulcerants - Guatemala Headquarter Address Samjin pharm Co., Ltd always strives for a better future on the basis 121 Wausan-Ro(Seogyo-dong), Mapo-Gu, of dignity of human life and company philosophy. 8. MAROBIVEN-A Inj. Antiinflammatory Enzymes - - Seoul, Korea The company pioneering a healthy life of people and challenging the 9. SYNERJET (Acetaminophen, Tramadol / Tablet) Analgesics & Antipyretics Philippines, Vietnam - Foundation Date prosperous future with mind of creation. Apr. 18. 1970 10.ARB-XG (Amlodipine, Valsartan / Tablet) Antihypertensive Agents Philippines, Vietnam - Focus Area : Cardiovascular system drugs, Analgesics & Antipyretics, Research Focus etc. AIDS, Dry eye, etc. Total Staff R&D Pipeline 688 persons Compound Name Code Use Stage of Development Representative Phone 82-2-3140-0700 - SJ-3366 AIDS Phase1/Preclinical

Web Dry eye syndrome, Oral Rebamipide Prodrug SA001 Phase II www.samjinpharm.co.kr treatment

Contact Person Dry eye syndrome, Eye drop - SJP002 Phase II Bum-Kyu Shin solution Contact Phone - SJP1601 Cancer Preclinical 82-2-3140-0673 Contact E-mail - SJP1602 Cancer Biological test [email protected] Financial Figures Aptamer-drug conjugate SJP1604 Cancer Preclinical

Summary (1 Million Won) - SJP1610 Cancer Biological test Fiscal Year 2015 2016 2017 Alzheimer's disease, - SJP1701 Biological test Sales 216,511 239,312 245,272 Parkinson's disease R&D Expenditure 15,748 17,437 19,932 Capital 13,900 13,900 13,900

184 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 185 Main Products Samyang Biopharmaceuticals Corporation Product (Ingredient/Formulation) Use Exporting Countries Remarks Asia, Europe, 1. Genexol® Inj. (Paclitaxel) Anti-Cancer - Middle East

2. Genexol-PM® Inj. (Paclitaxel) Anti-Cancer Africa, Asia -

3. Nanoxel®-M Inj. (Docetaxel) Anti-Cancer - -

Company Profile 4. Pemed® Inj. (Pemetrexed) Anti-Cancer Europe, Middle East - Samyang Biopharmaceuticals Corporation is focusing its efforts on 5. Protezomib® Inj. (Bortezomib) Anti-Cancer - - healthcare as its core strategic business of the 21st century. Samyang 6. Lenalid® Tab. (Lenalidomide) Anti-Cancer - - Biopharmaceuticals Corporation is developing proprietary and unique core technologies for the development of world class novel drug 7. Palseron® Inj. (Palonosetron) Nausea and vomiting - - delivery systems. 8. Zolenic® Inj. (Zoledronic Acid) Bone metastasis Europe - Focus Area : Oncology, GMP Manufacturing(APIs, Injections, Patches), DDS Technology 9. Rheumastop® Transdermal Patch Rheumatoid arthritis Africa, Middle East - Representative (Diclofenac Diethylamine) Taeung Eom 10. Tulobuterol Transdermal Patch Asthma acute bronchitis - - Headquarter Address 295 Pangyo-ro, Bundang-gu, Seongnam- 11. Fentaderm® Transdermal Patch (Fentanyl) Severe Pain - - si, Gyeonggi-do 13488, Korea 12. Rivastigmine Transdermal Patch Anti-Alzheimer - - Foundation Date Asia, Europe, Japan, 2011. 11. 01 13. Paclitaxel (API) Anti-Cancer - South America Research Focus novel drug delivery systems and medical devices R&D Pipeline Total Staff 276 persons Compound Name Code Use Stage of Development Representative Phone Paclitaxel - Market PM 82-2-2157-9857 (Polymeric Docetaxel - Cancer Market Micelle) Web Temsirolimus - Preclinical www.samyangbiopharm.com PNP Docetaxel - Clinical Contact Person (Polymeric Nano- Cancer Mr. Sung-Seup Shin Particle) Sirolimus - Preclinical Contact Phone Oral_CSDS Prednisolone - Ulcerative colitis Research 82-2-2157-9857 Oral_FDT Ramosetron - Vomiting Registration Contact E-mail Financial Figures Oral_BA - SYO-1644 Cancer Preclinical [email protected] Summary (1 Million Won) siRNA Fiscal Year 2015 2016 2017 SENS mRNA - Cancer Research Sales 62,634 70,300 80,500 pDNA R&D Expenditure 7,700 8,400 8,890 Capital 208,939 220,788 230,000

186 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 187 Main Products Seoul Pharma Co.,Ltd. Product (Ingredient/Formulation) Use Exporting Countries Remarks Lauched as Viagra L 1. VULTIS® (Sildenafil citrate/ ODF) Erectile dysfunction - in Korea 2. VULTEUM® (Tadalafil / ODF) Erectile dysfunction - - 3. ARTPEZIL® (Donepezil HCl / ODF) Dermentia - - 4. Diflu cap. (Fluconazole/capsule) Antifungal - - Company Profile 5. Aliver susp. (I-leucine,I-isoleucine,I-valine) Hypoalbuminemia - - Seoul Pharma Co., Ltd., (the “SPC”) has engaged in manufacturing 6. Sebron cap./syrup (acetylcystein/cap./syrup) Mycolytics - - and distribution of pharmaceuticals since its establishment in 1976 7. Seoul Amlodipine Besylate tab. Anti-Hypertension - - and established the Centralized R&D Centre in 1997 for the purpose (amlodipine besylate/tablet) of R&D on new drug delivery technology. SPC has produced more than 50 oral solid products mainly as Rx with such therapeutic categories as respiratory, infective, cardio-vascular, gastro-intestinal, endocrinal, anti-obesity, and so on. R&D Pipeline Representative In order to become a world-class pharmaceutical company, SPC has Compound Name Code Use Stage of Development Mr. Jungho Kim focused its R&D on the innovative and creative DDS technology such COPD agent as special formulations development and as its result, SPC developed - SPC-702 Preclinical Headquarter Address (W-peptide derivative) 21, Banpo-daero, Secho-gu, Seoul, 06710, a new Platform technology, named as “SmartFilm® Technology”, to - SPX-601 prevention and curing arthritis Phase II a Clinical Korea produce Orally Disintegrating Film(ODF) products. SPC has planned to penetrate the global market through SmartFilm® Technology with a Sildenafil citrate Vultis erectile dysfunction Launched May 2012 Foundation Date new cGMP/EU-GMP plant was built in Osong city, especially targeting A Domestic Patent 1976 Aug. to the US, EU, and other regulatory markets. Through SmartFilm® Donepezil HCl Artpezil Dermentia Registration Research Focus Technology, SPC is willing to enter the global challenge for the market - Aripiprazole ODF Schizophrenia MA completed NCE, IMD, ODF and be a Hidden Champion in the global pharmaceutical industry. Tadalafil Vulteum Erectile dysfunction Launched Sep 2015 Total Staff 218 persons - SPO-1107 Anti-emetic Formulation Research Representative Phone - SPO-1304 Antiviral Formulation Research 82-2-3470-2300 - SPO-1405 Obesity Formulation Research Web - SPO-1401 Anti-emetic Formulation Research www.seoulpharma.com - SPO-1406 Overactive bladder Formulation Research Contact Person Yongnam Jang Contact Phone 82-2-3470-2385 Other Contact E-mail [email protected] Financial Figures Our SmartFilm® technology, which is a DDS technology to produce Orally Disintegrating Film (ODF), results from our effort and [email protected] devotion to develop the new technology under our confidence since 2009 that our future depends on how to secure platform Summary (1 Million Won) technology and strengthen core competence. The SmartFilm® technology is differentiated from the existing platform one, because it is the globally leading technology to enable Fiscal Year 2015 2016 2017 to load the higher dose of active pharmaceutical ingredients, secure the optimal manufacturing process of ODF and mask the bitter Sales 44,731 45,920 46,652 taste of medicines. R&D Expenditure 2,505 2,127 2,526 We appreciate you for your continuous support and encouragement to us until our company becomes one of the global leading pharmaceutical companies through SmartFilm® technology. Capital 33,528 42,070 54,090

188 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 189 Main Products SHIN POONG PHARM. CO., LTD. Product (Ingredient/Formulation) Use Exporting Countries Remarks Medical device with 1. Medicurtain Inj. Surgical adhesion barrier - novel mode of action

2. Candeamlo Tab. Hypertension treatment - IMD, FDC

3. Ezerosu Tab. Hyperlipidemia treatment - IMD, FDC

Company Profile 4. Hyal Forte Inj. Osteoarthritis treatment - Leading product in Korea Shin Poong Pharm. Co., Ltd is a R&D oriented multinational pharmaceutical company headquartered in Seoul, South Korea, with 7 manufacturing site worldwide with global partners in over 59 countries. Main focusing areas are CV, CNS, surgical wound care, musculoskeletal, and anti-infective. R&D Pipeline Under the management philosophy of ‘for the health of the people’, Compound Name Code Use Stage of Development Shin Poong Pharm. Co., Ltd. specializes in manufacturing remedy SP-8008 - Anti-platelet (NCE) Preclinical Representative drugs with sincere efforts put into producing every single tablet of Jei Man Ryu life-saving drugs ranging from ingredients to finished products based SP-8232 - Heart failure (NCE) Preclinical on our state-of-the-art manufacturing facilities and quality assurance Headquarter Address system. We are committed to realizing the spirit of Shin Poong 3V SP-8356 - Atherosclerosis (NCE) Preclinical 161 Yeoksam-ro, Gangnam-gu, Seoul, (Vision, Venture and Victory) with top-notch competitiveness based FreeWink™ - Dermal/body filler (NME) Preclinical 0646, Korea on in-house ingredient synthesizing technologies obtained through rigorous R&D efforts and to further developing the company into the Osteoporosis/fracture healing Foundation Date SP-35454 - Phase I 1962.06.09 one that receives confidence from our customers and that contributes (NCE) to promoting the wellbeing of human beings. Research Focus HyalOne™ - Osteoarthritis (NME) Phase I CV, CNS, surgical wound care, musculoskeletal, anti-infective SP-8203 - Acute ischemic stroke (NCE) Phase II Total Staff Pyramax Granule - FDC/Pediatric malaria (NCE) Phase III-IV 765 persons Representative Phone 82-31-491-6191-2 Web www.shinpoong.co.kr/eng New Active Substances Contact Person Product (Ingredient) Use Approval Date/Country J. S. Hong 2011.08 / Korea Pyramax Tab. FDC/Malaria (NCE) 2012.02 / EU Contact Phone 82-2-2189-3509 Contact E-mail Financial Figures [email protected] Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 185,478 182,276 - R&D Expenditure 19,292 14,542 - Capital 23,790 27,593 -

190 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 191 Main Products SINSIN Pharmaceutical Cp., Ltd. Product (Ingredient/Formulation) Use Exporting Countries Remarks 1. SINSINPAS-RX Active ingredient : Out of 1 sheet (10x14cm, Indication 2,301.24mg) Muscular pain, Joint pain, U.S.A, Aisan Pain Relief L-menthol 90.9mg, dl-camphor 34.1mg, Shoulder pain, backache, sounties. Patch Mentha oil 45.46mg, Methyl salicylate 90.90mg, Bruise, Sprain Vanillyl Nonylamide 0.114mg

Company Profile 2. SINSIN PAS Pain relief Patch Active ingredient : Out of 1 sheet (6.2x 4.1cm, Indication In the year 1959, few years after Korean war, SINSIN Pharmaceutical 453.29mg) Muscular pain, Joint pain, U.S.A, EU, Asian Pain Relief Company was established during the reconstruction of post-war Methyl salicylate 29.98mg, Thymol 0.77mg, Shoulder pain, backache, countries. Patch period for the purpose of improving the national health. L-menthol 36.32mg, Bruise, Sprain DL-camphor 15.63mg, Borneol 1.20mg Amidst the devastating conditions of the 1950’s SINSIN committed to the development of top professional staff, research and Indication 3. SINSIN CAPSICUM PATCH development of new products and to the improvement of the Korean Muscular pain, Joint pain, Active ingredient : Out of 1 sheet (13x18cm, U.S.A, Middle East, Pain Relief pharmaceutical market. SINSIN’s efforts were successful in replacing Shoulder pain, 2,400mg) Asian countries. Patch the expensive Japanese Plaster and through superior quality Neuralgia, Rheumatism, Representative Capsicum extract 0.025% backache Hanki Kim management became the #1 Plaster company in Korea. Headquarter Address SINSIN began to export it’s products in 1971 and at present time Exporting country Korea Bio Park C - 4fl, 694-1, Sampyeong- it ships to over 30 different countries worldwide with trememdous Over 15 countries dong, Bundang-gu, Seongnam, success. including : • U.S.A Geyeonggi-do, Korea 463-400 Indication SINSIN has been given various awards including the Outstanding (CVS, Wal green) • Muscular pain Foundation Date Company Award and the Presidential award. These awards have • Poland 4. ICE COLD PAIN RELIEF PATCH • Joint pain motivated SINSIN to work harder to promote national health, which • U.K (Boots ) Pain Relief 1955 Active ingredients ( out of 8x12cm, 5.2g) • Shoulder pain is both our responsibility to society and our original goal as a leading • Asia Patch • L-Menthol 5% • backache Research Focus pharmaceutical company. • Russia • Bruise Pain reliving and wound care etc. ICE COLD PAIN • Sprain From environmental concerns to national health SINSIN RELIEF PATCH Total Staff Pharmaceutical will continue to diligently work for the improvement PAIN RELIEF HYDRO 240 persons of life. GEL PATCH Representative Phone Thank you for all of your support. Code :SSP 3405 82-31-776-1111 Exporting country Focus Area : Pain reliving patches, Liniment, Aerosol, Wound care Pain Relief Representative Fax Indication Over 10 countries product. Patch, • Arthritis Deformans including : 82-31-776-1117 5. KETOCLIN PLASTER Transdermal • Peri-arthritis of shoulder • HK Active ingredients (out of 10×7cm2, 0.7g ) Drug Web • Tendinitis • Vietnam • Ketoprofen 30mg Delivery http://global.sinsin.com • Peri-tendinitis • Macao System • Myalgia • Iran Contact Person (TDDS). • Guatemala Woongjin Han Contact Phone Financial Figures 82-31-776-1141 Summary (1 Million Won) Contact E-mail [email protected] Fiscal Year 2012 2013 2014 Sales 9,376 8,704 8,631 R&D Expenditure - - - Capital - - -

192 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 193 Main Products SK Chemicals Co., Ltd. Product (Ingredient/Formulation) Use Exporting Countries Remarks 1. OMED Tab. (Omeprazole) Gastric Ulcer EU -

2. SID710 Patch (Rivastigmine) Alzheimer's Disease EU -

Egypt, India, China, Hong Kong, 3. SK Albumin Inj. 20% (Human Albumin) Albumin Deficiency - Mongolia Dominican Company Profile Republic SK Chemicals is a member company of SK Group, the third largest Thailand, Peru, India, 4. LIV-Gamma Inj. (Human IgG) IgG Deficiency - company group in Korea. Egypt

Since founded in 1969, SK Chemicals has focused on the development Saudi Arabia, China, 5. Trast Patch (Piroxicam) Arthritis - of drug products targeting the diseases with unmet treatment needs Philippines in order to fulfill its vision; “Healthcare and Earthcare”. 6. Ginexin Tab. (Ginko biloba) Blood Circulation Enhancer Saudi Arabia - The R&D area of SK Chemicals covers a broad range of product lines, including new chemical entities, new herbal extract drugs, 7. Joins Tab. Arthritis Australia - Representative reformulated generics, vaccines and blood products. Owing to its In-Serk Lee continuous efforts on R&D, SK Chemicals was able to develop three 8. SID530 Inj. (Docetaxel) Anti-cancer EU - Headquarter Address new chemical entities (NCEs), novel drug delivery system (DDS) 9. SID820 Cap. (Esomeprazole) Gastric Ulcer EU - 686 Sampyeong-dong, Bundang-gu, flat foam technologies, recombinant DNA technology and in-house Seongnam-si 463-400, Gyeonggi-do, premium vaccines. 10. MvixS ODF (Mirodenafil) Erectile Dysfunction - - Korea On the basis of this strong R&D capability together with its outstanding marketing operations, SK Chemicals was selected as a Foundation Date R&D Pipeline 1969.07.01 member of the Korea Innovative Pharmaceutical Company. Ingredient Use Stage of Development Research Focus NCE, Herbal, Biologics NCE 401 Fibrosis Pre-clinical Total Staff NCE 403 Endometriosis Pre-clinical 1593 persons HMP 301 Asthma Phase III Representative Phone 82-2-2008-2008 HMP 302 Alzheimer's Disease Phase III

Representative Fax HMP 304 Irritable Bowel Disease Phase II 82-2-2008-2959 Prevention of infection caused by Pneumococcal NBP 606 Phase I Web bacteria www.skchemicals.com NBP 607 Prevention of infection caused by Influenza virus Phase I

Financial Figures New Active Substances Product (Ingredient) Use Approval Date/Country Summary (1 Million Won) Fiscal Year 2008 2009 2010 SUNPLA (Heptaplatin) Anti-cancer 1999 Sales 258,952 303,383 350,270 JOINS (Herbal Extracts) Arthritis 2002 R&D Expenditure 24,500 30,621 34,910 Mvix (Mirodenafil) Erectile Dysfunction 2007 Capital - - -

194 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 195 Main Products SS Pharm.Co.,Ltd. Product (Ingredient/Formulation) Use Exporting Countries Remarks 1. Acetyl-L-Carnitine Hydrochloride Nootropics & Neurotonics - KDMF

2. Bethanechol Chloride Other Genito-Urinary - -

3. Benfotiamine Anti-oxidant - -

4. Caffeine and Sodium Benzoate Respiratory Stimulants - -

Company Profile 5. Celecoxib COX-2 inhibitor - - SS Pharm is a manufacturer of APIs. 6. Citrulline Malate Amino acids and derivatives - - And our facilities and operations conforms to PIC/S and WHO GMP. 7. Clopidogrel Bisulfate Anti-thrombotic - KDMF

8. Doxofylline Anti-Asthmatics - -

Retinoids, Anti-Acne 9. Isotretinoin - - Preparations Representative 10. Talniflumate Anti-imflammatory - KDMF Koh, Jae-Won (CEO) Headquarter Address 11. Cilnidipine Cardiovascular agent - - 10, Beomjigi-ro 141beon-gil, Danwon-gu, Ansan-si Foundation Date 1995.11.21 R&D Pipeline Research Focus 2 973.783m Compound Name Code Use Stage of Development Total Staff Choline Alfoscerate - Nootropics & Neurotonics Under development 24 persons Examined for Product license Nafamostat Mesylate - Anti-coagulants Representative Phone by MFDS 82-31-491-6311 Examined for Product license R-Thioctic acid Tromethamine salt - diabetic neuropathy Web by MFDS www.susungpharm.co.kr Anti-histamines & anti- Contact Person Epinastine Hydrochloride - Under development allergics Park, Chul-Seo Contact Phone 82-31-491-6311 Contact E-mail [email protected] Financial Figures

Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 7,669 8,659 9,500 R&D Expenditure 95 89 100 Capital 2,030 2,030 2,030

196 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 197 Main Products Suheung Capsule. Co., Ltd. Product (Ingredient/Formulation) Use Exporting Countries Remarks 1. Empty hard gelatin capsules - more than 40 -

2. Empty hard fish capsules - more than 40 -

3. Empty hard HPMC capsules - more than 40 - Company Profile Since Establishment in 1973, Suheung Capsule Co., Ltd have sought to produce only the highest quality capsules and thus grown to be one of the world's leading manufacturers and exporters of empty hard gelatin, fish and HPMC capsules.

Representative Mr. Joo Hwan, YANG / CEO Headquarter Address Jung-An B/D 6F, 435-5 Jangan 1dong, Dongdaemun-gu, Seoul Foundation Date 1973 Total Staff 500 persons Representative Phone 82-2-2210-8193 Representative Fax 82-2-2217-2356 Web www.suheung.co.kr

Financial Figures

Summary (1 Million Won) Fiscal Year 2008 2009 2010 Sales 101,606 107,816 124,860 R&D Expenditure 748 505 547 Capital 5,902 6,084 6,084

198 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 199 Main Products Taejoon Pharmaceutical Product (Ingredient/Formulation) Use Exporting Countries Remark Ophthalmic solution The increase of tear production in patients whose tear production is presumed to be suppressed 1. Cyporin N ophthalmic solution (Cyclosporine) - due to ocular inflammation associated with keratoconjunctivitis sicca 2. MC Free ophthalmic solution Dry eyes for the temporary relief of burning, EU, USA (Sodium carboxymethylcellulose) irritation and discomfort Company Profile Bond and repair corneal epithelial cells, helps cure 3. Hyaluni ophthalmic solution corneal injuries and retain and stabilize tears, - - Taejoon Pharm., founded in 1978, is a global pharmaceutical company (Hyaluronic acid) dysfunction tear syndrome accomplished in exporting aseptic eye drops to Europe for the first 4. Taejoon Ultra ophthalmic solution Temporary relief of irritation and burning due to time in Korea. In addition, we are the first specialized company to USA - (Polyethylene Glycol) dryness of the eye have technologies to make all three fields of contrast media products: Reduction of elevated intraocular pressure in X-ray, MRI, and CT. Taejoon Pharm's Yongin plant, which was built 5. Xalost Plus ophthalmic solution patients with open-angle glaucoma or ocular EU, Russia, China (Latanoprost + Timolol maleate) in October, 2005, became Korea's first EU-GMP certified plant to hypertension produce qualified pharmaceutical products that export to Europe. Reduction of elevated intraocular pressure in Taejoon is implementing a marketing strategy, targeting countries 6. Xalost ophthalmic solution (Lataonoprost) patients with open-angle glaucoma or ocular EU, Russia, China - Representative hypertension Tae Young Lee of the world and continuously reinforcing pioneering movement by actively participating in internationally renowned academies 7. Alpaday ophthalmic solution (Olopatadine HCl) Relief of allergic conjunctivitis - - Headquarter Address and exhibitions. As a result, we were able to create a strong sales Inflammatory diseases of the anterior/external 8. Fluvin ophthalmic solution 8 Daesagwan-ro 31-gil, Yongsan-gu, network among more than 50 countries, including 30 European segment of the eye (blepharitis, conjunctivitis, - - (Fluorometholone) Seoul countries. On this basis, we plan to strengthen the sales network with keratitis, etc) Foundation Date the goal of simultaneous release into the world in the event of global Gastrointestinal agents 1978 product launch. We expect to increase the company's brand value by establishing the sales network through localized sales marketing in 9. Coolprep (PEG 3350) Preparation for colonoscopy - Research Focus Hemostasis and remission of subjective symptom particular countries, such as the U.S., China, Russia, and Europe. 10. Lamina G (Sodium Alginate) - Ophthalmology, Gastrointestinal agents, in gastric & duodenal ulcer, erosive gastritis Contrast media, etc Focus Area : Ophthalmology, Gastrointestinal agents, Contrast media, For elimination of gastric bubble for 11. Gasocol Susp. (Simethicone) - - etc. gastroendoscopy Total Staff 385 persons 12. Colyte (PEG 3350) Preparation for colonoscopy - - Representative Phone 13. Colyte F (PEG 3350) Preparation for colonoscopy - - 82-2-799-0072 Contrast Media 14. MRbester injection Contrast medium for cranial and spinal MRI/ whole Representative Fax Asia 82-2-798-6665 (Gadopentetate dimeglumine) body MRI Myelography, angiography, urography, contrast 15. Iobrix injection (Iohexol) Asia - Web enhancement of computerized tomography www.taejoon.co.kr Angiography throughout the cardiovascular system, Contact Person including cerebral and peripheral arteriography, coronary arteriography and ventriculography, Mr. Andy Lee pediatric angiocardiography, selective visceral arteriography and aortography, peripheral Contact Phone Financial Figures 16. Radisense injection (Iopamidol) Asia - 82-2-799-0072 venography (phlebography), and adult and pediatric intravenous excretory urography and intravenous Summary Contact E-mail adult and pediatric contrast enhancement of [email protected] Fiscal Year 2012 2013 2014 computed tomographic (CECT) head and body Sales $95,043,027 $94,325,508 $90,905,789 imaging R&D Expenditure $4,836,463 $6,355,765 $7,686,165 Capital $92,603,127 $101,850,598 $91,917,685

200 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 201 Product (Ingredient/Formulation) Use Exporting Countries Remark For cerebral angiography and peripheral arteriography, contrast enhanced computed 17. Iversense injection (Ioversol) - - Taiguk Pharm. co., Ltd. tomographic imaging of the head and body, venography, and intravenous excretory urography 1. Intra-arterial intra-arterial digital subtraction angiographyangiocardiography (left ventriculography and selective coronary 18. Visisense injection (Iodixadol) arteriography), peripheral arteriography, visceral - - arteriography, and cerebralarteriography 2. Intravenous CECT imaging of the head and body, excretoryurography, and peripheral venography. Company Profile Contrast enhanced x-rays or computed “Supply best quality pharmaceutical products to customer.” Since tomographic imaging (CAT scan, CT scan; a type established in 1957, Tai Guk Pharm. Co., Ltd. has been manufacturing of body scan that uses a computer to put together pharmaceutical products. We have focused on development of OTC 19. Solotop-HD (Barium sulfate) x-ray images to create cross-sectional or three Asia - dimensional pictures of the inside of the body) of products such a hydroquinone cream and professional and leading the esophagus (tube that connects the mouth and manufacturer of ointments(ointment, cream, gel) in Korea. We have stomach), stomach, and intestine largest plant in Korea for ointments at Buyeo and pushing to FDA approved Buyeo plant. We can also undertake contact manufacturing Tablet, Capsule, Internal & External liquid, and specially Ointments. Representative We are export to USA and many other countries. Chang Koo Lee Focus Area : Ointment & Cream Headquarter Address 123, Jeyakgongdan 3-gil, Hyangnam-eup, R&D Pipeline Hwaseong-si, Gyeonggi-do, Korea Compound Name Code Use Stage of Development Foundation Date Age-related Macular Degeneration 1957 - AMD Phase 2/3 (New Biological Entity) Total Staff Antibiotic product - Bacterial conjunctivitis Pre-clinical 284 persons (New Chemical Entity) Representative Phone Dry eye product - Dry eye Pre-clinical (New Chemical Entity) 82-2-3474-7761 Combination or Improved drugs - Ophthalmic/GI indications Phase 3 ~ Pre-clinical Representative Fax 82-2-2051-2597 Web http://www.taiguk.co.kr Contact Person You Mi Kim Contact Phone 82-2-3474-7761 Contact E-mail [email protected] Financial Figures

Summary (1 Million Won) Fiscal Year 2012 2013 2014 Sales 38,000 43,000 50,000 R&D Expenditure 160 190 420 Capital 16,000 17,000 20,000

202 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 203 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks THERAGEN ETEX CO., LTD. 1. Highrosone Cream Dermatitis Cambodia - (Hydrocortisone / Cream)

2. Paracool Cream (Methyl Salicylate, l-Menthol, dl-Camphor / Pain Relief Vietnam - Cream) Company Profile 3. Pramyxin Ointment (Bacitracin Zinc, Neomycin sulfate , Polymyxin B Antibiotics Hongkong - THERAGEN ETEX CO., LTD. is a leading pharmaceutical company to Sulfate, Pramoxine HCl / Ointment) develop innovative and personalized new drugs having a world class analysis technology of individual genome. 4. Partygel Suspension Excellent System : We have manufactured outstanding Hyperacid Vietnam - (Almagate / Gel) pharmaceuticals by controlling all lines at GMPs factory from manufacturing to quality controls in compliance with WHO/ICH 5. Miobi soft cap. Guideline. Multi Vitamin Ecuador - (Vitamin A and other ingredients / Capsule) Representative Best Bio center : Our laboratory having the best analysis technology JI KYU WON and excellent analysts of the genome in Korea. The first and the best Headquarter Address results of studies to be recognized in the world - Whole genome 5F, 32, Nonhyeon-ro 30-gil, Gangnam-gu, mapping of woman, tigers and whales(the first in the world) - Seoul, Korea Commercialized personal genome analysis service(the first in Asia) Foundation Date Innovative New drug : THERAGEN ETEX CO., LTD. has built 1st. OCT. 1990 databases and infrastructures to dvelop personalized pharmaceuticals by analysing individual's deases genes as the only pharmaceutical Research Focus manufacturing facilities and genome analysis service in Korea. First Generic & Slow release type drug Focus Area : E.N.T & Cardiovascular Total Staff 216 persons Representative Phone 82-2-3463-7111 Representative Fax 82-2-3463-8111 Web http://www.thera-gen.com Contact Person Sun-Hee, Kim Contact Phone 82-2-3463-7111 Financial Figures Contact E-mail Summary (1 Million Won) [email protected] Fiscal Year 2012 2013 2014 Sales 65,757 56,398 52,244 R&D Expenditure 5,710 3,914 2,815 Capital 13,627 13,887 13,887

204 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 205 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks Union Korea Pharma Co., Ltd. Memory disorder, 1. ETEXCITICOLINE Tab. (Cilticoline 500mg) Vietnam - Ischemic stroke

2. CELEMIN Cap. 200mg (Celecoxib 200mg) NSAID Vietnam -

3. NEXON Tab. 20mg/40mg Gastritis Vietnam - (Esomeprazole 20mg/40mg) Company Profile 4. RABEZOLE 10mg/20mg Gastritis Vietnam - (Rabeprazole 10mg/20mg) Union Korea Pharma is pharma manufacturing company, certificated GMP compliance of tablet, capsule, injection(ample, vial) and 5. EXPERA Tab. 5/80 cephalosporin powder from MFDS Korea. Hypertension Phillipine - (Amlodipine 5mg + Valsartan 80mg) We have exported to Vietnam, Cambodia, Philipine, Hongkong, Mongo, Peru, Chile, Bolivia, Yemen, Azerbaijan etc, and we had 6. ATOSEN Tab. (Atorvastatin 10mg) Hyperlipidemia Vietnam - received Presidental Award by small and medium enterprise export 7. ETEX ROSUVASTATIN Ca Tab. support center in 2009. Hyperlipidemia Phillipine - (Rosuvastatin Ca 5mg/10mg/20mg) Representative Focus Area : Antibiotics(Cepha inj.), Cardiovascular, Degenerative Sung Jun Kim Disease, Contrast media, Ophthalmology 8. ZAKUTEX Dry syrup 156.25mg/5mL (Amoxiciliine hydrate 21.6248g + Chronic branchitis Myanmar - Headquarter Address Diluted potassium calvulanate 10.8124g) Wonwae B/D 5F, 26, Olympic-ro 43-gil, Songpa-gu, Seoul, Korea 9. ZAKUTEX Neo Dry syrup (Amoxiciliine hydrate 54.5454g + Acute otitis media for children Vietnam - Foundation Date Diluted potassium calvulanate 7.8g) Nov. 1956 Research Focus 10. CLAROCIN Tab. (Clarithromycin 250mg) Antibiotics Vietnam - Infectious disease 11. UMCKAMAX Syrup Bronchitis Vietnam - Total Staff (Pelargonium sidoides 11%EtoH ext.17.16mg) Laryngopharyngitis 220 persons

12. CRANTOL Syrup Representative Phone Cough Nigeria - (Amboroxol HCl 150mg + Clenbuterol HCl 0.1g) 82-2-489-3611 Representative Fax 13. CITLEN Solution (Citrulline maleate 1g) Fatigue recovery Vietnam - 82-2-487-3611 14. ETEX CYCLOSERINE Cap. (Cycloserine 250mg) Tuberculosis Vietnam - Web www.ukp.co.kr Uzbekistan 15. ZENTOX Tab. (Albendazole 400mg) Anthelminthic Azerbaijan - Contact Person Kyrgyzstan Jeongsu Ock

16. OEANZIL Vaginal Soft Cap. Contact Phone Myanmar (Neomycin 35,000IU, Nystatin 10,000IU, Vaginal infection - 82-2-489-3611(Ext.311) Cambodia Financial Figures Polymyxin B sulfate 35,000IU) Contact E-mail Summary (1 Million Won) [email protected] 17. SIMTUM-TWO Tab. Fiscal Year 2012 2013 2014 (Acetaminophen 325mg, Phenylphrine HCl 5mg Cold Hongkong - Sales 42,294 40,467 48,715 Dextromethorphan hydrobromide 10mg, Chlorpheniramine maleate 2mg) R&D Expenditure 781 987 712 Capital 2,100 2,100 2,100

206 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 207 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks WHITE LIFE SCIENCE Respiratory system infection, infection related otolaryngology renal and urinary tract infection, septicemia meningitis, 1. Unitiaxone Inj. Vietnam, Philippines, prophylactic of pre/post operation - (Ceftriaxone Sodium 1g) Yemen infection, osteoarthritis, skin and soft tissue infection, cholecystitis, G.I. tract infection. Hepatic dysfunction - Acute and chronic Company Profile 2. Uni-Infusion Inj. hepatitis, alcoholic liver disease; post Vietnam, Mongol - White Life Sciences Co., Ltd. was founded in 2012 as White (L-Ornithine-L-Aspartate 500mg) hepatitis convalescence, cirrhosis, along with hepatotoxic drugs. Pharmaceuticals to create value for both clean and innovative companies through rapid change and innovation. Acute or chronic bronchitis, bronchiectasis, bacterial pneumonia, pneumonial abscess, We strive to be “company that contributes to the right of everyone to 3. Union Cefuroxime Sodium Inj. post-operational chest infection, sinusitis, Vietnam, Philippines - the same level of health care.“ (Cefuroxime Sodium 750mg) tonsilitis, pharyngitis, nephropyelitis, cystitis, cellulitis, eryspelas We launched a stomach medicine (“STOCURE“ Rebamipide) in October 2013. Since then, more than 200 items have been 4. Climycin Inj. Infections caused by susceptible anaerobic Vietnam, Philippines - Representative approved, including circulatory, respiratory, urinary, circulatory, and (Clindamycin phosphate 600mg) bacteria Yang Won Cheol musculoskeletal, and more than 100 items were sold. Also we are Fever and pain due to cold, headache, establishing a foundation to become Korea's leading global company 5. Unifenac Inj. neurodynia, muscle ache, menstrual Headquarter Address Vietnam - through partnership with multinational pharmaceutical companies. (Diclofenac Sodium 75mg) cramps, rheumatoid arthritis, arthralgia, 621,Yeongdongdaero,Gangnam-gu, Seoul, toothache Republic of Korea In 2017, we changed our company name to White Life Sciences, Foundation Date we will do business not only in medicines but also in biotechnology, 2012 medical devices and cosmetics. We promise to listen to the voice of the patient for 365 days and 24 hours and to be a pharmaceutical Research Focus company based on communication and trust based on customer's hypertension, diabetes mellitus, needs. We would like to extend my sincere gratitude to all those who Hyperlipidemia have supported the White Life Sciences Co.,Ltd., R&D Pipeline Total Staff Compound Name Code Use Stage of Development 100 persons Combined antibiotics with beta- bacterial infections (upper - Phase III trial Representative Phone lactamase respiratory tract infections). 82-2-541-4884 Web www.whitels.co.kr Contact Person Lee sang won Contact Phone 82-2-541-4884 Contact E-mail Financial Figures [email protected] Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 11,467 11,677 14,384 R&D Expenditure 430 324 365 Capital 3,370 4,203 4,203

208 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 209 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks WhanIn Pharm Co., Ltd. 1. Atrode Tab (atorvastatin calcium) Anti hypertension - -

2. Cholestop Tab (rosuvastatin calcium) Anti hypertension - -

3. Alforen soft Cap (choline alfoscerate 400mg) Anti psychotics - -

4. Itclor Cap (cefaclor) Anti biotic - -

5. Candino Cap (fluconazole) Anti fungal agent - - Company Profile WhanIn Pharm is Korea's No.1 CNS company. We provide the 6. Albid Tab best psychotherapeutic solutions which includes Antipsychotics, (ranitidine HCl, sucralfate, tripotassium bismuth Anti ulceratives - - Antidementia drugs, Antidepressants, Antiparkinson drugs, dicitrate) Antiepileptics, Anti-ADHD agents, Anxiolytics, and Alcoholism peripheral circulatory treatment. 7. Sarpogrel Tab (sarpogrelate hydrochloride) - - disturbance

8. Loxocool Tab (loxoprofen sodium) analgesic - - Representative 9. Rabepezole Tab (rabeprazole sodium) Anti ulceratives - - Wonbum Lee 10. Valsapine Tab (amlodipine besylate, valsartan) Anti hypertension - - Headquarter Address 11, Beobwon-ro 6-gil, Songpa-gu, Seoul, Republic of Korea Foundation Date June 5, 1978 R&D Pipeline Research Focus Compound Name Code Use Stage of Development CNS disorders & Neurodegenerative diseases, Age-related disorders and new Anti fungal agent WLS-001 Anti fungal agent Stability areas of unmet medical needs Obesity treatment WLS-002 Obesity treatment Formulation development Total Staff 460 persons analgesic WLS-003 analgesic Formulation development Representative Phone Anti ulceratives WLS-004 Anti ulceratives Formulation Research 82-2-405-3000 Anti hypertension WLS-005 Anti hypertension Formulation Research Web www.whanin.com Contact Person Seunghoon Suh Contact Phone 82-2-405-3049 Financial Figures Contact E-mail [email protected] Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 145,397 141,376 72,805 R&D Expenditure 5,522 7,834 4,638 Capital 206,594 220,130 231,460

210 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 211 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks Won Kwang Pharm. Co., Ltd 1. Quetapin tab. (Quetiapine) Antipsychotics Asia, Middle East - 2. Riperidon tab. (Risperidone) Antipsychotics Asia, Middle East - 3. Alpram tab. (Alprazolam) Anxiolytics & hypnotics Asia, Middle East - 4. WI Donepezil tab. (Donepezil Hydrochloride) Antidementia drugs Asia, Middle East - 5. U-Rantac tab./U-Rantac inj. (Ranitidine) Gastrointestinal drugs - - Company Profile 6. Zyrepin tab. (Olanzapine) Antipsychotics Asia, Middle East - Founded by Winkwang University on the basis of Bohwadang, a 7. Neuoxitam tab. (Oxiracetam) Nootropics - - pharmacy established in 1934 under the slogan"Save all living things 8. WI Acamprosate tab. (Acamprosate Calcium) Alcoholism treatment - - from distress and sickness" Wonpharm Co., Ltd. manufactures over 9. Proiban tab./Proiban inj. (Ibandronate) Osteoporosis treatment - - 180 medicines, lncluing Gyeongokgo under strict quality control, and over 20 health foods, incluing Wonkwang Bohwaokgo Bohwaokgo 10. Zolpiram tab. (Zolpidem Tartrate) Anxiolytics &hypnotics - - and Hyosam Forte, at its KGMP-certified factory equipped with clean facilities.

Headquarter Address Wonpharm CO., Ltd., which has been designated as cooperative R&D Pipeline 827 Shindong-ri, Chunpo-myeon, Iksan-si, business for research in pharrmaceutical resources as well as the practice factory for Pharmacy College, Wonkwang University, devotes Compound Name Code Use Stage of Development Jeonrabuk-do itself to technical development for a society free from disease. WIP-MO14 WIP-MO14 Dementia Clinical Foundation Date May, 1934 tit has aiso established a solid educational industrial research system WIB-801CE WIB-801CE Blood circulation Clinical with research system with medical College, Oriental Medical Center WIP-DT14 WIP-DT14 BPH Clinical Research Focus of Wonkwang University. Save all livings from distress and sichness WIP-LG15 WIP-LG15 Lumbar Spinal Stenosis Preclinical Total Staff WIP-PX16 WIP-PX16 Schizophrenia Research 40 persons WIP-AX16 WIP-AX16 Schizophrenia Research Representative Phone WIP-DX16 WIP-DX16 Dementia Research 82-80-359-3333 WIP-LX16 WIP-LX16 Anti-Epileptic Research Representative Fax 82-63-833-4114 WIP-DF17 WIP-DF17 Depression Research WIN-1601 WIN-1601 Memory impairment Research Web www.wonpharm.co.kr

New Active Substances

Product (Ingredient) Use Approval Date/Country NEPONID (Nemonapride) Antipsychotics Jan. 1994 / Republic of Korea Financial Figures

Summary Other Fiscal Year 2008 2009 2010 Sales 2,790,000,000 3,125,000,000 3,567,000,000 WhanIn provides you with best quality products with Bioequivalance study. We hope that we would make long and sincere relationship with you. R&D Expenditure 4,500 3,600 3,200 Capital 3,000,000,000 3,000,000,000 3,000,000,000

212 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 213 Main Products

BoHwa KyungOkKo is composed of Korean Ginseng Hoelen, Rehmannia juice, and sweet honey based on the prescription of the korean traditional medical book known as Dong Eui Bo Kam (UNESCO recognizes as a world legacy of the record). This product is WOORIDUL PHARMACEUTICAL LTD. well recognized as a restorative enforcing the vitality of whole organs, and also as elimination fatigues, exhaustion followed by weariness. Because of the special properties that had no any interferences against any foods, this product has been used by the ancient royal family and the nobles. Especially this product improves the growth df children and the recovery from weariness due to illness of stress.

Product (Ingredient/Formulation) Use Exporting Countries Remarks 1. Bohwa Kyungokgo - - - Company Profile 2. Bohwa Sohap won - - - WOORIDUL PHARMACEUTICAL LTD. was established in 1957, where it researched, produced and sold pharmaceutical products. 3.Woohwang chungsimwon Suspension liquid - - - Manufacturing plant is currently located in Hyang Nam Industrial complex in Gyeong gi province, which has GMP qualified manufacturing facilities with highly hygienic manufacturing environment and high technology. Thus, the plant can produce pharmaceutical products that will satisfy in both quality and quantity. In 1990, after initial public offering, our company has not only Representative continuously grown but also has been designated as one of growing Nam-Hyun Ryu export companies. Headquarter Address Our company also invests on researching new drugs and 10th Fl., Korea Fire Officials Credit Union Incrementally Modified Drugs. With continuous producing and Bldg., 274 Songpa-daero, Songpa-gu, researching based on Platform, R&D Power, our company researches Seoul, Korea, 05719 on safe and high-performance cosmetic products. Foundation Date 26.Oct. 1957 Research Focus ETC, OTC Drugs, Cosmetics, Food supplements Total Staff 245 persons Representative Phone 82-2-80-080-4211 Web http://wooridulpharm.com/main.do Contact Person Chul-Hee Choi Contact Phone 82-2-2194-3525 Financial Figures Contact E-mail [email protected] Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 60,405 71,546 79,846 R&D Expenditure 529 694 986 Capital 29,106 36,835 47,047

214 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 215 Main Products Product (Ingredient/Formulation) Use Exporting Countries YOOYOUNG PHARMACEUTICAL 1. NEPHRIS-S Tab. (Ononidis radix extract 100mg, Orthosiphon Adjunctive treatment of acute ∙ choronic nephritis, cystitis, bladder CAMBODIA folium extract 100mg, and kidney stones Solidaginis extract 200mg) 2. NEPHRIS Soft Cap. (Ononidis 1. Seasonal and perennial allergic rhinitis radix extract 30mg, Orthosiphon 2. Chronic idiopathic urticaria MONGOLIA extract 100mg, Uvae ursi extract 3. Dermatitis and eczema accompanied with itchiness, eczema 80mg) Company Profile 1. Seasonal and perennial allergic rhinitis 3. CETINZAL Tab. (Levocetirizine Yooyoung has established a foothold for growth through consistent 2. Chronic idiopathic urticaria CAMBODIA HCl 5mg) increasing sales, and we are growing as a leading pharmaceutical 3. Dermatitis and eczema accompanied with itchiness, eczema company in Korea by fulfilling our medium and long term mission. 1. Treatment of peripheral and central neuropathic pain in adults 4. PRENEW Cap. (Pregabalin 2. Epilepsy: Adjuvant for partial seizures with or without Focus Area : Arthritis, Anti-Thrombosis, Mixed-Dylipidemia, etc. - 75mg, 150mg) secondary systemic symptoms in adults 3. Treatment of fibromyalgia 5. POTALION Tab. (Bepotastine Allergic rhinitis, chronic urticaria, pruritus associated with skin - besilate 10mg) diseases(eczema, dermatitis, skin pruritus, prurigo) Representative 6. VARDIPINE Tab. 5/80mg, Mr. Woo-Pyoung Yoo Treatment for essential hypertension that is not controlled 10/160mg, 5/160mg - properly with monotherapy using amlodipine or valsartan Foundation Date (Amlodipine/Valsartan) Dec. 23, 1981 7. NEULOS Cap. (Gabapentin Epilepsy, neuropathic pain - 100mg, 300mg) Research Focus New Drug & IMD 8. LOXORON Tab. (Loxoprofen 1. Chronic rheumatoid arthritis, osteoarthrosis, low back pain - 60mg) 2. Acute upper respiratory inflammation Total Staff 1. Hyperlipidemia 320 persons 9. LIVATIN Tab. (Atorvastatin 2. Reduce risks of myocardial infarction, stroke, revascularization, - 10mg, 20mg) Representative Phone chronic angina 82-2-6207-6114 10. WOORIDUL RANITIDINE HCl Gastro-duodenal ulcer, Zollinger-Ellison syndrome, reflux - Tab. (Ranitidine 75mg, 150mg) esophagitis etc. Representative Fax 82-2-6202-7067 Web www.yypharm.co.kr R&D Pipeline Contact Person Compound Name Code Use Stage of Development Mr. Choi Confidential WRDP001 Central Nervous System Drugs Non-clinical Contact Phone Confidential WRDP002 Anti-Histamines Non-clinical 82-2-6202-7116 Antipyretic, Analgesic, Anti- Confidential WRDP003 Non-clinical Contact E-mail Inflammatory Drugs [email protected] Confidential WRDP004 Anti-Diabetics Non-clinical Financial Figures Confidential WRDP005 Anti-Diabetics Non-clinical Summary (1 Million Won) Confidential WRDP006 Anti-Atherosclerotics Non-clinical Fiscal Year 2012 2013 2014 Antipyretic, Analgesic, Anti- Sales 74,169 75,372 85,651 Confidential WRDN001 Research Inflammatory Drugs R&D Expenditure 3,535 2,640 3,418 Confidential WRDN002 Anti-Peptic Ulcer Drugs Research Capital 3,000 3,000 3,000

216 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 217 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks Yuhan Corporation Poland, Syria, UAE, Arthritis, Scapular CTD Dossier 1. Ati Injection Russia, Vietnam, periarthritis Available Japan

Arthritis, Scapular Poland, UAE, Russia, CTD Dossier 2. Atri Plus Injection periarthritis Malaysia Available

Russia, Syria, CTD Dossier 3. Cnoxane Injection LMWH : Anti-Coagulant Company Profile Philiphine, Vietnam Available Founded in 1926 with the mission of supporting South Korea by enhancing 4. Asasulfan Tablet Ulcerative colitis Japan - the quality of life for all Korean people, Yuhan has been providing high quality medicines for the last 91 years as one of the leading pharmaceutical companies in South Korea. API and Intermediate Yuhan provides the custom-tailored contract services in research, R&D Pipeline development, and manufacturing of APIs, key intermediates, and RSMs at two sites under cGMP, approved by FDA(US), EDQM(EU), TGA(Australia), Representative Compound Name Code Use Stage of Development PMDA(Japan) and MFDS(Korea), to the global pharmaceutical companies Junghee Lee Stem cell Neuronata-R ALS On Market with excellent quality. And Yuhan offers one-stop services from process Headquarter Address development through commercial manufacturing. IMD/DDS Artis-FR Gastic ulcer Registration 74, Noryangjin-ro, Dongjak -gu, Seoul, Finished product Korea Monoclonal Antibody YYB101 Anti-cancer Phase 1 Yuhan is supplying various categories of high quality pharmaceutical Foundation Date finished products including cardiovascular, metabolic, respiratory, antibiotic, IMD/DDS YY1201 OA Phase 1 Dec. 1926 anticancer products and OTC products to both domestic and overseas markets. In terms of Antiphlamine Lotion(anti-inflammatory agent) and IMD/New combination YYC301 Neuropathic Pain Preclinical Research Focus Yumangel suspension(antacid), they are all market leaders in the relevant Cancer, Metabolic disease market of Korea and Vietnam. IMD/Release control YYD601 GERD Preclinical Total Staff R&D IMD/New HA filter YYD701 Dermal Filler Preclinical 1,770 persons Yuhan is focusing its R&D capabilities on developing innovative small Fusion Protein YYB102 Anti-cancer Discovery Representative Phone molecule and biological medicines, especially in the therapeutic areas of 82-2-828-0181 cancer and metabolic diseases. Its advanced drug-delivery technology also supports the development of incrementally modified drugs (IMDs) such as Web fixed-dose combination and controlled release drugs. www.yuhan.co.kr Contact Person K. C. Lee Contact Phone 82-2-828-0194 Contact E-mail [email protected] Financial Figures

Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 1,120,937 1,312,018 1,451,988 R&D Expenditure 71,543 85,191 101,609 Capital 1,285,767 1,390,818 1,487,991

218 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 219 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks Yuyu Pharma., Inc. 1. CMO (New Drug APIs) HIV USA, Europe - 2. CMO (New Drug APIs) HCV USA, Europe, Asia - 3. CMO (New Drug API) Rheumatoid Europe - 4. CMO (New Drug APIs) ß-lactamase inhibitor Europe - 5. Levofloxacin (Generic API) Antibiotic Canada, Japan - 6. Cilostazol (Generic API) Anti-platelet Japan - Neonatal Respiratory Bovine lung Company Profile 7. Newfactan (Finished product) ASIA, Middle East Distress Syndrome surfactant Yuyu Pharma Inc, established in 1941, is a company that sales, Lotion type of 8. Antiphlamine S Lotion (Finished product) ASIA - markets and manufactures pharmaceutical products in Korea and Anti-inflammatory agent has developed its business through not only in-house developed new Fixed Dose drugs but also various partnerships with global companies such as Combination drug 9. Duowell tab. (Finished product) Hypertension, Hyperlipidemia Under registration Sanofi-Aventis, Pfizer, GSK and Novartis by incensing in their original of Telmisartan & products for the Korean market. Rosuvastatin 10. Nazacare Nasal Spray Sol. 140dose & Allergic rhinitis Nasal polyps Under registration - Yuyu Pharma has focused on how to serve the aging population, as 60dose (Finished product) Representative people are living longer and searching for ways to live a healthier r. Seungpil Yu, Ph.D. / CEO life. This has led us to be a specialist in the fields of neurology, osteoporosis, cardiovascular and nephrology. Yuyu’s treatment in R&D Pipeline Headquarter Address these areas has proven to be fruitful and we will continue to focus on Compound Name Code Use Stage of Development Hyein Building, 200 Jangchungdan-ro, these therapeutic categories. In order to expand the business, we are Jung-gu, Seoul, Korea - YHP1604 Hypertension/Dyslipidemia Phase 3 also expanding our presence in the field of gastrointestinal diseases and antibiotics. - YHP1701 Hypertension/Dyslipidemia Phase 3 Foundation Date - YHP14755 Dyslipidemia/Diabetes Phase 3 1941 Also, Yuyu has completed new state-of-art factory in 2006. The - YH22162 Hypertension Phase 3 Research Focus factory designed in accordance with cGMP and EU GMP. Tablets, capsules and cream are manufactured with advanced equipment - YHD1119 Neuropathic pain Phase 3 New Drug, Botanical Drug under cGMP compliance. - YH23537 Peridontitis/Arthritis Phase 2 Total Staff We would like to have an opportunity for the business relationship - YH26153 Peri-implantitis Phase 1 299 persons with your company who is dealing with imported finished - YH12852 Postoperative ileus Phase 1 Representative Phone pharmaceutical products. - YH25448 Cancer Phase 1/2 82–2–2253-6600 - YH26136 Dyslipidemia/Thrombosis Preclinical Web - YH25724 NASH Preclinical www.yuyu.co.kr - YH24931 Cancer Preclinical Contact Person Brian Jung New Active Substances Contact Phone 82-2-6972-9173 Product (Ingredient) Use Approval Date/Country Contact E-mail Revanex (Revaprazan) Duodenal Ulcer, Gastric Ulcer, Gastritis Sep. 2005 / Korea [email protected] Financial Figures

Summary (1 Million Won) Other Fiscal Year 2015 2016 2017 1. Yuhan is a leading pharmaceutical company in Korea with generating more than KRW 1.4trillion in sales. Sales 69,743 71,579 53,518 2. Yuhan has come out on top at the Korea's Most Admired Companies Awards in its industry category for 14 consecutive years. R&D Expenditure 1,245 2,246 2,000 3. Yuhan is strictly abiding by Compliance Program. Capital 7,835 7,835 7,835

220 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 221 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks C&R Research Inc. 1. Dusta soft capsule (Dutasteride) BPH&Alopecia Mongolia -

2. Bonky soft capsule (Calcitriol) Osteoporosis Malaysia, Cambodia -

3. Bonky Injection (Calcitriol) Hypocalcemia Malaysia, Azerbaijan -

4. Yupan-C tablet Vitamin-C Mongolia, Syria -

5. Yupan-C pop Vitamin-C Mongolia - Company Profile

6. Maxmarvil tablet (Alendronate, Calcitriol) Osteoporosis Thailand, Myanmar - We, the most representative Contract Research Organization in Korea, has performed over 1,200 clinical trials projects for drugs and 7. Yuachoo Day&Night (DL-Methylepadrine) Cold Mongolia - medical devices since it was built in 1997, and there are about 300 employees including professional medical doctors and experienced Colorless transparent & 8. Veonplus Gel (Heparin Sodium) Russia - smooth gel clinical specialists. Moreover, We have secured its position as a leading CRO since it was awarded (2008, Frost & Sullivan Awards).

Foundation Date Besides, C&R Research Ltd. Inc. has run various subsidiary companies 1997 such as Quality Assurance expert company (C&R QA), pharmacometric analysis center (Q-fitter) and education institution approved by MFDS Research Focus (C&R Academy) to offer multi-directional and professional clinical Contract Research Organization trial total solutions, and expanded global influences through Chinese R&D Pipeline Total Staff branch in Beijing, and C&R Healthcare Global in Singapore. 300 persons Compound Name Code Use Stage of Development Representative Phone YY-102 YY-102 Dry eye Preclinical 82-2-6251-1500 YY-201 YY-201 Benign prostatic hyperplasia Phase 1 Web YY-312 YY-312 Obesity NDA www.cnrres.com Contact Person Tanamin Tab. - Circulatory Improvement Launched Song, Yunseok Maxmarvil Tab. - Osteoporosis Launched Contact Phone Marvil W plus Tab. - Osteoporosis Launched 82-10-2342-2812 Contact E-mail Marvil M Tab. - Osteoporosis Launched [email protected] Newmacor soft capsule - Hyperlipidemia Launched

Dustar (6oblong) - Benign prostatic hyperplasia Launched

Dustar (2oval) - Benign prostatic hyperplasia Launched Financial Figures

Summary (1 Million Won) Fiscal Year 2015 2016 2017 Sales 20,273 23,348 29,360 R&D Expenditure - - - Capital (1,541) (1,422) 2,840

222 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 223 Other C&R Subsidiaries CrystalGenomics, Inc.

[C&R ACADEMY]

C&R Academy was founded in May 2010 aimed at being a clinical trial training center in Northeast Asia, offering a wide range of training programs related clinical trials.

Now C&R Academy provides professional, comprehensive and practical “hand-on” clinical research training and continuous Company Profile education programs to researchers (PI) and research nurses (CRC) as well as CRA, PM, CRM to improve the quality of clinical trials. CrystalGenomics, Inc. is a commercial stage biopharmaceutical company that Training programs of C&R Academy is consists of Fundamental Course, Basic Course, Monitoring Practice, Clinical Project is dedicated to the discovery and development of novel pharmaceuticals with Management, GCP Training, Oncology Clinical Trial, Early Phase Study, Introduction to Clinical Trial and so on. All training programs innovative platform technologies to address significant unmet medical needs can expect the effect of intensive training workshop conducted in the form of a small two-way communication. in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for multi-national In addition, since 2011, C&R Academy introduced LMS (Learning Management System) and have been strived to improve the clinical development in California, and it is publicly traded on the KOSDAQ validation and quality of educational services for all C&R Academy as ISO9001 certified company. C&R Academy will to be oriented exchange. to international standards of clinical training services continuously. CrystalGenomics currently has one product on the market and is developing Representative two additional novel drug candidates in different therapeutic areas. The Joong Myung Cho, Ph.D. marketed product is Acelex® (polmacoxib), a next generation COX-2 inhibitor [C&R QA] for the treatment of signs and symptoms of osteoarthritis. The first clinical Headquarter Address stage program is CG400549, a novel targeted antibiotic for MRSA where its C&R QA Inc., founded in Aug 2014, is the first company specialized in quality assurance of clinical trials in South Korea. 5th F. Bldg.A, Korea Bio Park, 700 phase 2a skin infection study in the US has been completed with a positive Daewangpangyoro, Bundanggu, outcome of 100% clinical cure rate. The second program is CG200745, an C&R QA is established for the purpose of enhancing the professionalism of the quality assurance work of clinical trials independently Seongnamsi, Gyeonggido, 13488 Korea epigenetic anti-cancer therapeutic for various types of solid and liquid tumors from C&R Research that had provided quality assurance services such as audits in a variety of therapeutic areas, education and and currently, two clinical studies are ongoing for pancreatic cancer and preparation for government authority inspection. As the importance of quality assurance of clinical trials has been increasingly Foundation Date MDS. emphasized, C&R QA is aiming to provide quality assurance services of clinical trials to customers with credibility. July 7, 2000 The Company's therapeutic candidates are discovered and developed through All auditors of C&R QA have a membership of RQA (Research Quality Assurance) and Auditor certificates, especially lead auditors Research Focus its proprietary discovery platform technology which employs integrated have a certificate of ‘Registered Quality Assurance Professional’ by SQA(Society of Quality Assurance). Discovery, R&D and commercialization of technologies of the SPS™ (technology for structure determination), the SCP™ novel therapeutics (technology for the generation of lead compounds) and the SDF™(technology C&R QA will continue to devote itself to be the best partner for customers in the field of quality assurance of clinical trials by used for lead optimization) technologies. Total Staff ensuring that the clinical trial is performed and the data are generated, documented (recorded), and reported in compliance with By leveraging its capabilities and the know-how in novel drug discovery and Good Clinical Practice (GCP) and the applicable regulatory requirement(s). 80 persons development, CrystalGenomics will continue to strive in making significant Representative Phone contributions to improve human health. 82-31-628-2700 [Q-fitter] Web Q-fitter Inc. is dedicated to help customer through the drug development process. Main job is to perform a high quality www.cgxinc.com pharmacometric analysis-the use of modeling and simulation that quantifies drug, disease and trial information to support efficient drug development and regulatory decisions- and provide clinical services to support the management of early phase clinical trials. Contact Person Steven Kim Contact Phone [C&R Healthcare Global] 82-31-628-2720 Financial Figures C&R Healthcare Global provides business platform that supports bio-healthcare industries in advancing to global market. Based on Contact E-mail accumulated clinical development experience and global network of leading CRO ‘C&R Research’. C&R Healthcare Global will fulfill [email protected] Summary (1 Million Won) the platform through incubation, matching the investment manufacture, and distribution to maximize corporate value. Fiscal Year 2015 2016 2017 Sales 6,136 14,525 14,685 R&D Expenditure 6,102 7,066 7,000 Capital 73,639 83,265 97,258

224 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 225 Main Products Product (Ingredient/Formulation) Use Exporting Countries Remarks GL PharmTech Dong-A ST: commercial Currently none; partner for Korea. Turkey, Lebanon, Saudi 1. Acelex® (polmacoxib) Osteoarthritis TR-Pharm: commercial Arabia, Kuwait, UAE: partner for Turkey & 2018~2019 (projected) MENA region

Company Profile R&D Pipeline GL PharmTech (GLPT) has focused on developing improved versions Compound Name Code Use Stage of Development of the currently marketed pharmaceutical products with reduced side effects, greater therapeutic efficacy and better patient compliance HDAC inhibitor (NCE) CG200745 Pancreatic cancer Phase 2 in progress using our proprietary drug formulation and delivery technologies since myelodysplastic syndrome HDAC inhibitor (NCE) CG200745 Phase 1b in progress 2002. (MDS) We have provided more than 50 pharmaceutical companies in Korea HDAC inhibitor (NCE) CG200745 Acute myeloid leukemia (AML) IND preparation with value-added drug formulations and delivery technologies for Phase 2a completed; Representative generic and improved version of marketed drug. FabI inhibitor (NCE)Polmacoxib & MRSA & other serious staph CG400549 IND preparation with newly Tramadol (FDC with NCE) infections Hunsik, Wang We are now transitioning from a being a technology transfer-based formulated drug product Headquarter Address operation to being a specialty pharmaceutical company capable of BTK/Flt3 inhibitor (NCE) CG100650 Various acute & chronic pain IND submitted #714 Jungang Induspia V, 137, developing and delivering new product lines by ourselves from 2010. We are doing this based on intensive investment in various clinical CG026806 Preclinical (Out-licensed to Sagimakgol-ro, Jungwon-gu, Seongnam, BTK/Flt3 inhibitor (NCE) AML, MCL, CLL (CG'806) Aptose Bioscienses in 2016) Gyeonggi-do, Korea studies of products currently in our pipelines and using our already- established drug delivery platform technologies. Foundation Date Aug, 2002 Technology - GLARS(Geometrically Long Absorption Regulated System) New Active Substances Research Focus IMD(Incrementally Modified Drugs) Conventional sustained release drug delivery systems such as ALZA’s Product (Ingredient) Use Approval Date/Country OROS (Osmotic Release Oral System) and Skyepharma’s Geomatrix, Total Staff have enjoyed great success in the field of a drug dosage form Acelex® (polmacoxib) Osteoarthritis Feb. 2015 / Korea 29 persons reformulation. Although these systems extend the drug release up to Representative Phone 24 or 48 hours, the simple extension of drug release time would be 82-31-739-5220~3 meaningless because a practical absorption site of overall drugs is generally limited to a small intestine consider the total transit time Web along the small intestine with absorption will be only 4 to 6 hrs. This http://www.glpt.co.kr means that relatively large amounts of the incorporated drug would Contact Person pass out without a sufficient practical absorption. Jun Sang Park Contact Phone 82-31-739-5220 (#324) Contact E-mail Financial Figures [email protected] Summary (1 Million Won) Fiscal Year 2014 2015 2016 Sales 7,301 6,475 4,636 R&D Expenditure 1,158 1,034 1,130 Capital 1,162 2,323 3,022

226 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 227 To overcome the shortcomings of the currently existing sustained Product (Ingredient/Formulation) Use Exporting Countries Remarks release drug delivery technologies we have recently developed a novel drug delivery system to enable a drug to be dissolved 8. GL1405(Paroxetine CR) Depression - - irrespective of the surrounding environment and further absorbed up 9. GL1502(Limaprost) Buerger's disease - - to colon. We coined this “Geometrically Long Absorption Regulated System (GLARS)”. 10. GL1505(Tolterodine LA) Benign Prostatic Hyperplasia - -

Basically, this system is a triple-layered tablet, comprised of upper 11. GL1507(Rabeprazole) Gastric ulcer - - and lower layers that swell and draw a sufficient amount of water, plus a highly water-soluble middle layer that rapidly draw water into 12. GL1606(Tramadol plus acetaminophen) Pain - - the tablet core simultaneously. 13. GL1608(Atorvastatin) Hyperlipidemia - - As the middle layer induces a rapid water draw into the tablet core, the penetrated water also diffuses to the upper and lower layers, 14. GL1712(Tacrolimus) Immunosuppressant - - which makes the tablet to rapidly swell and controls drug release. 15. GL2803(Gimepiride plus Metformin XL) Diabetes - - At virtually the same time, the swollen upper and lower layers form to surround a lateral side of the middle layer, which can, in turn, further control drug release. This relatively rigid swollen matrix structure makes drug release not affected by surrounding mechanical flux, which can provide relatively consistent in vivo drug release R&D Pipeline irrespective of degree of gastrointestinal motility. Compound Name Code Use Stage of Development The water drawn into the tablet (about 3 to 5 times the weight of the tablet itself) functions as an additional media which enables IMD additional and later drug release out of the dosage form. This serves Pregabalin QD GLA5PR Pain Phase III to overcome the shortage of surrounding media that has been Risedronate + Vitamin D reported to be one of the key reasons for mal-absorption of a drug in 3 GLE1RCW Osteoporosis Phase I colon. Effervescent tablet Paroxetine CR GLE3PA Vasomotor Symptoms Phase III

Generic

Ropinirole XL GL1901 Parkinson's disease Bioequivalence test

Mirabegron PR GLG1MI Overactive bladder Bioequivalence test

Main Products

Product (Ingredient/Formulation) Use Exporting Countries Remarks 1. G-soren Tab. (Artemisiae Argyi Folium Gastritis - - Isopropanol ext.(20 -> 1))

2. GL1203(Tamsulosin) Benign Prostatic Hyperplasia - -

3. GL1204(Felodipine ER) Hypertension - -

4. GL1314(Ramipril) Hypertension - -

5. GL1317(Pantoprazole) Gastric ulcer - -

6. GL1319(Nifedipine SR) Hypertension - -

7. GL1320(Doxazosin XL) Benign Prostatic Hyperplasia - -

228 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 229 Medi Help line Pharmicell Co., Ltd.

Company Profile Company Profile Since its foundation in Feb.1998, Medi Help Line has conducted Since its establishment in 2002, Pharmicell has devoted to developing average annual number of 150 RA projects for new drugs, innovative stem cell drugs to benefit more people with desperate needs and drugs, medical devices and quasi-drugs for 13 years and has a successfully developed the world’s first stem cell drug on July 1st, well-established business partnership with many domestic and 2011, marking a new era in the world history of cell treatment. international companies based on the performance of the strategic The path for innovation and challenge pioneered by Pharmicell to consulting services as well as RA outsourcing services, accumulated become the world first, has set Korean Standards in the area of stem database of the various projects and communication know-how with cell drugs and has changed the spectrum of the overseas stem cell the KFDA. industry beyond the boundary of Korea. In addition, Pharmicell has Representative Representative emerged as the global leader of biopharmaceutical raw materials We provide a real Total Package Service from the consulting service Mr. Ok-nam PARK/ CEO Hyun-Soo Kim, Seong-Lae Kim development and is recognized for its technology with our exporting for research and development strategy to the outsourcing services performance of raw medicine to prominent global pharmaceutical Headquarter Address including KFDA IND/NDA, HIRA listing and KGMP. Headquarter Address 8-1207 Woorim Lion's Valley, Digital 7th Floor, Ssangbong B/L, Unju-ro 874, companies. Moreover, Pharmicell strives further to develop the next 3rd Complex, 371-28 Gasan-dong, Gangnam-gu, Seoul Korea generation of new drugs based on the management value of fusion Geumcheon-gu, Seoul 153-786 and challenge. Pharmicell will take the lead for Korea to become Foundation Date the outstanding leader of biopharmaceutical industries of the world Foundation Date 1968. 8. 20 (Listing: 1988.5.20) through continuous R&D and ultimately create value for a healthy and 1998 Research Focus happy human life. Total Staff Stem Cell 30 persons Total Staff Representative Phone 115 persons 82-2-2026-0707 Representative Phone Representative Fax 82-2-3496-0114 82-2-2026-0708 Web Web http://www.pharmicell.com WWW.MEDIHELPLINE.NET Contact Person Sungpill Park Contact Phone 82-2-3496-0181 Contact E-mail Financial Figures [email protected] Financial Figures

Summary (1 Million Won) Summary (1 Million Won) Fiscal Year 2008 2009 2010 Fiscal Year 2015 2016 2017 Sales 1,558 1,338 1,590 Sales 25,176 27,839 25,197 R&D Expenditure - - - R&D Expenditure 2,597 4,941 4,029 Capital 50 - - Capital 28,617 29,191 29,204

230 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 231 Main Products

Product (Ingredient/Formulation) Use Exporting Countries Remarks 1. Cellgram-AMI Acute myocardial infarction - World first stem cell drug

R&D Pipeline Compound Name Code Use Stage of Development Expected to be launched Cellgram-LC - Liver Cirrhosis in May 2018 Cellgram-ED - Impotence Phase 1 KPBMA Member Cellgram-IS - Acute cerebral infarction Phase 3 Cellgram-SCI - Spinal cord injury Phase 2/3 Company List Cellgram-CLI - Critical lower limb ischemia Phase 1

2018 DIRECTORY OF KOREAN PHARMACEUTICAL INDUSTRY

232 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY Regular Members(2018. 4) No Company Phone Fax Address Homepage 24, Pangyo-ro 255beon-gil, Bundang-gu, 26 Corestem Inc. 82-2-497-3711 82-2-6349-8666 www.corestem.com No Company Phone Fax Address Homepage Seongnam-si, Gyeonggi-do, Korea 1 Aestura Corporation - - 100 Cheonggyecheon-ro, Jung-gu, Seoul www.aestura.com/ 218-7 Anyang7-dong Manan-gu, Anyang si, www. 27 Crown Pharm. Co., Ltd. 82-31-443-3922 82-31-443-3921 993-75 Daelim-dong, Yeongdeungpo-gu, Gyeonggi-Do crownpharm.co.kr 2 Ahn-Gook Pharm. Co., Ltd. 82-2-3289-4200 82-2-847-8867 www.ahn-gook.com Seoul Koreabiopark A, 5F, 700, www. www. 28 Crystal Life Sciences. 82-31-628-2900 82-31-628-2901 Daewangpangyo-ro, Bundang-gu, crystallifescience. 3 Aju Pharm Co., Ltd. 82-2-2630-0700 82-2-2636-7519 413-13 Shindolim-dong, Guro-gu, Seoul asiapharm.co.kr Seongnam-si, Gyeonggi-do com CTC Building, 13 Jungdaero 40 gil, 662 Jinjeong-ri, Sanyang-myeon, www. 29 CTCBIO, Inc 82-2-70-4033-0200 82-2-449-6966 www.ctcbio.com 4 Alpha Pharm. Co., Ltd. 82-54-552-5381 82-2-54-552-5385 Songpa-gu, Seoul Mungyeong-si, Gyeongsangbuk-do alphapharm.co.kr 778-1 Ilpae-dong, Namyangju-si, 13F. TWO IFC Bldg. 10 Gukjegeumyung-ro, www. 30 C-Tri 82-31-557-0001 82-31-557-6622 www.c-tri.co.kr 5 Alvogen Korea. Co., Ltd. 82-2-2047-7700 82-2-443-0589 Gyeonggi-do Yeongdeungpo-gu, Seoul, Korea alvogenkorea.com www. (Namsung Plaza, Gasan-dong) 405, 130, 31 Dae Woo Pharm. Ind. Co., Ltd. 82-51-204-3831 82-51-202-3397 153 Dadaero, Saha-gu, Busan daewoopharm.com 6 Antrogen. Co., Ltd. 82-2-2104-0391 82-2-2104-0393 Digital-ro, Geumcheon-gu, Seoul, 08589, www.antrogen.com 122B-9L, 692-8, Gojan-dong, Namdong-gu, www. Korea 32 Daebong LS 82-32-712-8800 82-32-817-8808 Incheon daebongls.co.kr 545, Dunchon-daero, Jungwon-gu, www. 7 Aprogen Pharmaceuticals 82-31-625-4045 - 308 Masan-ri, Heongseong-gun, Seongnam-si, Gyeonggi-do aprogen-pharm.com 33 Daehwa Pharm. Co., Ltd. 82-33-342-5140 82-33-342-0576 www.dhpharm.co.kr Gangwon-do Alico Building, 70-5 Yangjae-dong, Seocho- 8 Arlico.co.Ltd. 82-2-520-6943 82-2-3474-3281 www.arlico.co.kr www. gu, Seoul 34 Daewon Pharm. Co., Ltd. 82-2-2204-7000 82-2-498-9108 229-3 Yongdap-dong, Seongdong-gu, Seoul daewonpharm.com GumHa B/D 6F 41-2 Chungdam-dong, www. 9 ASTELLAS Pharm Korea, Inc 82-2-3448-0504 82-2-3448-0510 www. Gangnam-gu, Seoul astellas.com/kr 35 Daewoong Pharm. Co., Ltd. 82-2-550-8800 82-2-550-3530 163-3 Samsung-dong, Gangnam-gu, Seoul daewoong.co.kr Posco center 13F, 892 Daechi-dong, 10 B. Braun Korea. Co., Ltd 82-2-3459-7800 82-2-3453-3060 www.bbraun.co.kr 8-3 Yangpyeong-dong 4-ga, Yeongdeungpo- Gangnam-gu, Seoul 36 Dai Han Pharm. Co., Ltd. 82-2-2678-8445 82-2-2671-9636 www.daihan.com gu, Seoul 11 Baxter Inc. 82-2-6262-7100 82-2-6272-7101 KNTO B/D 5F,10 Da-dong, Jung-gu, Seoul www.baxter.co.kr Posco West 3F, Daechi4-dong, Kangnam-gu, www. Kyung B/D .Gaepo-dong 1184-8 , Gangnam- 37 Daiichi Sankyo Korea Co.,Ltd. 82-2-3453-3300 82-2-3452-9756 12 Bc world pharm. Co.,Ltd. 82-2-2182-0403 82-2-574-5064 www.bcwp.co.kr Seoul daiichisankyo.co.kr gu, Seoul 907-5 Sangsan-ri, Hyangnam-eup, www. Ilshin B/D, Dohwa-dong 541, Mapo-gu, 38 Dalim Biotech Co., Ltd. 82-31-535-6091 82-31-535-6093 13 Binex Co., Ltd. 82-6710-7235 82-2-6710-7299 www.bi-nex.com Hwaseong-si, Geonggi-do dalimmedical.co.kr Seoul 491 Mansu-ri, Gangwoe-myeon, 307-1 Songsan-ri, Yanggam-myeion, 39 DHP Korea Co., Ltd. 82-43-239-3303 82-43-239-3308 www.dhpkorea.co.kr 14 Bolak. Co., Ltd. 82-31-352-6455 82-31-352-4341 www.bolak.co.kr Cheonggwon-gun, Chungcheongbuk-do Hwaseong-si, Gyeonggi-do Shiwah Complex 1 Ra No.603,1248-8 www. Boryung B/D, 66-21 Wonnam-dong, Jongno- 40 Dong In Dang Pharm. Co., Ltd. 82-31-319-1990 82-31-319-1995 15 Boryung Pharm. Co., Ltd. 82-2-708-8000 82-2-708-8439 www.boryung.co.kr Jungwang-dong, Siheung-si, Gyeonggi-do dongin-dang.co.kr gu, Seoul 41 Dong Koo Pharm. Co., Ltd. 82-2-2688-5421 82-2-2681-1880 195-2 Gocheok 2-dong, Guro-gu, Seoul www.dongkoo.co.kr 16 Bukwang Pharm. Co., Ltd. 82-2-828-8114 82-2-828-8029 398-1 Daebang-dong, Dongjak-gu, Seoul www.bukwang.co.kr 42 Dong Kook Pharm. Co., Ltd. 82-2-2191-9900 82-2-566-8542 997-8 Daechi 3-dong, Gangnam-gu, Seoul www.dkpharm.co.kr 17 Celltrion Pharm. Inc 82-32-850-5000 82-32-850-4309 13-6, Songdo-dong, Yeonsu-gu, Incheon www.celltrionph.com Daeyeongak tower 12F, 25-5 Chungmuro www. 43 Dong Kwang Pharm. Co., Ltd. 82-2-776-7641 82-2-777-4874 7 Neungan-ro, Danwon-gu, Ansan-si, 1-ga, Jung-gu, Seoul dkpco.co.kr 18 Chemtros Co., Ltd 82-31-491-0653 82-31-491-0881 www.chemtros.com Gyeonggi-do www. 44 Dong Wha Pharm. Ind. Co., Ltd. 82-2-2021-9300 82-2-778-2336 5 Sunwha-dong, Jung-gu, Seoul Ace Techno Town 1F, 55-7 Moonrae-dong 3 dong-wha.co.kr 19 Cho-a Pharm. Co., Ltd. 82-2-2166-4000 82-2-2166-4111 www.choa.co.kr ga,Youngduengpo-gu, Seoul 45 Dong-A Pharmaceutical 82-2-920-8112 - 64 Cheonhodaero, Dongdaemun-gu, Seoul en.dapharm.com 20 Chodang Pharm. Co., Ltd. 82-2-869-0181 82-2-869-1192 44 Guro 5-dong, Guro-gu, Seoul www.chodang.com 46 Dong-A ST 82-2-920-8111 - 64 Cheonhodaero, Dongdaemun-gu, Seoul en.donga-st.com/ Chong Kun Dang B/D 368, Chungjeongno www.dongsung- 21 Chong Kun Dang Pharm. Corp. 82-2-2194-0300 82-2-2194-0369 www.ckdpharm.com 47 Dongsung Pharm. Co., Ltd. 82-2-6911-3600 82-50-5191-69081 703-14 Banghak-dong, Dobong-gu, Seoul 3-ga, Seodaemun-gu, Seoul pharm.co.kr 246-47 Dodang-dong, Wonmi-gu, Pucheon- Revessant B/D 10F, 147-17Samseong-dong, 22 Chunhedang Pharm. Co., Ltd. 82-31-675-5561 82-31-676-6320 - 48 Eisai Korea Inc. 82-2-3451-5500 82-2-3451-5599 www.eisaikorea.com si, Gyeonggi-Do Gangnam-gu, Seoul CJ Cheiljedang Center, 330, Dongho-ro, 2F Kyungpung Building, 788-26 Yeoksam- 23 CJ Healthcare 82-2-6740-2119 - www.cjp.co.kr/ 49 Elyson Pharmaceutical Co. Ltd. 82-2-6342-7001 82-2-6342-7003 www.elyson.co.kr Jung-gu, Seoul 100-400, Korea dong, Gangnam-gu, Seoul 7F MJL Building, 204-5 Nonhyun-dong, www. Daekwan B/D 5F, 15-1 Yangjae-dong, www. 24 CMG Pharmaceutical CO.,Ltd. 82-2-3453-8816 82-2-3453-8819 50 Estech Pharma Co., Ltd. 82-2-3471-2078 82-2-3471-2079 Gangnam-gu, Seoul cmgpharma.co.kr Seocho-gu, Seoul estechpharma.com 157-3 Dodang-dong, Wonmi-gu, Pucheon- Songwon B/D 7F, 59-5 Banpo-dong, Seocho- 25 Cmic CMO Korea Co.,Ltd. 82-32-678-5771 82-32-675-3385 www.cmic-cmo.co.kr 51 Ferring Pharm. Korea Co.,Ltd. 82-2-534-2761 82-2-534-2956 www.ferring.co.kr si, Gyeonggi-Do gu, Seoul

234 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 235 No Company Phone Fax Address Homepage No Company Phone Fax Address Homepage 47, Baekseokgongdan 1-ro, Seobuk-gu, 1529-4, Songjeong-dong, Gangseo-gu, 52 Firson Co., Ltd. 82-2-1833-8200 82-41-566-8321 www.firson.co.kr 77 Huniz. Co., Ltd. 82-51-831-1030 82-51-831-1040 www.huniz.kr Cheonan-si, Chungcheongnam-do, Korea Busan SaemaeulUndong B/D 3F, 1008-4 Daechi- www. C-901 PangyoInoBelly, 621 Sampyeong- 53 Fresenius Kabi Korea Ltd. 82-2-3484-0900 82-2-3484-0957 dong, Gangnam-gu, Seoul fresenius-kabi.com 78 Huons Co., Ltd 82-31-854-4700 82-31-6455-0740 dong, Bundang-gu, Seongnam-si, Gyeonggi- www.huons.com do Fresenius medical care korea Landmarktower 7F, 837-36 yeoksam-dong, www. 54 82-2-2112-8800 82-2-2112-8804 co.,Ltd Gangnam-gu, Seoul fmc-korea.co.kr 555-2 Yeongchun-ri, Dongtan-myeon, 79 Hutecs Korea Co., Ltd 82-31-377-7900 82-31-377-7911 www.hutecs.co.kr Hwaseong-si, Gyeonggi-do Bando B/D 7F, 48-1 Banpo-dong, Seocho- www. 55 Galderma Korea Ltd. 82-2-6717-2000 82-2-6717-2001 gu, Seoul galdermakorea.com Hyungai pharm B/D, 204-4 Nonhyeon-dong, www. 80 Hyundai Pharm. Ind. Co., Ltd. 82-2-2600-3813 82-2-2693-7628 LS Youngsan tower 9F, 92, Hangang-daero, Gangnam-gu, Seoul hyundaipharm.co.kr 56 GlaxoSmithKline Korea 82-2-709-4116 82-2-796-4710 www.gsk-korea.co.kr Yongsan-gu, Seoul Room 1305 Technopark Techcentre, 190- GlaxoSmithKline Korea LS Youngsan tower 9F, 92, Hangang-daero, 81 Icure Pharm. Inc. 82-31-776-3776 82-31-776-3770 1 Sangdaewon-dong, Jungwon-gu, www.icure.co.kr 57 82-2-709-4305 82-2-798-0985 www.gsk-korea.co.kr Consumer Healthcare Yongsan-gu, Seoul Seongnam-si 2F, 4159 Shingil 6-dong, Yeoungdeungpo- Iksoo B/D, Amsa-dong 488-20, Kangdong- 58 Green Pharm. Co., Ltd. 82-2-842-1301 82-2-842-1302 - 82 Ik-Su Pharm. Co., Ltd. 82-2-416-1112 82-2-416-1118 www.iksu.co.kr gu, Seoul gu, Seoul 303 Bojeong-dogn, Giheung-gu, Yongin-si, www. 83 Il Dong Pharm. Co., Ltd. 82-2-526-3114 82-2-526-3030 60 Yangjae-dong, Seocho-gu, Seoul www.ildong.com 59 Greencross Corporation 82-31-260-9300 82-31-260-9413 Gyeonggi-do greencross.com 84 Ilsung Pharm Co., Ltd. 82-2-3271-8800 82-2-2701-6335 44-7 Wonhyoro1-ga, Yongsan-gu, Seoul www.ilsung-ph.co.kr 4&6th floor, 278, Beotkkot-ro, Geumcheon- www. 85 Ilwha Co., Ltd. 82-31-550-0100 82-31-550-0105 437 Sutaek1-dong, Guri-si, Gyeonggi-Do www.ilhwa.co.kr 60 Greencross Cell 82-2-2101-0600 82-2-2101-0601 gu, Seoul, 08511, Korea greencrosscell.com 86 Il-Yang Pharm. Co., Ltd. 82-2-570-3700 82-2-570-3708 544-5, Dogok-dong, Gangnam-gu, Seoul www.ilyang.co.kr 7th Floor, Dodam bldg B-dong, 246 www. Inist Bio Pharmaceutical. Co., 34-40, Jaeyakgongdan 2-gil, Hyangnam- www.inist.co.kr/ 61 Greencross WellBeing 82-31-629-8600 82-31-629-8601 Hwangsaeul-ro, Bundang-gu, Seongnam, 87 82-31-370-7300 82-31-354-1539 greencrosswb.com Ltd. eup, Hwaseong-si, Gyeonggi-do inistbio Gyeonggi-do 701, 2nd Geumgang High-Tech 159, 94-119 Yeoungdeungpo-dong 2-ga, www. 62 Guju Pharm. Co., Ltd. 82-2-2672-1122 82-2-2679-7569 www.gujup.co.kr 88 Inist ST Co., Ltd. 82-31-669-9520 82-31-737-4198 Sagimakgolro, Joongwon-gu, Seongnam-si, Yeongdeungpo-gu, Seoul inist.co.kr/inistst Gyeonggi-do 8F Joil Building 62 Nonhyeon-dong, www. 63 Hamsoa Pharm. Co., Ltd. 82-2-2176-2180 82-2-3443-0825 Yeonse medical school 6F, Sinchon-dong Gangnam-gu, Seoul hamsoapharm.com 89 Isu Abxis Co., Ltd. 82-2-2227-8888 82-2-2227-8887 www.abxis.com 134, Seodaemoon-gu, Seoul 1181 Geodu-ri, Dongnae-myeon, www. 64 Han Kook Korus Pharm. Co., Ltd. 82-33-264-5771 82-33-264-5774 25F LG Yongsan Tower B/D, 191 Hangang- www. Chuncheon-si, Gangwon-do koruspharm.co.kr 90 Janssen Korea Ltd. 82-2- 2094-4500 82-2- 538-5632 ro 2ga , Yongsan-gu, Seoul janssenkorea.com Rocket B/D 6~7F, 747-29 Yeogsam-dong, 65 Hana Pharm. Co., Ltd. 82-2-577-7667 82-2-577-6003 www.hanaph.co.kr 91 Je Il Pharm. Co., Ltd. 82-53-583-6226 82-53-583-5775 Daechun-dong 739, Dalseo-gu, Daegu city www.jeilphar.co.kr Gangnam-gu, Seoul Jamsil I-Space 6F, 11-10 Shinchon-dong, 92 Jeil Pharm. Co., Ltd. 82-2-549-7451 82-2-549-4045 343, Sapyeong-daero, Seocho-gu, Seoul www.jeilpharm.co.kr 66 Hanall Bio Pharm. Co., Ltd. 82-2-2204-1928 82-2-2414-7474 www.hanall.co.kr Songpa-gu, Seoul www. 93 Jin Yang Pharm. Co., Ltd. 82-2-3470-0300 82-2-3470-0390 1532-9 Seocho-dong, Seocho-gu, Seoul 67 Handok Pharm. Co., Ltd. 82-2-527-0114 82-2-527-5001 132 Teheran-ro, Gangnam-gu, Seoul www.handok.co.kr jinyangpharm.com 805-15 Jungsan-ri, Yangchon-myeon, www. 68 Hankooksinyak Pharm. Co., Ltd. 82-41-740-8900 82-41-740-8849 www.hsp.co.kr 94 JW Pharmaceutical 82-2-840-6777 82-2-841-1213 698 Shindaebang-dong, Dongjak-gu, Seoul Nonsan-si, Chungcheongnam-do jw-pharma.co.kr 3F 13cha Daeryung Techno Tower, Gasan- www. 69 Hanlim Pharm. Co., Ltd. 82-2-3489-6000 82-2-3489-6101 1656-10 Seocho-dong, Seocho-gu, Seoul www.hanlim.com 95 JW Shinyak 82-2-2109-3300 82-2-2109-3388 dong, Geumcheon-gu, Seoul jw-shinyak.co.kr Hanmi Tower, 45 Bangi-dong, Songpa-gu, 70 Hanmi Pharm. Co., Ltd. 82-2-410-9114 82-2-410-9259 www.hanmi.co.kr 492-12, Maetan 3-dong, Yeongtong-gu, Seoul 96 KMS Pharm Co., Ltd. 82-31-215-5456 82-31-215-5925 www.kmspharm.com Suwon-si, Gyeonggi-do 71 Hanpoong Pharm. Co., Ltd. 82-2-586-5211 82-2-583-8584 981-52 Banbae-dong, Seocho-gu, Seoul www.hanpoong.co.kr 170-7 Seojeong-ri, Jeonui-myeon, Yeongi- 41 Poseunggongdan-ro, Poseung-eup, www. 97 Kolmar Korea 82-41-862-1057 82-41-862-7637 www.kolmar.co.kr 72 HanseoChem 82-31-682-8655 82-31-682-8656 gun, Chungcheongnam-do Pyeongtaek-si, Kyeonggi-do hanseochem.co.kr 93 Biovalley 2-ro, Jecheon-si, Chungpyeong-gil 2-11 (Docheong-lee 98 Kolmar pharma 82-43-640-0088 82-43-640-0007 www.kolmar.co.kr www. Chungcheongbuk-do 73 Hansol Pharm. Co., Ltd. 82-43-881-6333 82-43-881-6332 33-32), Geumwang-eup, Eumsung-gun, hansolpharm.com Floor 7, Kolon Tower annex, Kolon 13, Choongcheongbook-Do 99 Kolon Life Science Inc. 82-2-3677-4150 - www.kolonls.co.kr Gwachun-si, Gyunggi-do 74 Hanwha Pharma. Co., Ltd. 82-2-959-3161 82-2-959-3621 261 Seokkwan 2-dong, Seongbuk-gu, Seoul www.hwpharm.com 6F Annex to Kolon Tower, 1-22 Byeoryang- www. www. 100 Kolon Pharma 82-2-2120-8300 82-2-2120-8301 75 Hawon Pharm. Co. 82-2-554-2012 82-2-554-4557 788-1 Yeogsam-dong, Gangnam-gu, Seoul dong, Gwacheon-si, Gyeonggi-do kolonpharm.co.kr hawonpharm.co.kr Advanced Reactor Development Institute, Korea Atomic Energy Research Room 502 Anyang-megavalley, 268 Hagui- 101 82-42-868-4641 82-42-868-2106 Daedeok-daero 989-11, Yuseong-gu, www.kaeri.re.kr 76 Humedix. Co., Ltd. 82-70-7492-5600 82-31-420-5650 humedix.com Institute ro, Dongan-gu, Anyang-si, Gyeonggi-do Daejeon

236 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 237 No Company Phone Fax Address Homepage No Company Phone Fax Address Homepage 417-4, Seokchon-ri, Jongcheon-myeon, www. Myungin B/D, 1539-9 Seocho-dong, www. 102 Korea Global Pharm. Co., Ltd. 82-41-951-4300 82-41-951-4344 127 Myung In Pharm. Co., Ltd. 82-2-587-9060 82-2-585-0352 Seocheon-gun, Chungcheongnam-do globalpharm.co.kr Seocho-gu, Seoul myunginph.co.kr 7F Gookmin-1 B/D, 302 Yeongdong-daero, www. Myungmoon B/D, 946-18 Dogok-dong, 103 Korea Kowa Company Ltd. 82-2-6930-4800 82-2-6930-4808 128 Myung Moon Pharm. Co., Ltd. 82-2-6711-2000 82-2-572-5137 www.mmpharm.co.kr Gangnam-gu, Seoul kowakorea.com Gangnam-gu, Seoul 713-2, Jung-ri, Dongtan-myeon, Hwaseong- www. Nelson B/D 3F, Seocho-dong 1462-17, www. 104 Korea mcnulty. Co., Ltd. 82-31-378-1460 82-31-378-1468 129 Nelson Korea Pharm Co.,Ltd. 82-2-588-0941 82-2-588-0170 si, Gyeonggi-do koreamcnulty.co.kr Seocho-gu, Seoul nelsonkorea.co.kr 105 Korea Otsuka Pharm. Co., Ltd. 82-2-3287-9000 82-2-3287-9019 770-9 Yeoksam-dong, Gangnam-gu, Seoul www.otsuka.co.kr 836 Seryu3-dong, Gwonsun-gu, Suwon-si, 130 Nensys Co., Ltd. 82-31-232-5285 82-31-234-4410 www.nensys.co.kr Baeklim B/D 8F, 823-33 Yeogsam-dong, www. Gyeonggi-Do 106 Korea Pharma Co., Ltd. 82-2-558-1277 82-2-558-1677 Gangnam-gu, Seoul koreapharma.co.kr BK Tower 11F, 942-2 Daechi 2, Gangnam- www. 131 Newgenpharm Inc. 82-2-580-5900 82-2-580-5999 Daein Building, 158-3 Daein-dong, Dong-gu, www. gu, Seoul newgenpharm.com 107 Korea Prime Pharm. Co., Ltd. 82-62-233-1110 82-62-233-3298 Gwangu koreaprime.co.kr 13F, The-K twin towers B, 50 Jong-ro 1-gil, 132 Ono Pharma Korea Co., LTD. 82-2-928-8423 82-2-925-2151 www.ono.co.jp/eng/ 108 Korea United Pharm. Inc. 82-2-512-9981 82-2-548-4599 154-8 Nonhyun-dong, Gangnam-gu, Seoul www.kup.co.kr Jongno-gu, Seoul Doowon B/D, 87-3 Garak-dong, Songpa-gu, www. PharmaResearch Products Co., 74, Pangyo-ro 255beon-gil, Bundang-gu, www. 109 Korea Vaccine Co., Ltd. 82-2-443-1961 82-2-443-4484 133 82-31-8039-1500 - Seoul koreavaccine.com Ltd. Seongnam-si, Gyeonggi-do pr-products.co.kr www.nicepharma. 7F Samhomulsan Building A, 275-1 Yangjae- 110 Korean Drug Co., Ltd. 82-2-529-6100 82-2-529-6114 423-2 Dogok-dong, Gangnam-gu, Seoul 134 Pharmbio Korea Co., Ltd 82-2-587-2551 82-2-587-2552 www.pharmbio.co.kr com dong, Seocho-gu, Seoul Osong B/D 27-11Jeong-dong, Jung-gu, 135 Pharvis Bio Tech Korea Corp. 82-2-579-6262 82-2-579-0880 517-9 Doggok-dong, Gangnam-gu, Seoul www.pharvis.co.kr 111 Kuhnil Pharm. Co., Ltd. 82-2-714-0091 82-2-719-0493 www.kuhnil.com Seoul 726-4 Bugok-dong, Sanrok-gu, Ansan-si, www. 136 PMG PHARM Co., Ltd 82-31-439-5470 82-31-405-5471 49 Sandan-ro, Heungdeok-gu, Cheongju-si, www. Gyeonggi-do pmgpharm.co.kr 112 Kukbo Science Co., Ltd. 82-43-264-7765~8 82-43-267-7769 Chungcheongbuk-do kukboscience.co.kr www. 137 Reyon Pharm. Co., Ltd. 82-2-793-5557 82-2-798-7538 38-6 Dongbinggo-dong, Yongsan-gu, Seoul 513-2 Yatap-dong, Bundang-gu, Seongnam- www. reyonpharm.co.kr 113 Kukje Pharm. Ind. Co., Ltd. 82-31-781-9081 82-31-781-6040 si, Gyeonggi-do kukjepharm.co.kr Danam B/D 22F, 120 Namdaemoonno 5-ga, 138 Richwood Trading Co., Ltd. 82-2-757-3071 82-2-3789-6993 www.richwood.net 114 Kwang Dong Pharm. Co., Ltd. 82-2-6006-7777 82-2-6006-7024 1577-4 Seocho-dong, Seocho-gu, Seoul www.ekdp.com Jung-gu, Seoul 345-6 Silok-dong, Asan-si, Chuncheongnam- 139 RP BIO. Co., Ltd 82-2-568-0051 82-2-554-0871 163-3 Samsung-dong, Gangnam-gu, Seoul www.rpskorea.com 115 Kyongbo Pharm. Co., Ltd. 82-41-545-0456 82-41-546-8427 www.kbpharma.co.kr do Samoh B/D 4F, Yeoksam1-dong 751-10, 140 Sae Han Pharm. Co., Ltd. 82-2-533-7417 82-2-553-7416 www.shpharm.co.kr Kyowa Hakko Kirin Korea Co. 5F Poonglim Building, 823 Yeoksam-dong, www.kyowa-kirin- Kangnam-gu, Seoul 116 82-2-3471-4921 82-2-3471-4322 Ltd. Gangnam-gu, Seoul korea.com 141 Sam Chun Dang Pharm. Co., Ltd. 82-2-2046-1100 82-2-2046-1101 Seocho-dong 1606-1, Seocho-gu, Seoul www.scd.co.kr 117 Kyung Dong Pharm. Co., Ltd. 82-2-576-6121 82-2-577-5195 1659-5 Inheon-dong, Gwanak-gu, Seoul www.kdpharma.co.kr Sama B/D, 80-18 Cheongdam-dong, www. 142 SamA Pharm. Co., Ltd. 82-2-2056-7200 82-2-2056-7300 www. Gangnam-gu, Seoul samapharm.co.kr 118 Kyung Nam Pharm. Co., Ltd. 82-2- 3490-5105 82-2- 3490-5129 889-13 Daechi-dong ,Gangnam-gu, Seoul kyungnampharm. Dongbo B/D 4F, 1253 Sungin-dong, Jongno- co.kr 143 Samik Pharm. Co., Ltd. 82-2-928-0661 82-2-924-3749 www.samik.co.kr gu, Seoul LG Gwangwamoon Building, 92 Sinmun-ro 119 LG Chem 82-2-3773-1114 82-2-6924-3051 www.lgchem.com www. 2ga, jongno-gu, Seoul 144 Samil Pharm. Co., Ltd. 82-2-520-0300 82-2-588-5924 990-1 Bangbae1-dong, Seocho-gu, Seoul samil-pharm.com 3, 8F Medica Building, 1489-2 Seocho 3 www. 120 Medicakorea Co., Ltd. 82-70-4018-8000 82-2585-9689 www. dong, Seocho-gu, Seoul medicakorea.com 145 Samjin Pharm. Co., Ltd. 82-2-3140-0605 82-2-338-8032 338-8 Seokyo-dong, Mapo-gu, Seoul samjinpharm.co.kr 626 Teheran-ro, Gangnam-gu, Seoul, 99-1 Sang-ri, Geumsan-eup, Geumsan-gun, www. 121 Meditox 82-2-3471-8319 82-2-3476-8372 Republic of Korea (Medytox Building, www.medytox.com 146 Samnam Pharm. Co., Ltd. 82-41-754-3771 82-41-752-0086 Chuncheongnam-do samnam51.com Daechi-dong) Yangjae B/D, Yangjae-dong 261, Seocho-gu, www. 147 Samsung Pharm. Ind. Co., Ltd. 82-2-3408-4500 82-2-3408-4702 614-4 Junggok-dong, Gwangjin-gu, Seoul www.sspharm.co.kr 122 MG Co., Ltd. 82-2-2057-1002 82-2-2057-1003 Seoul medi-green.co.kr www. www. 148 Samyang Biopharm. Corp. 82-2-740-7116 82-2-743-6626 263 Yeonji-dong, Jongno-gu, Seoul samyangbiopharm. 123 Mirae Pharma. Korea 82-2-583-9077 82-2-583-7421 174 Saimdang-ro, Seocho-gu, Seoul miraepharmkorea. co.kr co.kr www. 149 Samyang Chemical Co., Ltd. 82-2-3488-5592 82-2-521-3100 1500-10 Seocho 3-dong, Seocho-gu, Seoul Mitsubishi Tanabe Pharma Korea R902 9F Yookyung Building, 239-1 www.mt-pharma- samyangchem.com 124 82-2-579-0121 82-2-579-0125 Co., Ltd Nonhyeon-dong, Gangnam-gu, Seoul korea.com Yonsei severance B/D 18F, 84-11 150 SANDOZ Korea Co., Ltd 82-2-768-9300 82-2-753-1287 www.sandoz.com 1-702 Gasandigital 2-ro, Geumcheon-gu, www. Namdaemonn-ro 5ga, Junggu, Seoul 125 Mother's Pharmaceutical co., Ltd 82-2-2026-8890 82-2-2026-8094 Seoul motherspharm.com 151 Santen Pharm. Korea Co., Ltd. 82-2-754-1434 82-2-754-2929 1678-4 Seocho-dong, Seocho-gu, Seoul - www. www.seoulpharma. 126 Mundipharma Korea 82-2-568-5689 82-2-568-5634 541 Namdaemoon-ro 5, Jung-gu, Seoul 152 Seoul Pharma co. Ltd. 82-31-497-1931 82-31-431-0715 Kyungje-ro 59, Siheung-si, Gyeonggi-do mundipharma.co.kr com

238 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 239 No Company Phone Fax Address Homepage No Company Phone Fax Address Homepage www. Yu Yu B/D, 358-9 Shindang-dong, Jung-gu, 153 Shin Poong Pharm. Co., Ltd. 82-2-2189-3426 82-2-2189-3439 748-31 Yeoksam-dong, Gangnam-gu, Seoul 178 Yuyu Pharma, Inc. 82-2-2253-6600 82-2-2253-6200 www.yuyu.co.kr shinpoong.co.kr Seoul Sinil B/D, 315-18 Jangan 2-dong 154 Sinil Pharm. Co., Ltd. 82-2-2211-6700 82-2-2212-6539 www.sinilpharm.com ,Dongdaemun-gu, Seoul 776-6 Wonsi-dong, Danwon-gu, Gyeonggi- 155 Sinsin Pharm. Co., Ltd. 82-31-491-6151 82-31-491-6153 www.sinsin.com do 686 Sampyung-dong, Bundang-gu, www. Associated Members(2018. 4) 156 SK Chemicals Life Science 82-2-2008-2008 82-2-2008-2009 Seongnam-si, Gyeonggi-do skchemicals.com No Company Phone Fax Address Homepage 533-2 Bongkok-ri, Banpo-myun, Gongju-si, www. 157 SS Pharm Co.,Ltd 82-31-491-6311 82-31-491-4797 Room1704 Ace High-end Tower2, 222-14 Chungchungnam-do susungpharm.co.kr 1 Abnoba Korea Co.,Ltd 82-2-6340-5114 82-2-6340-5588 www.krabnoba.com Guro3-dong, Guro-gu, Seoul 435-5 Jangan 3-dong, Dongdaemun-gu, 158 Suheung Capsule. Co., Ltd. 82-2-2210-8116 82-2-2217-2357 www.suheung.co.kr 13 Techno8-ro, Yuseong-gu, Daejeon, www. Seoul 2 BioLeaders 82-42-934-7671 82-42-934-7670 Korea bioleaders.co.kr Sungwon Adcock Pharm. Co., Room 302 Gayang-technotown, 1487 159 82-2-3665-2872 82-2-3665-2874 www.swpharm.com R519 Seoul Technopark, 172 Gongneung www. Ltd. Gayang 3-dong, Gangseo-gu, Seoul 3 Biosolution Co., Ltd. 82-2-3446-8884 82-2-3445-1380 2-dong, Nowon-gu, Seoul biosolutions.co.kr 160 Taejoon Pharm. Co., Ltd. 82-2-798-6601 82-2-795-8873 657-87 Hannam-dong, Yongsan-gu, Seoul www.taejoon.co.kr Daerung Techno Town 17th, 25 Gasan 4 BL&H Co., Ltd. 82-2-3282-4710 82-2-3281-9081 www.blnh.co.kr Seowoo B/D 6F, Yeoksam-dong 837-12, Digital 1-ro, Geumcheon-gu, Seoul 161 Taiguk Pharm. Co., Ltd. 82-80-3474-7761 82-2-3472-5501 www.taiguk.co.kr Kangnam-gu, Seoul 6th Floor, Seoul National University Cancer Takeda Pharmaceuticals Korea 12F KT&G Cosmodaechi Tower, 945-10 www. 5 CellBion Co., Ltd. 82-2-743-3311 82-2-743-3399 Research Institute 101, Daehak-ro, Jongno- www.cellbion.co.kr 162 82-2-3484-0800 82-2-3484-0808 Co., Ltd. Daechi-dong, Gangnam-gu, Seoul takeda-asia.com gu, Seoul C-403 ,253, Pangyo-ro, Bundang-gu, 6 Central Medical Service 82-10-4070-2417 82-2-3394-5165 793 Cheonho-daero, Gwangjin-Gu, Seoul www.cmscorea.co.kr 163 TDSPHARM Co., Ltd. 82-31-8018-7337 - www.tdspharm.com Seongnam-si, Gyeonggi-do 5F, Garosu Bldg., 103, Bokjeong-ro, www. www. 7 CorePharmBio 82-2-927-8220 - Sujeong-gu, Seongnam-si, Gyeonggi-do, 164 Teva-Handok. Co., Ltd. 82-2-521-5501 82-2-527-5510 132 Teheran-ro, Gangnam-gu, Seoul corepharmbio.com teva-hahdok.co.kr 13112 Kyunghee B/D 5F, 517-5 Dogok-dong, 3F Leeyangwon Building, 63-7 Kyungwoon- 165 Theragen Etex Pharm. Inc. 82-2- 3463-7111 82-2- 3463-8111 www.etexpharm.com 8 C&R Research 82-2-6251-1500 82-2-6251-1504 www.cnrres.co.kr Gangnam-gu, Seoul dong, Jongno-gu, Seoul 5F, Tower A, Korea Bio Park 700, R38 6F Asandigital Park, 1123 Shingil-dong, www. www. 166 UK Chemipharm Co., Ltd. 82-31-310-1983 82-31-310-1985 9 Crystalgenomics 82-31-628-2700 82-31-628-2701 Daewangpangyo-ro, Bundang-gu, Danwon-gu, Ansan-si, Kyunggi-do ukchemipharm.com crystalgenomics.com Seongnam-si, Cyeonggi-do Unimed B/D, 250-8 Jamsilbon-dong, 167 Unimed Pharm. Inc. 82-2-2240-5100 82-2-2240-5115 www.unimed.co.kr Daegu-Gyeongbuk Medical www. Songpa-gu, Seoul 10 82-53-790-5113 82-53-790-5119 2387 dalgubeol-daero, Suseong-gu, Daegu Innovation Foundation medivalley.re.kr Wonwae B/D 5F, 389-1 Poongnap 2-dong, 168 Union Korea Pharm. Co., Ltd. 82-2-489-3611 82-2-487-3611 www.ukp.co.kr R1010 Jeokseon-Hyundai Building, 80 Songpa-gu, Seoul 11 DreamCIS Inc. 82-2010-4500 82-2-720-5385 www.dreamcis.com Jeokseon-dong, Jongno-gu, Seoul 169 Whan In Pharm. Co., Ltd. 82-2-405-3000 82-2-404-2518 84-1 Munjeong-dong, Songpa-gu, Seoul www.whanin.com B-4F Korea Bio Park, 694-1, Sampyeong- White Global Pharmaceutical 12 Genexine Co.,Ltd. 82-31-628-3200 82-31-628-3229 dong, Bundang-gu, Seongnam-si, www.genexine.com 170 82-2-541-4884 82-2-541-8448 621, Yeongdong-daero, Gangnam-gu, Seoul www.whpharma.com Corp. Gyeonggi-do 827 Shindong-ri, Chunpo-myeon, Iksan-si, www. R714 Chungang Induspia 5th, 171 Won Kwang Pharm. Co., Ltd 82-63-832-3114 82-63-833-4114 Jeonrabuk-do wonpharm.co.kr 13 Glpharmtech.corp. 82-31-739-5220~3 82-31-739-5224 Sangdaewon-dong, Jungwon-gu, www.glpt.co.kr Seongnam-si, Gyeonggi-do 10F, Korea Fire Officials Credit Union www. 172 Wooridul Pharmaceutical Ltd. 82-2-582-4211 82-2-582-5666 Building, 274, Songpa-daero, Songpa-gu, 141 Gajeong-ro, Yuseong-gu, Daejeon 305- wooridulpharm.com 14 Korea Institute of Toxicology 82-42-610-8250 82-42-610-8085 www.kitox.re.kr Seoul 343 R1207 Woorim Lions Building B, 371-28 www. 173 Yoo Young Pharm. Co., Ltd. 82-2-6207-6114 82-2-6207-6135 915-9 Bandbae 1-dong, Seocho-gu, Seoul www.yypharm.co.kr 15 Medi help line 82-2-2026-0707 82-2-2026-0708 Gasan-dong, Geumcheon-gu, Seoul medihelpline.co.kr 174 Young Poong Pharm. Co., Ltd. 82-2-823-3251 82-2-821-2913 402-1 Daebang-dong, Dongjak-gu, Seoul www.yppharm.co.kr 12F Chungho Building, 120 Dosandae-ro, www. 16 PHARMICELL Co.,Ltd 82-2-3496-0114 82-2- 3496-0159 Gangnam-gu, Seoul pharmicell.com 175 Yuhan Corp. 82-2-828-0181 82-2-828-0300 49-6 Daebang-dong, Dongjak-gu, Seoul www.yuhan.co.kr www. 17 Samsung Bioepis Co., Ltd 82-32-455-3114 82-32-455-6119 107, Cheomdan-daero, Yeonsu-gu, Incheon 365-1 Shinwon-ri, Iwol-myeon, Jincheon- samsungbioepis.com 176 Yuil Pharm Tech. Co., Ltd. 82-43-537-2161 82-43-537-2163 www.yuilpharm.co.kr gun, Chungcheongbuk-do 394 Songjeong-ri, Byungcheon- www. 18 SK Bioland 82-41-564-8615 82-564-8619 myeon, Dongnam-gu, Cheonan-si, 177 Yungjin Pharm. Co., Ltd. 82-2-2041-8200 82-2-2041-8219 451-20 Chonho 3-dong, Gangdong-gu, Seoul www.yungjin.co.kr biolandkorea.com Chungcheongnam-do

240 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 241 MEMO MEMO

242 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 243 MEMO MEMO

244 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY 245 MEMO

246 2018 DIRECTORY OF KOREA PHARMACEUTICAL INDUSTRY